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1 Introduction  
1.1 Acute Myeloid Leukemia  
All blood cells originate from hematopoietic stem cells (HSCs) in the bone marrow. HSC can 
differentiate to multipotent stem cells and further to lymphoid or myeloid progenitor cells. 
Myeloid progenitor cells give rise to red blood cells, platelets, eosinophils, basophils, 
neutrophils and monocytes which further differentiate to macrophages or DCs. Lymphoid 
progenitor cells can differentiate to natural killer cells, B cells and T cells 
1
.  
In patients with acute myeloid leukemia (AML) a cancer of myeloid blood cells this 
differentiation is altered. This leads to a high number of progenitor cells without any function 
and a reduced number of erythrocytes, thrombocytes and leucocytes. It is the most common 
type of acute leukemia in adults. As its incidence is rising with age as well as life expectancy, 
the number of AML patients will also increase 
2
. In older patients, prognosis is poor due to 
high relapse rates after induction chemotherapy. But the prognosis also depends on recurrent 
molecular and cytogenetic abnormalities and the mutational load of the patients. Today about 
35-40% of patients under 60 years go to remission after chemotherapy and stem cell 
transplantation 
3
. Also, mutation specific and immunomodulatory treatments are under 
investigation in ongoing clinical studies like fms-like tyrosine kinase 3 (FLT3) and isocitrate 
dehydrogenase (IDH) 1 and 2 inhibitors 
4,5
 
1.1.1 Mutations in AML 
There are multiple recurrent genetic mutations known in AML, but as with most cancer types 
the disease-causing mutations differ between subtypes of AML. The mutations known in 
AML can be classified in 9 categories, transcription factor fusions, the nucleophosmin 1 
(NPM1) genes, tumor suppressor genes, DNA methylation-related genes, myeloid 
transcription factor genes, cohesion complex genes, and spliceosome complex genes 
6–8
. 
There are also mutations interfering with more than one cellular process. Some mutation lead 
to a gain of function like in the case of the IDH, others are driver mutation. IDH mutations are 
no driver mutations, the mutation alone is not able to start leukemia development 
9
. The 
mutational landscape of AML patients is dynamic due to coexisting competing clones, there is 
disease evolution. Based on the genetic abnormalities patients can be classified in risk 
categories (favorable, intermediate and adverse). For example are mutations in the NPM1 
gene are favorable, FLT-3 gene abnormalities are highly diverse and are found in all 
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categories and DNA methyltransferase 3A (DNMT3A) and IDH mutations are not yet 
classified 
8
. 
FLT3 is involved in proliferation, differentiation and survival of early hematopoietic 
progenitor cells. An internal tandem repeat mutation (repetition of one or more base pairs 
inside the gene) in the FLT3 gene is present in 20% of all AML patients 
10
. In patients 
younger than 65 years with normal karyotype the prognosis of patients with a FLT3 mutation 
is poor in other patient groups the prognosis is still unclear 
11–14
. 
NPM1 is mutated in 30% of AML patients. NPM1 is a protein moving proteins from 
cytosol to nucleus and back to prevent accumulation of proteins in nucleolus. NPM1 is 
involved in other cellular processes such as the regulation of centrosome function and 
biosynthesis of ribosomes and p53 tumor suppressor pathways 
15
. 40% of patients with NPM1 
mutation also have a FLT3-internal tandem duplication (ITD) mutation and in 25% additional 
to NPM1 IDH is mutated. If NPM1 is mutated without an FLT3 mutation, younger adults had 
a higher relapse free and overall survival 
14,16
. 
Mutations in DNMT3A lead to an altered epigenetic landscape. DNMT3A is 
responsible for de novo methylation of DNA after replication. Methylations of promotor 
regions are associated with gene silencing. Mutation in DNMT3A may lead to a lack of 
silencing of self-renewal genes during differentiation of hematopoietic stem cells. DNMT3A 
mutations are present in 20% of AML patients; the mutation is conserved during blast 
evolution. In clinical studies patients with a DNMT3A mutation had a shorter event free and 
overall survival than patients expressing wild type DNMT3A 
14,17,18
. Another mutation 
interring with the epigenetic landscape is the IDH mutation. 
1.1.1.1 IDH mutation  
There are three isoforms of the metabolic enzyme IDH. IDH1 is present in cytoplasm, while 
IDH2 and IDH3 are mainly present in mitochondria. IDH converts isocitrate to -
ketoglutarate. Alternatively -ketoglutarate can also be generated from glutamine taken up 
from the extracellular space (glutaminolysis) 
19
. 
If IDH is mutated it gains the ability to convert -ketoglutarate to the onco-metabolite 
D-2-hydroxyglutarate (D-2-HG) 
20,21
. The mutation of the IDH2 gene, has a frequency of 
about 10% in AML patients. The most frequent mutation of IDH2 is the substitution of 
arginine with glutamine at position 140 (R140Q); there is another mutation at position 172 
where an arginine is substituted by lysine (R172K). IDH1 mutations are less frequent in AML 
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patients (6%) 
22
. There are six mutations known IDH1 -R132H, -R132C, -R132S, -R132L, -
R132G and -R132P. The most common are the IDH1-R132C and -R132H mutations (together 
about 50% of IDH1 mutation) 
23
. 
1.1.1.1.1 Prognosis in AML patients with IDH mutation 
As IDH mutations promotes tumorgenesis, but could not cause leukemia by its own it is 
difficult to estimate its impact on prognosis of AML patients 
9
. In the case of gliomas its more 
straightforward several studies have shown that glioma patients with an IDH1 mutation 
showed a higher overall survival 
24–26
. In AML, the prognosis of patients with IDH mutations 
is not yet clarified. Wang et al analyzed 2-HG serum level in AML patients. They found that 
high 2-HG (produced by mutant IDH1/2) levels were associated with lower overall survival 
and event-free survival in cytogenetically normal AML patients 
27
. Other studies showed 
similar results in IDH1 mutated AML patients, they had a reduced event-free survival but 
comparable overall survival 
28,29
. Another study with 826 patients (165 mutated; 59 IDH1-
R132, 83 IDH2-R140, and 23 IDH2-R172) found no difference in the cohorts IDH wild type 
and mutated 
30
. To conclude the prognosis of AML patients with IDH mutation depends on 
mutation site. In general, prognosis also depend on patient age and treatment regime and 
cannot be generalized.  
1.1.1.1.2 Production of 2-hydroxyglutarate  
As mentioned above mutations in the IDH gene leads to the production of D-2-HG. D-2-HG 
can be measured in sera of AML patients (up to 600 µM) 
28
 but also in much higher 
concentrations in tissues of glioma patients. Here concentrations up to 35 mM were measured 
31
. In AML patients D-2-HG level in sera differ depending on the IDH mutation. In a study 
were 2-HG level of AML patients with IDH1 R132H mutations were compared with IDH2 
R140Q and R172K revealed a comparable level of 2-HG in IDH1 R132H and IDH2 R140Q 
mutated patients but a higher level in patients with IDH2 R172K mutation 
32
. In another study 
IDH1 R132H mutated patients had the highest 2-HG level in the sera 
33
. But there are tumor 
entities with high 2-HG level without an IDH mutation. In breast cancer cells expressing the 
transcription factor MYC 2-HG level were also elevated, due to production of 2-HG from 
glutamine-derived ketoglutarate (glutaminolysis) supported by MYC signaling 
34
.  
In addition to the D enantiomere also L-2-HG can be produced. L-2-HG is produced in 
healthy cells under hypoxic conditions. Malate dehydrogenase 1 and 2 and lactate 
dehydrogenase A produce L-2-HG out of -ketoglutarate derived from glutamine 35. L-2-HG 
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is also known to accumulate in renal cell carcinoma; here a mutation in the gene of 
L-hydroxyglutarate dehydrogenase (LHGDH), an enzyme responsible for the breakdown of 
L-2-HG, is mutated 
36
.  
D-2-HG can be degraded and converted back to α-ketoglutarate; this is catalyzed by 
D-2-HG dehydrogenase. In this reaction the co-factor FAD is reduced to FADH2. 
Ketoglutarate can enter the citric acid cycle and fuel energy production 
37
. 
1.1.1.1.3 Effects of 2-hydroxyglutarate 
There are several effects and enzyme targets of 2-HG already known. For 2-HG production 
NADPH is needed and NADP
+
 produced, this alters the NADPH/NADP
+
 ratio and possibly 
has an influence on the redox balance 
38–40
.  
As shown in Figure 1.1 D-2-HG and L-2-HG inhibit a-ketoglutarate dependent 
dioxygenases like lysine demethylases (KDM) and Tet methylcytosine dioxygenase 2 (TET2). 
These enzymes change chromatin accessibility and thereby regulate also gene transcription. 
The alteration of the epigenetic landscape can lead to a block in differentiation and thereby to 
tumorigeneses 
41,42
.  
2-HG also interferes with Prolyl hydroxylase 2, which destabilize HIF-1a 
43,44
. This 
induces for example the expression of glucose transporters and thereby alters the glucose 
metabolism of the cell. Collagen maturation is also inhibited by D-2-HG 
39,45
.  
 
Figure 1.1: Production and effects of 2-HG on -ketoglutarate dependent dioxygenases  
Isocitrate dehydrogenase 2 converts isocitrate to -Ketoglutarate in citric acid cycle. It acts as a homodimer. If there is a 
mutation in the enzyme it gains a new function and is able to produce D-2-HG from -Ketoglutarate and act as a heterodimer 
with one wild type and one mutated unit. This reaction consumes NADPH and thereby changes the ratio of NADPH/NADP+ 
and redox regulation. D-2-HG itself inhibits -Ketoglutarate dependent dioxygenases due to the structural similarity to -
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Ketoglutarate. Dioxygenases like TET2 and KDM are involved in DNA and histone methylation. If these enzymes are 
inhibited changes in the epigenetic landscape may cause a block in differentiation. Prolyl hydroxylase 2(PhD) is also 
inhibited by D-2-HG, this leads to a stabilization of HiF-1. C-H4P and PLODI-3 is also inhibited by 2-HG, this interferes 
with collagen maturation. KDM, lysine demethylase; TET2, Tet methylcytosine dioxygenase 2; PhD, Prolyl hydroxylase; C-
H4P, collagen heavy chain precursor 4. (Adopted from 45) 
1.2 Epigenetic 
Epigenetic factors change gene expression but not by changing the gene sequence; they cause 
a phenotypic alteration without changing the genotype. The epigenetic landscape can be 
altered by environmental chemicals, pharmaceuticals/drugs, aging/reactive oxygen species 
and the diet 
46,47
. Epigenetics mainly focus on histone and DNA modification. Triggered by an 
epigenetic factor, histones can for example acetylated which alters how tight DNA is wrapped 
around histones and finally gene accessibility. The same is true for DNA methylations; here 
one or more methyl groups are added to DNA base 
46,48
. 
1.2.1 DNA Methylation  
In general DNA methylation occurs in cytosine and guanine rich areas, so called “CpG 
islands”. Methylation can be added or removed to C-5 position of the cytosine ring to 
modulate gene expression. Sites can be de novo methylated or re-established after replication. 
De novo methylations are performed by DNA methyltransferases (DNMTs), as mentioned 
above mutation in these genes are present in leukemia patients.  
DNA methylation in most cases is associated with gene silencing 
49
. During 
differentiation cells need to change the portfolio of expressed genes, so the methyl groups 
must be removed. This is done by demethylases, for example in dendritic cells (DCs) the 
dominant demethylase is TET2. TET2 is responsible for the demethylation of gene regions 
important for differentiation of monocytes to DCs 
50
. 
1.3 Immunological background 
1.3.1 T cells  
There are two main classes of T cells defined by expression of either the costimulatory 
molecule CD4 (T helper cell) or CD8 (cytotoxic T cells). Depending on the cytokines in the 
environment CD4 T cells can differentiate into regulatory T cells (Treg, regulation of immune 
responses) TH1 cells (protection against intracellular microbes), TH2 cells (protection against 
parasites) and TH17 cells (control of infections) 
1
.  
CD8 T cell receptors (TCR) recognize peptides of a length of 8-10 amino acids bound 
to HLA (human leukocyte antigen) class I molecules, while CD4 T cells recognize 14-20 
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amino acid peptides bound to HLA class II molecules. In general HLA class I peptides are 
derived from proteins in the cytosol like viral or mutated proteins. HLA class I molecules are 
expressed on all nucleated cells, while under non-inflammatory conditions class II molecules 
are only expressed on immune cells and present peptides from phagocytosed extracellular 
proteins. In some cases also HLA class I molecules can present exogenous proteins, this is 
known as cross-presentation 
1
.  
Dendritic cells (DCs) are the only antigen presenting cells (APCs) able to prime and 
activate naïve T cells 
1
. For T cell priming adhesion molecules of DCs (ICAM-1, ICAM-2 and 
CD58) bind to adhesion molecules on T cells (LFA-1 and CD2). This is important for T cells 
to scan HLA molecules loaded with antigens presented on HLA molecules of DCs. If naïve T 
cells recognize their HLA-peptide ligand with the TCR, the affinity of the adhesion molecules 
increases; this is needed for proliferation and differentiation into effector T cells 
1
.  
Binding of the TCR, the CD4/CD8 co-receptor and the CD3 molecule (T cell site) to 
peptide bound HLA molecule (DC site) is only one of at least three signals T cells need to get 
activated and become a full functional T effector cell. Survival of T cells is induced by 
binding of the costimulatory molecule CD28 to CD80 or CD86 expressed on APCs (second 
signal). Finally, the secretion of pro-inflammatory cytokines like interleukine-6 (IL-6), IL-12, 
IL-4 and IL-23 leads to T cell differentiation and activation 
1
. CD28-dependent co-stimulation 
also leads to IL-2 production and IL-2 receptor α chain (also known as CD25) synthesis. 
Bevor stimulation only the β and γ chains of the IL-2 receptor are expressed, and the α chain 
increases the affinity of the receptor to IL-2. This leads to a higher proliferation rate 
1
. After 
the activation of T cells, they can execute their function as an effector cell and kill pathogens 
or activate other immune cells. If the activation was strong enough memory cells are 
generated for a faster response in case of a second infection 
1
. 
1.3.2 Antigen presenting cells 
Professional APCs are DCs, macrophages and B cells. B cells take up antigens by antigen 
specific receptors, while DCs and macrophages perform micropinocytosis (non-selective 
uptake of solute molecules, nutrients and antigens) or phagocytosis (uptake solid matter or 
pathogens). As mentioned above these antigens are then presented on HLA molecules. 
1.3.2.1 Dendritic cells 
Immature DCs are characterized by high phagocytic activity. After phagocytosis and/or 
contact with bacterial components, such as lipopolysaccharide (LPS), DCs get activated. LPS 
Introduction 
7 
 
is a bacterial molecule present in the membrane of gram-negative bacteria. LPS activates toll-
like receptor 4 (TLR4). They are 10 TLRs known in human. Binding of LPS to TLR4 
sequentially leads to the activation of Mitogen-activated protein kinase (MAPK) and 
transcription factor nuclear factor-kappaB (NF-κB). This finally leads to activation of DCs 
and the production and secretion of pro-inflammatory cytokines like IL-12, IL-6 and TNF 
51
. 
After activation DCs leave the peripheral tissue and migrate through the lymph system to 
secondary lymphoid organs. This is possible due to a reorganization of adhesion molecules 
and the cytoskeleton. During maturation, DCs upregulate the expression of costimulatory 
molecules and surface marker like CD80/CD86, DC-SIGN and HLA class I and II molecules. 
1.3.2.2 HLA class II molecules 
The main regulator of HLA class II gene expression is the class II major histocompatibility 
complex transactivator (CIITA), which is constitutively expressed in professional APCs 
(DCs, B cells) and can be induced in non-professional APCs for example by interferon γ 
(IFNγ). DCs and B cells upregulate HLA class II expression during differentiation 52,53. 
After translation HLA class II molecules enter the endoplasmatic reticulum (ER) and 
associate with the invariant chain (Ii). Through golgi aperatus traffic machinery HLA class II 
molecules get delivered to the cell membrane. From there HLA class II molecules reach the 
multivascular antigen-processing compartments, in these compartments the Ii is cleaved and 
only the class II-associated invariant chain peptide (CLIP) remains bound in the peptide 
groove of the HLA class II molecule 
54
.  
HLA-DM also present in the antigen-processing compartment, enables the binding of 
peptide antigens and is regulated by HLA-DO 
55
. Antigens enter the antigen-processing 
compartment through clathrin-mediated endocytosis, macropinocytosis autophagy and 
phagocytosis. The antigens get proteolytic cleaved in vesicles (endosomes, macropinosomes, 
autophagosomes and phagolysosomes). These vesicles then fuse to the antigen-processing 
compartment 
54
. It was also shown that HLA molecules bound to Ii reach the antigen-
processing compartment without being on the cell membrane before 
56
. 
If peptides are bound on HLA class II molecule the compartment does a tubulation 
which allow peptide bound HLA molecule to traffic to and to get released on the cell 
membrane 
57,58
. 
Walseng et al. estimated that about 80% of peptide bound HLA class II molecules are 
on the cell membrane and 20% intracellular. HLA class II molecules get recycled after 
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peptide binding and internalization, but this is only possible in mature DCs. After one peptide 
is released from the HLA class II molecule it can be loaded with another peptide and 
transported again to the cell membrane 
56
.  
Electron microscopic analysis revealed different compartments containing HLA class 
II molecules, there are simplified summarized from literature in Figure 1.2. How these 
compartments are formed and how they are related is not fully understood. 
 
Figure 1.2: Compartments containing HLA molecules. There are different compartments in the cell were HLA class II are 
present in antigen presenting cells. HLA-DR gold staining revealed the presents of HLA-DR in multilaminar bodies and 
multivascular bodies (MVB). MVB undergo tubulation under their maturation. In the tubular structure small vesicles 
containing peptide loaded HLA-DR get separated and transported to the cell surface (Adopted from 57–60). 
1.4 Cellular therapy as cancer treatment  
In the last decades cellular therapy is evolved a promising strategy to cure cancer. For cellular 
therapy modified autologous or allogenic cells are transferred to patients for anti-tumor 
response. Somehow also allogenic stem cell transplantation is a cellular therapy in which the 
immune cells of the donor eliminate remaining tumor cells after chemotherapy (so called 
Graft-versus-leukemia effect). To optimize anti-tumor activity, immune cells can be 
genetically modified before the transfer into patients. T cells are one of the most promising 
cell types for immune therapy. 
It is known that T cells can infiltrate tumor tissue. Clinical studies showed a positive 
correlation between infiltrated T cells and patients overall survival 
61
. In another studies in 
hepatocellular carcinoma and breast cancer, it was found that it was critical which subset was 
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present, activated CD8 T cells were favorable, while high numbers of regulatory T cells (Tregs) 
were not 
62,63
.  
One advantage of using T cells for cellular therapy is that they circulate in blood and 
lymph nodes scanning for abnormalities and inflammation. As they circulate in the whole 
body, they can find tumor cells in the whole body. Tumor specific T cells get stimulated by 
tumor proteins, to proliferate and survive as long as the tumor cells are present. T cells are 
also able to generate cellular memory by differentiation into memory T cells; they persist and 
can protect patients from relapse. 
1.4.1 Target antigen for cellular therapy 
The most important point in the treatment of cancer with cellular therapy is the right cellular 
target to specifically kill tumor cells without harming healthy cells. There are different types 
of antigens used as cellular target.  
Tumor-associated antigens are over expressed in tumors but also expressed on healthy 
body cells. But therapies based on tumor-associated antigens showed low efficacy, due to the 
clearance of TCRs against self-antigens in T cell development 
64
. One example are the cancer 
testis antigens found in melanoma patients, melanoma-associated antigen (MAGE)-1 was the 
first protein discovered in patients, later also related proteins were found. These proteins are 
only expressed in tumor cells and healthy testis, MAGE pattern antigens are therefore known 
as cancer testis (CT) antigens 
65
. 
Another more promising approach is the use of the tumor-specific antigens (TSA), 
these antigens are based on somatic missense mutations which are responsible for tumor onset 
or progression and therefore not expressed in healthy non-tumor cells. T cells stimulated with 
such antigens would specifically eliminate tumor cells without harmful side effects. In the 
first part of my PhD project we stimulated T cells with peptides specific for the IDH2 R140Q 
mutation, where, as mentioned above, the arginine residue present in the wild type enzyme at 
position 140 is exchanged by a glutamine. Viral proteins in tumors caused by virus injections 
also give rise to TSAs 
66
.  
But cellular therapy only targeting one antigen drives the tumor towards a clonal 
evolution and antigen loss to escape the immune systems. Other strategies are the down 
regulation of HLA molecule expression. This lowers the level of presented putative tumor 
specific antigens on tumor cells. Another way is to upregulate inhibitory molecules like PD-
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L1, which inhibit T cell function. Tumor cells can also secrete anti-inflamatory cytokines like 
IL-10 to recruit Tregs and inhibit maturation of DCs 
67,68
. 
1.5 Metabolites interfere with immune cells 
As mentioned above (1.1.1.3) D-2-HG accumulates in cells with IDH mutations. There are 
also mutations known in succinate dehydrogenase and fumarate hydratase, which lead to an 
accumulation of succinate and fumarate. All three mutations support the transformation of 
cells into tumor cells. The metabolites lead to DNA and histone hypermethylation, metabolic 
changes and changes in post-translational modifications 
69
. Accumulation of metabolites in 
the tumor environment possibly inhibit immune response and lead to an immune escape 
44,69
. 
One example is lactate, a metabolite produced by anaerobic metabolism of tumor cells, which 
inhibits T cell and DC function 
70,71
. There is one recently published report showing the effect 
of D-2-HG on T cells. They show that D-2-HG leads to hypoxia inducible factor 1 (Hif 1) 
destabilization and thus to an increase in oxidative phosphorylation activity. They also saw a 
higher frequency of regulatory T cells and a reduced polarization towards Th17 cells 
72
. This 
is in line with results obtained from Xu et al. where there so a reduced Th17 polarization 
73
. 
1.5.1 Glucose metabolism  
Glucose is transported through the cell membrane by glucose transporters such as Glut1. In 
the cytosol glucose gets metabolized to pyruvate in glycolysis. In this process 2 ATP 
molecules and 2 NADH+ 2 H
+
 are produced (Glucose + 2 Pi + 2 ADP + 2 NAD
+
 into 2 
Pyruvate + 2 ATP+ 2 NADH+2 H
+
 + 2 H2O). Under anaerobic conditions pyruvate is 
converted to lactate. This is done to recycle NAD
+
 as an electron acceptor for glycolysis 
74
. 
1.5.2 Citric acid cycle 
If oxygen is available pyruvate is metabolized further in the mitochondria to acetyl-coA 
(oxidative decarboxylation) which fuels the tricarboxylic acid (TCA) cycle. TCA cycle is a 
cycle of 8 enzymes where the released energy and electrons are stored in GTP, NADH and 
FADH. TCA cycle intermediates serves as a source of precursors for amino acid and lipid 
synthesis. The high energetic molecules NADH and FADH enter the electron transport chain 
in the inner mitochondrial membrane 
74
. 
1.5.3 Oxidative phosphorylation  
Oxidative phosphorylation takes place in the mitochondria, more precise in the inner 
mitochondrial membrane. The inner membrane is folded into numerous cristae, to increases 
Introduction 
11 
 
their surface and provide more space for complexes of the respiration chain. Between the 
inner and outer mitochondrial membrane, in the intermembrane space, the proton gradient is 
built through oxidative phosphorylation 
74
.  
From the mitochondrial matrix protons and electrons of NADH+H
+
 enter complex I 
(NADH dehydrogenase) of the respiration chain. FADH2 is already produced by complex II 
(succinate dehydrogenase) as an enzyme of the TCA cycle and fuels its proton and electron 
directly in complex II. Protons are transported through mitochondria matrix into the 
intermembrane space. Electrons are transported further to complex III (ubiquinol–cytochrome 
c oxidoreductase) through ubiquinone (Q) which can move in the mitochondria matrix along 
the inner membrane. Complex III and IV (cytochrome c oxidase) also transport protons into 
the intermembrane space. The proton gradient is used to activate ATP synthase and induce the 
movement of the upper part of the ATP synthase (proton motoric force). This is needed for 
ATP production from inorganic phosphate and ADP 
74
.  
 
Figure 1.3: Complexes of electron transport chain in the inner mitochondrial membrane 
Electrons from NADH/FADH are transported through the complexes of electron transport chain (ETC) to complex IV were 
water is produced. Protons from NADH/FADH were transported into intermembrane space of mitochondria to establish 
proton gradient. Proton gradient is used to produce ATP from inorganic phosphate. Respiration activity can be modulated by 
the addition of different inhibitors. Rotenone inhibits complex I, myxothiaxol or antimycin A inhibit complex II and 
ccomplex V is inhibited by oligomycin. Glutamate, malate and pyruvate are substrates for complex I, while succinate enters 
oxidative phosphorylation from complex II. (Adopted from 75) 
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1.5.4 Metabolism of dendritic cells 
During DC differentiation from monocytes metabolism is mainly based on oxidative 
phosphorylation in the mitochondria. Monocyte culture with granulocyte– macrophage 
colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) leads to an increased expression 
of peroxisome proliferator-activated receptor-γ (PPARγ) 76,77. PPARγ a transcription factor 
regulating lipid metabolism, and controls PPARγ co-activator 1α (PGC1α). Both, 
upregulation of PPARγ and PGC1α leads to an increase in mitochondrial biogenesis 78. In 
vitro DC development out of monocytes also depend on fatty acid synthesis 
79
. Fatty acid 
oxidation is also the main metabolic process in immature DCs 
80
. 
Activation of DCs by TLR agonists leads to a rapid increase of glucose uptake and 
lactate production 
79
. These metabolic changes are caused by downstream pathway of TLRs 
that involves protein kinase B (AKT), TANK-binding kinase 1 (TBK1), inhibitor of nuclear 
factor-κB kinase subunit-ε (IKKε) and hexokinase 2 (HK2).  
In the activated stage DCs remain glycolytic under the control of mammalian Target of 
Rapamycin (mTOR) and HIF1α 80. Glycolysis is important for activation as inhibition of 
glycolysis with 2-deoxyglucose (an inhibitor of hexokinase) also inhibits DC activation 
81
. 
1.5.5 Oxidative stress 
Oxidative stress rises if there is an imbalance of free radicals produced and the buffering 
capacity of the antioxidant defense system. Oxidative stress can lead to modifications on 
proteins, lipids and DNA 
82
.  
1.5.5.1 Production of reactive oxygen species 
During electron transport through the inner membrane of the mitochondria in oxidative 
phosphorylation reactive oxygen species (ROS) may be formed. Electrons which prematurely 
exit the chain may reduce oxygen to form superoxide (O2
-•
). Each complex in the electron 
transport chain can form superoxides, while complex I and III are the main producer in the 
mitochondria. It is estimated that about 0.2-2.0% of the oxygen consumed is transformed to 
ROS 
75
.  
 Another source of ROS is the NADPH oxidase. NADPH oxidase catalyzes the 
production of superoxide from oxygen and NADPH. Also, other ROS like peroxide can be 
produced by dismutation of superoxide. NADPH oxidase is present in professional 
phagocytes neutrophils, eosinophils, monocytes and macrophages in stages of their 
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development. NADPH oxidase produces agents, which get released (oxidative burst) to kill 
pathogens in contact with the phagocyte. Neutrophils, monocytes and macrophages then take 
up the pathogens 
81
. 
1.5.5.2 Role of ROS in DCs 
There are different studies done on the role of ROS in the differentiation and activation of 
DCs. Harari and Liao et al. showed an inhibitory effect of antioxidant addition (during DC 
differentiation) on HLA class II expression 
83
. ROS were also reported to be important for DC 
activation as LPS increase ROS level in DCs 
84
 and addition of ROS led to the activation of 
DCs 
85
. Del Prete et al. also suggest that ROS play a crucial role in DC differentiation and 
addition of catalase (neutralize peroxide) inhibit DC function 
86
. In contrast to this, Malinarich 
et al. showed that induced tolerogenic DCs (induced by dexamethasone and vitamin D3) 
showed higher ROS production due to a higher mitochondrial activity 
87
.  
1.6 Project aims 
In AML there are high relapse rates especially in elderly. The aim of my first PhD project was 
the generation of leukemia specific T cells. As a target the mutant IDH2 R140Q was chosen 
because is not expressed in healthy cells and therefore a tumor specific tumor antigen. 
For the generation of IDH2 specific T cells, T cells were stimulated with a IDH2 
R140Q specific antigen bound to an HLA molecule on APCs. The specific antigen was 
provided by expression, processing and presentation of the mutated protein (IDH2 R140Q) in 
DCs or by exogenous loading of mutation specific peptides. The reactivity of these T cells 
was assayed by interferon γ ELISpots. T cells specificity against the mutated protein or 
peptide was evaluated with corresponding wild type peptide loaded and IDH2 wild type 
expressing DCs. If IDH2 R140Q specific T cells were generated, in long perspective, they 
should be used for cell therapy to eliminate blasts in patients with minimal rest disease.  
 
The “oncometabolite” D-2-HG produced by IDH has several known targets in the cell 
which promotes tumorgenesis but could not cause leukemia by its own. The aim of my second 
project was to find out how D-2-HG interferes with the differentiation from monocytes to 
DCs. This was analyzed by flow cytometric analysis of dendritic cell specific surface marker 
expression (HLA class I and II, costimulatory molecules, differentiation marker). Further 
characterization was done by cytokine ELISAs and functional tests like phagocytosis assay 
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and mixed lymphocyte reaction in an allogeneic setting. The influence of D-2-HG on the 
metabolism of DCs was analyzed by glucose, oxygen and lactate concentration analysis and 
reactive oxygen species measurements. 
Based on the results we tried to rescue the effects caused by D-2-HG with anti-
metabolic and anti-oxidative drugs. 
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2 Material and Methods 
2.1 Material 
2.1.1 Equipment and consumables 
Table 1: List of equipment 
Advice Company 
Steri-cycle CO2 incubator Fischer Scientific 
Reaction tube centrifuge Eppendorf 
Centrifuge 16R, 40R Fischer Scientific 
Lamina flow Fischer Scientific 
Scale Kern 
Inverted microscope Zeiss 
Flow cytometer, BDCalibur Becton Dickinson 
Cell sorter, BD Aria III Becton Dickinson 
CASY Cell Counter and Analyzer System 
Model TT 
Roche Innovatis AG 
pH-Meter Hanna Instruments 
Well wash 4 MK 2 Thermo Electron Corporation 
NanoDrop ND1000 PeqLab 
CTL Elispot reader ImmunoSpot 
Pipet boy Integra 
Centrifuge Avanti J-20XP; Rotor JE 5.0 Beckmann Coulter 
Elutriator Avanti J-20XP Beckmann Coulter 
Flow chamber (elutration) Beckmann Coulter 
Shaker Heidolph 
Electrophorese system BioRad 
Blotting device Blue power plus 
Photometer  Eppendorf 
Western blot imager, Fusion Pulse Vilber 
Bioluminescence reader Berthold 
Typhoon Gel and Blot Imaging Systems GE healthcare 
Gene pulser, eletrcoporator Biorad 
PCR cycler Eppendorf 
 
Table 2: List of plastic consumables  
Component Company 
Plates for ELISA Costar 
Sterile Filter Millipore 
Pipettes (2, 5, 10, 25, 50 ml) Greiner 
Cell culture flasks (T25, T75, T175) Greiner 
Cell culture plates Greiner 
14mL, 50mL tubes Greiner 
Polyprene tubes Becton Dickinson 
0.5, 1.5, 2.0 mL tubes (safe look, RNase free) Eppendorf 
Kuvette  (electroporation) Biorad 
Kuvette plastic (OD measurement) Roche 
 
Table 3: Equipment and consumables used for respiration analysis 
Equipment  Company 
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Gastight 1700 Syringes (10,25,50μl) Hamilton 
Hot-Air Disinfectable Gassed Incubator BBD Termo Fisher 
OxoDish®, HydroDish® PreSens 
Oxygraph-2k Oroborus Instruments 
SDR SensorDish® Reader PreSens 
 
2.2.1 Chemicals 
Table 4: List of chemicals 
Component Company 
L-2-HG, D-2-HG Sigma Aldrich 
Trolox Sigma Aldrich 
Tempol Santa cruz 
Ethanol (96%) Roth 
Milk powder Sucofin 
Isopropanol Roth/Braun 
Chloroform Sigma Aldrich 
Phenol/chloroform Roth 
BSA Sigma Aldrich 
Vitamin C Sigma Aldrich 
Metformin Sigma Aldrich 
Pioglitazone Sigma Aldrich 
Peroxide Sigma Aldrich 
Methanol Merck 
DMSO Roth 
Malate Sigma Aldrich 
Digitonin Sigma Aldrich 
ADP Sigma Aldrich 
MgCl2 Roth 
Pyruvate Sigma Aldrich 
Glutamate Sigma Aldrich 
Succinate Sigma Aldrich 
FCCP Sigma Aldrich 
Rotenone Sigma Aldrich 
Myxothiazol Sigma Aldrich 
TMPD Sigma Aldrich 
Sodium azide Sigma Aldrich 
EGTA Roth 
MgCl2 6 H2O Roth 
Lactobionic acid Sigma Aldrich 
Taurine Sigma Aldrich 
KH2PO4 Sigma Aldrich 
HEPES Sigma Aldrich 
D-Sucrose Sigma Aldrich 
BSA, essentially fatty acid free Sigma Aldrich 
RIPA Buffer Sigma Aldrich 
Protease inhibitor  Roche 
Dimethylformamid Sigma Aldrich 
 
Table 5: Reagents used for flow cytometry analyses 
Reagent Company 
FACS clean BD Biosciences, Franklin Lakes, NJ, USA 
Material and Methods 
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FACS flow BD Biosciences, Franklin Lakes, NJ, USA 
FACS rinse BD Biosciences, Franklin Lakes, NJ, USA 
 
Table 6: Material and reagents used for SDS gels and western bloting 
Reagent/Material Company 
SDS Sigma 
Acrylamid 30% Carl Roth 
Tris/HCl Roth 
Glycerin Roth 
2-Mercaptoethanol Sigma Aldrich 
Bromphenolblau Sigma Aldrich 
Methanol Roth 
ε-Amino-n-caproic acid  Sigma Aldrich 
polyvinylidene fluoride membrane Millipore 
Filter paper 3MM Whatman, Dassel, Germany Filter paper 3MM Whatman, Dassel, 
Germany 
Tween Sigma Aldrich 
APS  Merck Millipore 
TEMED Sigma-Aldrich 
Triton X100 Sigma-Aldrich 
ReBlot Plus Mild  Milipore 
Kaleidoscope Pre-stained Standard  BioRad 
 
Table 7: Components of agarose gel to analyze RNA 
Component Company 
Formaldehyde Sigma Aldrich 
MOPS Sigma Aldrich 
Sodium Acetat Sigma Aldrich 
EDTA Roth 
Agarose Roth 
RotiSafe Roth 
DEPC Sigma Aldrich 
Formaldehyde loading dye Ambion 
 
2.3.1 Fluorescence probes and antibodies 
Table 8: List of antibodies used for flow cytometry analyses 
Specificity Clone Company Volume for 200,000 cells 
HLA-DP PE BRAFB6 Santa cruz 1 µl 
HLA-DQ FITC Tu169 BD bioscience 1 µl 
HLA-DR APC L243 BD bioscience 1 µl 
HLA-ABC PE G46-2.6 BD bioscience 1 µl 
DC-SIGN PE FAB161P R&D 1 µl 
CD1a PECy7 HI149 BD bioscience 1 µl 
ILT-3 APC ZM4.1 BioLegend 2 µl 
ILT-2 PE Cy 7 GHI/75 BioLegend 2 µl 
TIM-3 PE Cy 7 F38-2E2 BioLegend 2 µl 
BTLA PE MIH26 BioLegend 2 µl 
CD80 FITC L307 BD bioscience 2 µl 
CD86 FITC 2331 BD bioscience 2 µl 
CD83 FITC HB15e BD bioscience 2 µl 
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CD4 FITC RPA-T4 BD bioscience 1 µl 
CD4 V450 RPA-T4 BD bioscience 1 µl 
CD25 APC BC96 BioLegend 1 µl 
FoxP3 PE PCH101 eBioscience 5 µl 
CD14 FITC M5E2 BD Bioscience 1 µl 
CD3 APC UCHT1 BD Bioscience 1 µl 
CD45RA PE HI100 BD Bioscience 2 µl 
 
Table 9: List of fluorescence probes used in flow cytometry 
Substance Company 
MitSox Invitrogen 
Mitotracker Invitrogen 
DCFDA Sigma Aldrich 
 
Table 10: List of antibodies used for western blot analyses 
Specificity Clone Company Dilution 
Rabbit anti-LC3B EPR16883 Abcam 1:500 
Rabbit anti-PKC M110 Abcam 1:1000 
Rabbit anti-Rab9 EPR13272 Abcam 1:1000 
Mouse anti-MHC II EPR11226 Abcam 1:10000 
Rabbit anti-actin G250 Cell signaling, 1:1000 
Goat anti-rabbit HRP P0448 Dako, P0448 1:2500 
Goat anti-mouse HRP P0447 Dako, P0447 1:2500 
 
2.4.1 Cell culture material 
Table 11: Cell culture media and supplementaries  
Suplementary Company 
RPMI Gibco 
AIMV Gibco 
Hepes buffer 1M Sigma Aldrich 
penicillin/streptamycin Gibco 
Glutamine Gibco 
Human sera Bavarian Red Cross 
Fetal calf sera Sigma Aldrich 
 
Table 12: List of cytokine used in cell culture 
Cytokine Company 
IL-1b Miltenyi Biotec 
IL-2 Novartis 
IL-4 Miltenyi Biotec 
IL-6 Miltenyi Biotec 
IL-7 Miltenyi Biotec 
IL-15 Miltenyi Biotec 
IFN eBioscience 
TNF PromoCell 
GM-CSF Sanofi 
PGE2 Sigma Aldrich 
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Table 13: Other substances 
Substance Company 
Phosphat buffered saline (PBS) Sigma Aldrich 
Pancoll PAA 
HANKs Buffer Sigma Aldrich 
 
Table 14: Material for magnetic-activated cell separation 
Component Company 
LS collumns Miltenyi Biotec 
Pre-seperation filters Miltenyi Biotec 
QuadroMACS separator Miltenyi Biotec 
CD4 magnetic Beads Miltenyi Biotec 
CD8 magnetic Beads Miltenyi Biotec 
CD45RA magnetic Beads Miltenyi Biotec 
 
Table 15: Material and reagents used for ELISpot 
Reagent/Material Company 
ELISpot Platte Milipore 
Capture Antibody (Anti-human IFNγ-Mab1-
D1K) 
Lophius 
Detection Antibody (Ak 7B61) Lophius 
Streptavidin ABC solution vectastain Vector Laboratories 
PBS powder Biochrom 
Tween Sigma Aldrich 
Ethanol Roth 
BSA Sigma 
Peroxide Sigma 
3-Amino-9-Ethyl-carbazole Sigma 
 
Table 16: Enzymes 
Enzyme Company 
Restriction enzyme Xba I New England Biolabs 
Restriction enzyme Xho I New England Biolabs 
Restriction enzyme Spe I New England Biolabs 
T4 Ligase New England Biolabs 
Alkalic Phosphatase CIP New England Biolabs 
 
2.5.1 Kits 
Table 17: List of kits 
Kit Company 
mMESSAGE mMACHINE T7 Ultra Kit Ambion 
RNA-Recovery with RNeasy® Mini Kit-RNA 
cleanup 
Quiagen 
DNeasy Blood and tissue Quiagen 
Intracellular FACS staining BD, eBioscience 
DNA methylation kit Zymo research europa 
IL-12, IL-10, TNF, IFN, IL-6 ELISA R&D 
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cAMP determination kit Cell signaling 
ATP determination kit Thermo fischer 
DC protein assay (protein determination) BioRad 
ECL substrate solution GE Healthcare 
Cytofix/Cytoperm Fixation and Permeabilization 
Solution 
BD 
 
2.6.1 Software 
Program Company 
CellQuestPro  BD 
GraphPad Prism 6 GraphPad Software 
Microsoft Office 2011 Microsoft Redmond 
DatLab4 Oroboros instruments 
PreSense PreSens, Regensburg 
FlowJo v9.5.3 FlowJo,LLC 
ImageJ National Health Institute 
Clone manager  Sci-Ed Software 
Soft Max Molecular devices 
Mendeley Elsevier 
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2.2 Methods 
2.2.1 IDH2Mut specific stimulation of T cells 
T cell stimulation was done with peptide (IDH2 R140Q specific) loaded APCs and DCs 
expressing mutant IDH2R140Q. For peptide stimulation, peptide antigens were predicted with 
online tools and loaded on APC.  
2.2.1.1 In silico Peptide prediction 
Online tools (SYFPEITHI, BIMAS, NetMHCpan) were used to predict peptide epitopes 
specific for mutated isocitrate dehydrogenase 2. We focused on 8-10 meres spanning the 
mutated amino acid at position 140 were arginine is substituted with glutamine (R140Q). For 
all prediction tools amino acid sequence of the IDH2 R140Q protein was entered for peptide 
epitope prediction. In the following, the used platforms are summarized. Results of peptide 
prediction are summarized in Table 3.1. 
2.2.1.1.1 SYFPEITHI 
SYFPEITHI algorithm predicts T cell epitopes. In simple words, the algorithm gives scores to 
amino acid at each position of the possible peptide sequences based on known T cell receptor 
epitopes, natural ligands or binding peptides. Prediction efficacy depends on the amount of 
known binders to the selected HLA class I molecule. The higher the score, the more likely 
that the predicted peptide is a T cell epitope 
88
. 
2.2.1.1.2 BIMAS 
BIMAS algorithm predicts HLA peptide binding. It calculates half-time of dissociation to the 
selected HLA class I molecule. This is also made based on known peptide HLA class I 
molecule interactions. The higher the score, the stronger the predicted binding to the HLA 
class I molecule 
89
. 
2.2.1.1.3 NetMHCPan 
NetMHCpan server uses artificial neural networks trained with quantitative binding data of 
more than 150 different HLA molecules. The binding of peptides with a length of 8-14 amino 
acids can be predicted to HLA class I molecules (HLA-A, B, C, E and G alleles), while the 
prediction of 9mer peptides are the most accurate. As a result an IC50 is calculated, the lower 
the value the higher the affinity to the selected HLA molecule 
90
.   
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2.2.1.2 IDH2 R140Q specific Peptides  
Peptides which had a high probability to be presented on HLA class I molecules were 
purchased from JPT Peptide Technologies. In addition, peptides overlapping the mutated site 
at position 140 (R140Q) were designed and purchased also at JPT Peptide Technologies. 
Peptide sequences are shown in Table 19. 
 
Table 19: Peptide sequences of IDH2 and IDH2 R140Q specific peptides 
IDH2 IDH2 R140Q Company 
IRNILGGTVF IQNILGGTVF JPT Peptide Technologies 
IRNILGGTV IQNILGGTV JPT Peptide Technologies 
TIRNILGGTV TIQNILGGTV JPT Peptide Technologies 
SPNGTIRNI SPNGTIQNI JPT Peptide Technologies 
- QNILGGTVF JPT Peptide Technologies 
- TIQNILGGT JPT Peptide Technologies 
- GTIQNILGG JPT Peptide Technologies 
- NGTIQNILG JPT Peptide Technologies 
- PNGTIQNIL JPT Peptide Technologies 
- SPNGTIQNI JPT Peptide Technologies 
- KSPNGTIQN JPT Peptide Technologies 
- WKSPNGTIQ JPT Peptide Technologies 
 
2.2.1.4 Preparation of IDH mRNA 
In the second stimulation protocol the coding region of wild type IDH2 including an HIS tail 
was bought in a production vector at Gene ART. The insert containing the coding region and 
the HIS tail was transferred in pGEM4Z-65A vector for in vitro mRNA transcription 
91
. 
Nucleotide exchange with the quickchange kit revealed the corresponding sequence of IDH2 
R140Q. Both constructs were used to transfect DCs for T cell stimulation (IDH2 R140Q) or 
reactivity assays. In another approach the insert was further modified with a signal peptide 
and the DC lamp1 gene (purchased) and processed like described in the following.  
2.2.1.4.1 Digestion 
Plasmid was digested to isolate the coding region of the IDH2 gene from the vector. For this 
50 µl DNA was mixed with 7 µl cutsmart buffer (10x), the restriction enzymes Xba and 
Xho 3 µl each and 7 µl water. Mixture was incubated 16 h at 37°C.  
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2.2.1.4.2 Agarose gel 
After digestion an agarose gel was ran to check if digestion was successful. For that 6 g of 
agarose was mixed with 60 ml TRIS-Acetate-EDTA (TAE, 40 mM Tris-acetate and 1 mM 
EDTA, pH 8.3) buffer and heated in the microwave till it was dissolved. After solution came 
back to a temperature of 65°C 3 µl RotiSafe was added to stain DNA. After gel was hard gel 
was run at 100 V for 50 minutes. Gel was images with gel imager typhoon. 
2.2.1.4.3 PCR Purification with High pure PCR product purification kit  
PCR purification was performed between enzyme incubation, to separate the enzymes from 
the DNA. PCR product was bound on a column containing silica in high-salt buffer and eluted 
with low-salt buffer elution buffer. 50 µl DNA reaction (e.g. after digestion or 
dephosphorylation) was transferred to the column and further processed like described in the 
manufactures’ protocol Purified DNA was eluted with 50 µl elution buffer. 
2.2.1.4.5 Dephosphorylation of phosphates on the ends of the linearized vector 
Digested vector was incubated with alkaline phosphatase from calf intestinal (CIP). CIP 
nonspecifically catalyzes the dephosphorylation of 5´ and 3´ ends of DNA and RNA 
phosphomonoesters, this prevents the re-ligation of the sticky ends of the vector with itself. 
For this reaction the following components were mixed and incubated for 2 h at 37°C.  
 
Table 20: Dephosphorylation reaction 
Component Volume 
Vektor  50 µl 
10x Cut Smart Buffer  6 µl  
Nuclease Free Water 1 µl 
CIP 3 µl 
 
After the incubation time 2 µl of fresh CIP was added and sample was incubated another 30 
minutes at 55°C. After that another PCR purification was performed as mentioned above. 
2.2.1.4.6 Ligation of insert in the vector 
For ligation of dephosphorylated and purified vector and purified insert the following enzyme 
and solutions were used: 
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Table 21: Reagents for ligation 
Reagent Sample [µl] Control [µl] 
Vector  1 1 
Insert 15 - 
T4 Ligase buffer 2 2 
Nuclease Free Water 1 16 
T4 Ligase 1 1 
 
The reagents were mixed and incubated 16 h at 16°C.  During this time the ligase ligated the 
sticky ends of the vector and insert together, the product is a circular vector containing the 
insert. 
2.2.1.4.7 Transformation of Plasmid DNA 
To amplify the amount of insert containing plasmid, the construct was transformed in 
bacteria. Competent cells (JM109, E.coli) was thawed on ice and then mixed with 10 µl of 
ligated plasmid containing IDH2 wild type coding region. Bacteria solution was incubated 30 
minutes on ice and mixed now and then. Bacteria were incubated 45s at 42°C, to deliver the 
DNA plasmid into bacteria. After 1 minute incubation on ice bacteria were transferred in 1 ml 
LB (composition shown in Table 22) and incubated 40 minute at 37°C and 280 rpm shaking. 
After incubation solution was transferred in 1.5 ml tube and centrifuged 5minute at 4000 rpm. 
Flow through was discarded and pellet was resuspended in 50 µl LB media and seeded on LB 
plates supplemented with Ampicilin (100 µg/µl). Vector also contains an ampicillin resistance 
gene, which allow transformed bacteria to growth on these plates. Plate was incubated at 37°C 
overnight.  
 
Table 22: Components of lysogeny broth (LB) media 
Component Amount for 1l 
Yeast 5 g 
Trypton 10 g 
NaCl 10 g 
Millipore Water Up to 1 l after set pH to 7 
 
2.2.1.4.8 Plasmid isolation out of bacteria 
Depending on the amount of DNA needed Mini- or Midi preparation kits purchased from 
Quiagen were performed. The used method is based on alkali lysis 
92
. Buffer 2 containing 
SDS solves phospoholipids and proteins out of the cell membrane. The high pH denaturates 
proteins, chromosomal DNA as well as plasmid DNA, this is neutralized by buffer 3. In 
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parallel high salt conditions lead to a precipitation of the denaturated protein, chromosomal 
DNA and cell debris with SDS. While plasmid DNA gets renatured and solved. Plasmid DNA 
binds to a silica membrane in a centrifugation column and gets washed. Plasmid DNA gets 
eluted with nuclease free water and stored at -20°C. 
2.2.1.4.9 Concentration measurement with nano drop 
If samples with suitable size of vector and insert were observed (checked with agarose gel), 
their concentration was measured. For concentration measurement of DNA or RNA the nano 
drop device was used, it measures absorbance of sample at different wavelengths and so 
determents the concentration and contamination with proteins, phenols or other contaminants.  
 
Table 23: Values for DNA/RNA purity 
ratio Values 
260/280 DNA sample: value of 1.8 is pure DNA 
RNA sample: value of 2.0 is pure DNA 
260/230 without contamination 2.0-2.2 
with contamination lower 
 
For a measurement, 1 µl sample was transferred to the measuring chamber and spectra were 
measured. As an output you get the concentration and purity of the sample. The meaning of 
purity values is summarized in Table 23. 
2.2.1.4.10 Sequencing of inserts 
After measuring concentration of DNA construct, samples were sent to GATC for Light RUN 
sequencing. 5 µl of plasmid DNA (100 ng/µl) was mixed with 5 µl primer (5 µM) for 
sequencing (for sequence see Table 24). After receiving sequencing data from GATC, 
sequence identity was analyzed with Clone manager.  
 
Table 24: Sequencing primer  
Name Sequence 
for_pGEM4Z_S CGCCCAGCTCTAATACGACTC 
rev_pGEM4Z_S GGAGCAGATACGAATGGCTAC 
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2.2.1.4.11 Mutagenese Quickchange 
With QuikChange Site-Directed Mutagenesis Kit site directed mutagenesis was performed to 
exchange the nucleotide responsible for the exchange of arginine to glutamine in the amino 
acid sequence of IDH2 (IDH2 R140Q). A mutation site overlapping (15-20bp) primer was 
designed (total length 29bp, CCC CAG GAT GTT CTG GAT AGT TCC ATT GG) and used in a 
PCR cycling program. Addition of a restriction enzyme (DpnI) which degraded methylated 
template plasmid by sparing newly synthesized unmethylated mutated DNA. 
 
Table 25: Reagents used for quickchange mutagenese 
Component Amount 
5µl 10x reaction buffer 
50 ng Plasmid DNA 
125 ng Primer 1 
125 ng Primer 2 
1 µl  dNTP mix 
To 50µl Nuclease Free Water 
 
Reagents were mixed as described in Table 25 and transferred in PCR cycler. Cycling 
program for PCR was started as described in the following table. 
 
Table 26: Cycler protocol for quickchange mutagenesis 
Segment  Cycles  Temperature  Time  
1  1  95°C 30 seconds  
2  12–18  95°C 30 seconds  
  55°C 1 minute  
68°C 2 minutes  
(minute/kb of plasmid length) 
 
During the PCR program the mutation containing primer gets elongated to form a plasmid 
containing the mutated site. Addition of DpnI degraded methylated template vector, as a result 
all plasmid DNA contained the mutated site.  
PCR product was used for transformation in XL-blue E. coli strand as described in 
section 2.2.1.2.6. Colonies were analyzed by miniprep and sequencing as described above. 
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Correct clone was duplicated with a midiprep and used as a construct for in vitro synthesis 
and electroporation experiments.  
Finally, the construct contained the following parts. Before the insertion site a T7 
promotor was present to allow in vitro mRNA synthesis. The insert was ligated with the 
restriction enzymes XbaI and XhoI. Here the insert containing the mutated IDH2 R140Q is 
followed by a histidine tag to control expression. The construct was inserted into a pGEM4Z-
65A vector backbone. 
 
Figure 2.1: Map of pGEM4Z-65A vector containing the IDH2 R140Q coding region. Insert (IDH2 R140Q coding 
region) was ligated with XbaI and XhoI restriction sites into the pGEM4Z-65A vector. The pGEM4Z-65A vector also carried 
an ampicillin resistance which is not shown here 91. 
2.2.1.4.12 Linearization of vector 
Genes inserted to vectors containing a T7 promotor were generated like described above. 
Before mRNA transcription the vector had to be linearized and purified. Vector was 
linearized with the restriction enzyme Spe I over night with the following reagents: 
 
Table 27: Components for linearization of plasmid 
Component Amount  
DNA 20 µg 
SpeI 3 µl 
Cutsmart 10x 1:10 dependent on total volume 
Nuclease Free Water up to the next  
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2.2.1.4.13 Phenol-Chlorophorm extraction 
After linearization, DNA was purified by phenol-chlorophorm extraction to remove residual 
salts from buffers and proteins. Linearized plasmid DNA was filled up to 400 µl with DEPC 
H2O and mixed with 400 µl Phenol/Chlorophorm/Isoamylalcohol solution by vortexing. Tube 
was centrifuged 5 minutes at maximal speed to achieve phase separation. Upper aqueous 
phase was transferred in a tube with 400 µl Phenol/Chlorophorm/Isoamylalcohol and washed 
again. In total, five washing steps with Phenol/Chlorophorm/Isoamylalcohol solution were 
performed. Followed by 5 washing steps with 400 µl Chlorophorm, after the last washing the 
upper phase was transferred in an RNase free tube and mixed with 40 µl sodium acetate (3M), 
ethanol (100%) was added and tube was incubated 2-24 h at -20°C. Sample was centrifuged 
30 minutes at maximal speed at 4°C. Supernatant was discharged and pellet was resuspended 
in 1400 µl cold 70% ethanol and centrifuged as before. Supernatant was discharged, and 
pellet was air dried at room temperature. Pellet was resuspended in 40 µl DEPC H2O and 
concentration was measured with nano drop devise (2.2.1.2.8). 
2.2.1.4.14 In-vitro transcription and purification of mRNA 
Linearized and purified plasmid DNA was in vitro transcribed under RNase-free conditions. 
Prerequisite to use this mMESSAGE mMACHINE T7 Ultra Kit is a T7 RNA polymerase 
promotor which is here already inserted in the pGEM4Z-65A backbone. Protocol was 
performed as described by the manufacture. Besides the 1 h incubation where the anti-reverse 
cap analog (ARCA) was build at the 5’ end of the product was increased to 3 h. The cap 
analog is modified (OCH3 group instead of a fourth 3'-OH group) which optimized the yield 
of functional mRNA. In general caps or also the poly A tail improve the stability of the 
mRNA in vivo. After that the DNA templet was digested with DNase and a Polyadenylation 
was performed, here the incubation time was increased to 1 h. After that 700 μl RLT buffer 
and 500 μl ethanol was mixed with the reaction mix and the mRNA was purified from 
enzymes and buffer with the RNeasy Mini Kit-RNA cleanup kit from Quiagen. RNA was 
eluted with 80 µl RNase free water and stored at -80°C.  
2.2.1.4.15 RNA gel 
In vitro transcribed and purified mRNA was analyzed with an agarose gel, to check integrity, 
length and poly adenylation of RNA. 1.2 g of agarose was solved in 5 ml 10x MOPS (0.2 M 
MOPS, 20 mM sodium acetate and 10mM EDTA) buffer and 45 ml of DEPC water was 
added to get a 1.2% gel. Agarose was solved in the microwave and cooled down to 65°C 
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before 900 µl, Formaldehyde and 3 µl RotiSafe was added under the safety hood. Agarose 
solution was cast in a chamber under the hood and incubated till it was solid. Gel was 
equilibrated 30 minutes in running buffer (1X MOPS buffer, 2% Formaldehyde in DEPC 
water). Samples were prepared by mixing 2 µl RNA sample to 1 µl loading buffer 
(Formaldehyde loading buffer from mMESSAGE mMACHINE kit) and 10 µl DEPC water. 
Sample mixtures were heated to 65°C for 5 minutes and chilled on ice before gel loading. Gel 
was ran 45 minutes at 100 V. Gel was imaged with typhoon advice.  
2.2.1.5 General cell culture 
All cells used were cultivated at 37°C 5% CO2 and about 100% humidity. Cells were only 
handled sterile under the laminar flow and counted with Neubauer counting chambers and 
trypan blue. Trypan blue solution was used to exclude dead cells which appear blue in phase 
contrast microscopy because the dye is not able to move across intact cell membrane. Culture 
media supplemented with phenol red was used. Phenol red is a pH indicator; it turns reddish if 
the solution has a neutral pH and gets yellowish if pH drops. Cells produce acids during 
metabolism, for energy production necessary for cell proliferation. The color of the media, 
remaining growth area and cell number was used to decide if the cells had to be sub-cultured. 
In general if not mentioned cells were centrifuged at 1500 rpm for 5 minutes. 
2.2.1.5.1 Counting of cells 
Cells were resuspended and 50 µl cell suspension was mixed with the same volume of trypan 
blue. This results in a 1:2 dilution. This solution was transferred into a Neubauer chamber and 
2 big squared were counted. Cell number counted was divided by 2 and multiplied with 10
4
 
and the dilution factor 2.  
2.2.1.5.2 Thawing of cells 
Long time storage of cells was done in the nitrogen tank at -150°C. Cells were thawed in the 
water bath at 37°C till half of cell suspension was thawed. Then cells were put in 20 ml media 
and centrifuged. Pellet was resuspended in fresh culture media and seeded according to their 
cell number. 
2.2.1.5.3 Freezing of cells 
Cells were harvested and centrifuged. Pellet was resuspended in 1 ml FCS with 10% DMSO 
per cryo tube. Cell suspension was aliquoted into the cryo tubes and put in a freezing 
container filled with 100% isopropanol to assure a slow and gentle (cooling rate 1°C/minute) 
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cell freezing without ice crystals which could destroy the cells. Freezing container was stored 
at -80°C overnight and then cells were frozen and put on their storage place in the nitrogen 
tank. 
2.2.1.6 Isolate Peripheral blood mononuclear cell from blood samples of healthy donors 
As a source of peripheral blood mononuclear cells (PBMCs) residual cells from platelet 
donations of healthy donors from the transfusion medicine of the University Hospital 
Regensburg were used and preceded like following. 
2.2.1.6.1 Pancoll separation 
Human blood was diluted 1:2 with PBS. Mixture was carefully added dropwise on 15 ml 
Pancoll, to avoid mixing of the two phases. Tubes were centrifuged 20 minutes at 2200 rpm 
without break. After centrifugation peripheral blood mononuclear cells (PBMC) were 
separated from granulocytes and red blood cells (Figure 2.2).  
 
 
Figure 2.2: Phase separation after pancoll density separation. Diluted blood was put on top of pancoll solution. Then the 
tube was centrifuged, and the different phases separated. In the lowest phase red blood cells (RBC) accumulate, the layer on 
top is enriched for granulocytes. The transparent layer on top consists of plasma diluted with PBS, the next white interface is 
enriched for PBMCs and the layer underneath is made up by pancoll. 
 
The white interphase containing PBMCs was put in another tube and washed twice 
with 50 ml PBS (10 minutes and 5 minutes 1500 rpm) and resuspended in 40 ml PBS for 
counting. Cells were aliquoted and frozen like described in 2.2.1.3.3 and stored in the nitrogen 
tank or used fresh in experiments. 
2.2.1.6.2 Isolation of CD8 positive cells from PBMCs by Magnetic-activated cell 
separation (MACS) 
As a starting population for T cell stimulation to generate IDH2Mut specific T cell by peptide 
stimulation CD8 T cells were used. CD8 T cells were isolated from PBMCs (isolated like 
described in 2.2.1.3) of healthy donors. PBMCs were resuspended in 640 µl MACS buffer 
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(PBS supplemented with 2mM EDTA and 0,5% BSA). After adding 160 µl anti-CD8 beads 
the mixture was incubated 20 minutes at 4°C. Mixture was mixed again after 10 minutes. In 
this time the bead bound CD8 specific antibody bind to CD8 on the surface. As a result, CD8 
positive T cells are labeled with the magnetic beads. Cells were washed with 5ml MACS 
buffer to remove unbound beads. LS column was put in MACS separator and pre-separation 
filter was put on top. For equilibration 3ml of MACS buffer was put on the filter and column. 
Pellet was resuspended in 600 µl MACS buffer and put on the pre-separation filter. CD8 
positive cells are labeled with magnetic beads and remain in the column because of the 
magnetic force. Non-labeled cells leave the column as flow through. Flow through was 
collected in a tube and used as a source of antigen presenting cells for re-stimulation of 
T cells. Column was washed three times with 3 ml MACS buffer. This was done to wash 
unlabeled CD8 negative cells away and put out of the separator on a new tube. The cells were 
eluted with 5 ml MACS buffer by removing the column out of the magnetic field from the 
MACS separator and put on a 15 ml tube. Column was eluted two times with 5 ml MACS 
puffer, to get 10 ml CD8 positive cells. Cells were counted and seeded 1.5*10
6
 cells/ml in a 
24-well plate (2 m per well). 25 U/ml IL2 was added and the cells were seeded together with 
APCs. 
2.2.1.6.3 Isolation of CD4 and CD8 positive cells from PBMCs  
Electroporated cells were used to stimulated CD4 and CD8 T cells. The protocol is the same 
as described in 2.2.1.4.2 but less cells were used because CD4 T cells are more abundant in 
the blood than CD8 positive cells and anti-CD4 beads instead of anti-CD8 beads. About 20% 
of PBMCs are CD4 positive, while only 10% are CD8 positive, so only about a half of the 
starting cell number was used and CD4 specific beads. In the same way bulk CD4 T cells 
were generated for allogenic mixed lymphocyte reactions (MLR) with DCs matured and 
differentiated with or without D-2-HG. 
2.2.1.6.4 Isolation of CD45RA positive cells from PBMCs 
For allogenic MLRs to test the functional consequences of D-2-HG treatment also naïve 
enriched CD4 T cells were used. Therefore, a MACS was performed using CD45RA specific 
beads followed by FACS cell sorting of CD4 like described in the following chapter.  
2.2.1.6.5 Fluorescent associated cell sorting  
Enrichment of naïve T cell populations was done with fluorescent associated cell sorting. 
CD4 or CD8 positive cells isolated with MACS were stained with CD3 and CD45RA (55 µl 
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each) in PBS supplemented with 2% FCS. CD45RA positive cells isolated the same way were 
stained with CD4-V450 antibody. After incubation of 30 minutes at 4°C in the dark, cells 
were washed with PBS supplemented with 2% FCS and filtered to remove cell clumps. Cells 
were resuspended in a concentration of 20x10
6
 cells/ml in PBS supplemented with 2% FCS. 
Cells were sorted by Irina Fink (AG Edinger/Hoffman). Double positive population (CD3-
APC/CD45RA-PE) or CD4 positive population was sorted in a tube containing 1 ml human 
sera. Human sera get diluted with the sorted cells solved in FACS flow. Cells were counted 
after cell sorting and seeded in the desired concentration. 
2.2.1.6.6 Generating of mature FAST-DC for T cell stimulation 
FAST-DCs were generated like described by Dauer et al. and Felzmann et al. 
93,94
. PBMC 
isolated from whole blood cells like described in 2.2.1.4 were seeded in a 6-well plate 
(15-20 x10
6
/well) and incubated 1.5 h in the incubator (37°C, 5% CO2) in AIMV+1% HS. At 
this time, the monocytes should get adherent to the surface, while other cells like mainly 
lymphocytes should stay in suspension. After incubation wells were washed with warm PBS 
till only the adherent monocytes were left. Cells were cultured 500 IU/ml IL-4 and 1000 U/ml 
GM-CSF in AIMV+1% HS for at least 24 h. For maturation 1000 IU/ml IL-6, 10 ng/ml TGF-
β, 10 ng/ml IL-1β and 1µg/ml PGE2 were added. After another 24 h the cells can be harvested 
with cold PBS and used for peptide incubation or electroporation. 
2.2.1.6.7 Transfection of in vitro transcribed mRNA and T cell stimulation with DCs 
expressing IDH2 R140Q 
Electroporation was performed to transfer in vitro transcribed mRNA of IDH2 R140Q into 
APCs adopted form Schaft et al. 
91
. APCs should translate the mRNA in a protein and process 
and present it on their surface. First the cells were washed with RPMI and optiMEM both 
without phenol red or other supplementaries (1500 rpm, 5 minutes). Cell pellet was 
resuspended in 200 µl optiMEM per electroporation sample (maximum 10x10
6
 cells). In vitro 
transcribed mRNA (20 µg) was put in an electroporation cuvette together with 200 µl cell 
suspension. DCs were electroporated with 400 V for 5 ms (square-wave pulse). Cells were 
transferred in culture media provided in a 6-well plate and cultivated 16 h. After 16 h 
expression of IDH2 R140Q was confirmed by flow cytometric detection of HIS tag. 
Electroporated DCs were frozen in small portions and thawed on the day of T cell stimulation 
or T cell reactivity test with ELISpot. For T cell stimulation DCs were thawed and irradiated 
(70 Gy). DCs were seeded together with bulk or naïve enriched CD4 and CD8 T cells in 24-
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well or 96-well plates. In 24-well plates 1.5x10
6
 T cells were seeded together with 1.5x10
5
 
DCs, in 96-well plates 1x10
5
 T cells were seeded with 1x10
4
 DCs. AIMV was supplemented 
with 10% human sera and IL-7 (5 ng/ml), IL-12 (2 ng/ml) and IL-15 (5 ng/ml). T cells were 
re-stimulated every 7 days with electroporated DCs. On day 14 IL-12 was exchanged with IL-
2. On day 14 the first IFNγ ELISpot was performed by using 20 µl of T cell culture for each 
well of the IFNγ ELISpot well to test each well for reactivity.  
 
2.2.1.6.8 T cell stimulation with Peptide loaded APCs 
T cells were isolated from blood of healthy donors like described in 2.2.1.4.1. CD8 and CD4 
T cells were isolated like described in 2.2.1.4.2 and 2.2.1.4.3 or further enriched for naïve T 
cells (2.2.1.4.4 and 2.2.1.4.5). T cells were seeded in 24-well plates in AIMV supplemented 
with 10% human sera and IL-7 (5 ng/ml), IL-12 (2 ng/ml) and IL-15 (5 ng/ml). For 
stimulation PBMCs and DCs were incubated with 10 mM peptide (IQN9/IQN10) for 4h at 
37°C. PBMCs were irradiated with 35 Gy and DCs with 70 Gy and washed before seeding. In 
each well 1.5x10
6
 T cells and 3x10
6
 PBMCs or 1.5x10
5
 DCs were seeded. Every 7 days T 
cells were re-stimulated with peptide loaded APCs like for the first stimulation. IL-12 was 
exchanged with IL-2 on day 14 of culture. On day 14+5 first functional analysis of T cells 
were done by IFNγ ELISpot and repeated on day 21+5 or 28+5. This protocol was adopted 
from Thomas et al. 
95
. 
2.2.1.6.9 Measurement of IFNγ secretion by ELISpot 
Enzyme-linked immunosorbent spot (ELISpot) is an enzyme based assay to determine 
cytokine producing cells 
96
. ELISpot plates were activated with 35%vol ethanol in water. 
After washing tree times with PBS, plate was coated with first antibody against human IFNγ 
over night at 4°C. The antibody solution was discarded and the plate was washed three times 
with PBS supplemented with 0.05% SDS. To avoid unspecific binding the plate was blocked 
with culture media (AIMV supplemented with 10% HS) for at least one h at 37°C. As target 
cells autologous PBMCs were used they were pre-incubated with the peptides (10
-6 
M) 1h at 
37°C. Responder T cells (15,000 cells/well) and target cells (50,000 cells/well) were seeded 
and incubated 20h at 37°C.  
Plate was washed six times with washing buffer (PBS supplemented with 0.05% SDS) 
and incubated with a second antibody for 2h at 37°C. In this step the IFN was now between 
the first antibody coated on the plate and the second biotinylated antibody similar like an 
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sandwich ELISA. 30 minutes before incubation stops the streptavidin peroxidase solution was 
prepared (10 ml PBS supplemented with 0.001% Tween + 1 drop solution A + 1 drop solution 
B) and incubated 30 minutes in the dark at room temperature. After washing six times with 
washing buffer and tapped it dry the solution was added and the plate was incubated 1h at 
room temperature in the dark. Plate was washed with washing buffer and PBS three times 
each. Then the AEC-substrate solution (3-Amino-9-Ethyl-carbazole, for 500 ml 10 pills of 
dimethylformamid were solved in acetate buffer) supplemented with H2O2 (0.5 µl/ml) was 
incubated 8-10 minutes depending on the signal strength. In this step the AEC substrate 
solution was oxidized by the peroxidase. Plate was washed with tap water, the bottom was 
removed and the plate was air dried. Plate was analyzed with CTL ELISpot Reader. 
2.2.3 Analyzing effect of D-2-HG metabolism and differentiation to monocyte-derived 
DCs 
In the following methods are shown to analyze the effect of D-2-HG on DC differentiation, 
maturation and metabolism. 
2.2.3.1 Isolation of monocytes by elutriation 
PBMCs were isolated from leukapheresis products of healthy donors by density gradient 
centrifugation over a pancoll (2.2.1.4.1). Monocytes were isolated from PBMCs by 
countercurrent centrifugation (elutriation). 
Elutriation was performed in a Beckman Avanti J-20XP centrifuge equipped with an 
elutriation centrifugation rotor and a flow chamber. All components were sterilized with 6% 
H2O2 for 20 minutes and washed twice with PBS. Pump was calibrated at 2500 rpm and 4°C 
with Hanks balanced salt solution (BSS). Pump was calibrated and PBMCs were loaded at the 
lowest flow rate (about 53 mL/min) after collecting one fraction the flow rate was increased to 
a maximum of about 130 mL/min. In the last fraction monocytes were enriched because there 
are the largest cells within the PBMCs, but there were also monocytes in the fractions before 
detectable. The first fraction was enriched for platelets, in the following fractions B and T 
cells and neutral killer cells were enriched. Monocyte enrichment was analyzed by CD14 
antigen expression (only expressed on monocytes and macrophages), the purity was higher 
than 85%.  
Monocyte fraction (last fraction) was centrifuged (8 minutes, 300×g, 4°C), 
resuspended in RPMI culture medium and counted. Monocyte yield was donor dependent, 
typically between 8-15% of total PBMCs.  
Material and Methods 
 
35 
 
2.2.3.2 Generation of monocyte-derived DCs  
DCs were generated using the monocyte fraction gained by elutriation as described previously 
71
. Briefly, monocytes were seeded in RPMI supplemented with 10% FCS, glutamine (2 mM), 
penicillin (100 U), streptomycin (100 µg/ml), HEPES (10 mM), IL4 (150 U/ml), GM-CSF 
(230 U/ml) at a concentration of 2x10
6
 /well in a 6-well plate in 3 ml of medium or 7x10
6
 in a 
T25 culture flask in 10 ml medium. D-2-HG was added immediately after seeding the cells 
once for the whole period of culture. Cells were cultured for 7 days to generate immature 
DCs. For maturation 100 ng/µl LPS was added for 24 hours. Peroxide (1 mM), vitamin C (2 
mM), trolox (50 µM), pioglitazone (25 µM) and metformin (5 mM) were added together with 
D-2-HG directly after seeding of the cells. 
2.2.3.3 Electron microscopic analyses of DCs treated with D-2-HG 
After generating immature and mature DCs treated with or without D-2-HG like described in 
2.2.2.2., DCs were harvested (1x10
7
 cells per treatment) and washed with PBS and transferred 
in a 1.5 ml centrifugation tube. DCs were centrifuged at 300g for 5 minutes, pellet was fixed 
with Karnovsky-fixative for at least 2 h and further processed and analyzed in cooperation 
with the pathology department of the University Hospital Regensburg. 
2.2.3.4 Phagocytosis Assay 
Competent JM109 were transformed with pGEM4Z-65A vector carrying the GFP gene and an 
ampicillin resistance (see Transformation in section 2.2.1.2.6) and plated on LB plates 
containing ampicillin (100 µg/ml).  
One colony was picked and transferred in 25 ml LB media containing ampicillin (100 
µg/ml). Bacteria were incubated 10 to maximal 12 h at 37°C and 280 rpm. 500 µl of bacteria 
suspension was transferred in 49.5 ml LB media containing ampicillin (100 µg/ml) and 
incubated till the optical density was between 0.65 and 0.85 (165-195 minutes) at 600 nm. 
Suspension was transferred in 50 ml tube and span down (1500 rpm, 10 minutes). Pellet was 
resuspended in 2 ml phagocytose buffer (10% not heat inactivated human sera, 20% PBS, 
70% BSS, 1 mM CaCl2 and 0.5 mM MgCl2) and incubated 30 minutes at 37°C and 180 rpm. 
In the meantime 250.000 cells per sample were resuspended in 500 µl phagocytose buffer and 
transferred in a 24-well plate. The plate was pre-warmed in the incubator (37°C, 5% CO2). 
OD600nm was measured in bacteria suspension (1:10 diluted in phagocytose buffer) and cell 
number was calculated according to the following equation: 
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𝑐𝑒𝑙𝑙𝑛𝑢𝑚𝑚𝑒𝑟
𝑚𝑙
= 8 × 109 × 𝑂𝐷600𝑛𝑚 1:10 𝑑𝑖𝑙𝑢𝑡𝑒𝑑 
6,25x10
6
 cells in 500 µl phagocytose buffer were used per sample and transferred in 
24-well plate. Here the MDDCs got in contact with the bacteria (1 MDDC to 25 bacteria 
cells). There was also a negative control were no bacteria cells were added. After 10 minutes 
of incubation in the incubator the cells were transferred in a FACS tube and spun down (1500 
rpm, 10 minutes). Another set of samples were incubated 30 minutes to distinguish bacteria 
on the surface and inside the cell, because in 30minutes all GFP expressed by phagocytized 
bacteria should be degraded and only the bacteria which stick to the surface will make a GFP 
signal. Pellets were resuspended in 200 µl FACS buffer (PBS+5% FCS) and measured with 
the Calibur flow cytometer in the FITC channel.  
2.2.3.5 Allogeneic mixed lymphocyte reaction 
To investigate the stimulation capacity of DCs allogeneic mixed lymphocyte reactions (MLR) 
were performed like described previously 
72
. Immature DCs generated like described in 
2.2.2.2 were co-cultivated with allogenic CD8 or CD4 T cells isolated like described in 
2.2.1.4.1, 2.2.1.4.2 and 2.2.1.4.3. T cells were seeded in a 96-well plate together with DCs 
generated in the presence or absence of D-2-HG in RPMI supplemented with 2 mM 
glutamine, 25 U/ml IL2 and penicillin streptomycin. 100,000 T cells were cultured with 
10,000 DCs for one week. Activation of T cells was analyzed using flow cytometry. Cells 
were stained on day 4 of culture with antibodies against the IL-2 receptor CD25 and CD69 
which are early activation marker of T cells. In addition, staining of FoxP3 was performed to 
analyze if regulatory T cells were generated. The staining was repeated on day 7, where also 
the cell number was counted.  
2.2.3.6 Enzyme-linked immunosorbent assay (ELISA) 
During the differentiation and maturation of monocytes to dendritic cells supernatants were 
collected for cytokine secretion measurement. Supernatants were stored at -20°C. An ELISA 
is a biochemical test to detect antigens in solution is analyzed by specific antibodies, one 
antibody is coated on the plate to capture the antigen, another specific antibody binds the 
analyte at another side to increase specificity of the detection the second antibody is coupled 
to an enzyme which reacts with the substrate which leads to a shift in its emission, this can be 
measured with a plate reader at 450 nm. 
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The plates were coated overnight with the capture antibody specific for the cytokine of 
interest in PBS. Plate was washed three times with 250 µl wash buffer (PBS supplemented 
with 0.05% Tween 20). Residual liquid was removed and plate was blocked with 300 µl 
reaction diluent (PBS supplemented with 1% BSA) for one h. After the plate was washed 
again and residual liquid was removed, the plate was loaded with standard and sample probes. 
A series of 1:1 dilutions were made from a 2000 pg/ml (or 1000 pg/ml) stock to 31.3 pg/ml 
and 100 µl was pipetted in each well (duplicates) on the first two rows of the plate. 
Supernatant samples were loaded undiluted or 1:10 diluted in reaction diluent. Plate was 
incubated for 2 h and washed three times before 100 µl of the detection antibody was added 
for 2 h. Plate was washed and incubated 20 minutes with 100 µl streptavidin-HRP working 
solution. Plate was washed and incubated 20 minutes with the 100 µl substrate solution, then 
the stop solution was added to the well. The plate was measured at 450 nm with a plate 
reader. Calibration curve and concentration of the samples was calculated by the software of 
the plate reader. 
2.2.3.7 Measurement of cAMP level by ELISA 
cAMP levels were measured in immature DCs (cultured for 7 days) differentiated in the 
presence or absence of 20 mM D-2-HG. iDCs were harvested and 1x10
6
 cells were placed in 
tubes, centrifuge for 7 minutes at 1400 rpm, supernatants were discarded and DCs were 
washed two times in 1 ml of cold PBS. Cells were then lysed by adding 200 μl 1x lysis buffer 
(included in the cAMP determination kit diluted in H2O, stored at -20°C), incubated on ice for 
10 minutes, centrifuged for 4 minutes at 1600 rpm and supernatants containing cAMP were 
collected and stored at -80°C. cAMP levels were measured by using the cAMP XP Assay 
according to manufacturer protocol. 
2.2.3.8 Flow cytometric analyses 
Flow cytometry allows the detection of extra- and intracellular molecules by binding the 
target of interest to an antibody conjugated to a fluorophore on a single cell level. The dye 
gets excited by a laser beam and the fluorescence signal is detected. Measuring the 
fluorescence intensity allows an estimation of the abundance of the molecule of interest, thus 
flow cytometry is a semi-quantitative method 
2.2.3.8.1 Staining of surface molecules  
Cells were harvested, transferred in polystyrene tubes and washed with PBS supplemented 
with 2% FCS (1500 rpm, 5 minutes). Supernatant was discarded and cells were stained with 
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antibodies coupled to specific fluorescence dyes for 20 minutes in the dark. Subsequently, 
cells were washed with 1 ml PBS supplemented with 2% FCS and resuspended in 250 µl PBS 
supplemented with 2% FCS. Cells were measured using a BD Calibur. Data analysis was 
performed using the FlowJo software. 
2.2.3.8.2 Intracellular staining  
Intracellular FOXP3 staining was combined with staining of extracellular surface markers. 
Extracellular markers were stained first as described above, and subsequently cells were 
permeabilized by incubating cells in Fix-Perm solution for 20 minutes at 4°C. After washing 
twice FoxP3 antibody was added, incubated for 20 minutes at 4°C. Cells were washed twice 
and resuspended in PBS supplemented with 2% FCS for the measurement. To analyze 
intracellular expression of HLA class II molecules as well as the active form of mTOR DCs 
were washed with PBS supplemented with 2% FCS and incubated with Fix-Perm solution and  
further processed as described above.  
2.2.3.8.3 Measurement of cytosolic ROS with 2′,7′-Dichlorofluorescin diacetate  
2′,7′-Dichlorofluorescin diacetate (DCFDA) was solved in pure methanol to get a 400 µM 
stock solution. Stock solution was freshly diluted 1:50 with media and 12.5 µl were added to 
500 µl of cell suspension in a FACS tube. DCFDA comes as a AM ester which makes it cell 
permeable, unspecific esterases cleave this ester-bounds and release the dye in the cytosol 
where it can react with ROS. The more ROS is present in the cytosol the higher the 
fluorescent intensity of the cells. As an unstained control cells only were transferred in a 
FACS tube. Cells were incubated 20 minutes in at 37°C in the incubator. Cells were washed 
with cold PBS, resuspended in PBS supplemented with 2% FCS and immediately analyzed in 
the FL-1 channel of the BD Calibur flow cytometer. Data were analyzed with the FlowJo 
software. 
2.2.3.8.4 Cystine staining 
Cystine uptake was analyzed using a FITC coupled cysteine probe kindly gifted by Dr. Peter 
Siska who established a protocol to produce cysteine FITC 
97
. Cells were washed with PBS 
and re-suspended in 250 µl Krebs buffer (115 mM NaCl, 2 mM, KCl, 1 M NaHCO3, 1 mM 
MgCl2, 0.25% BSA) and incubated for 1h at 37 °C and 5% CO2. To stain the cells 250 µl of 
Krebs buffer containing 2 µM cytine FITC was added 20 minutes at 37 °C and 5% CO2 (final 
concentration 1 µM cystine FITC). Cells were washed twice with cold PBS containing 2% 
FCS and analyzed in the FL1 channel of a FACS Calibur flow cytometer. 
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2.2.3.8.5 Measurement of mitochondrial ROS with MitoSox red 
Mitochondrial superoxides were measured with the fluorescent MitoSox probe. MitoSox is 
cell permeable and has a cationic residue which targets into the mitochondria. Here MitoSox 
red gets oxidized by superoxide and exhibits red fluorescence. MitoSox red was solved in 
pure DMSO to get a 5 mM stock. Cells were incubated with 5 μM MitoSox in buffer 
containing 135 mM NaCl, 1 mM MgSO4, 20 mM HEPES, 0.4 mM KH2PO4, and 5 mM KCl 
for 10 minutes at 37 °C and 5% CO2. Cells were washed with PBS containing 2% FCS and 
analyzed in the FL-3 channel of a FACS Calibur flow cytometer. 
2.2.3.8.6 Staining of mitochondria with Mitotracker Green  
MitoTracker green is a fluorescent dye which stains whole mitochondria volume. On day 7 
DCs were harvested and 400,000 DCs were resuspended in 1 ml RPMI supplemented with 
2 mM glutamine. Mitochondria were stained with 50 nM MitoTracker green solved in DMSO 
for 2 h at 37°C. Cyclosporine A (60.8 nM) inhibits mitochondrial permeability transition pore 
opening and for that was added during incubation to inhibit the transport out of mitochondria. 
Cells were washed with PBS supplemented with 2% FCS and resuspended in 200 µl PBS 
supplemented 2% FCS for FACS measurement (FL-1). For the unstained control, the same 
amount of DMSO was added as added with MitoTracker staining. 
2.2.3.9 Determining mitochondrial respiration by high-resolution respirometry 
2.2.3.9.1 Oxygen measurement in whole cells 
Oxygraph high resolution respirometry is a method to measure the oxygen consumption rate 
(OCR) in whole cells, like previously described 
98
. The system is closed so absolute values 
can be measured. The aperture has two measuring chambers to measure two samples 
simultaneously. On one side of the chamber there is a clark electrode which is an oxygen 
sensitive electrode. On the button of the chamber there is a stirrer, which provides a constant 
oxygen concentration in the whole chamber. 
For storage the chamber was filled with 70% ethanol, before starting the measurement 
it was aspirated and the chamber was washed three times with Millipore water. Media was put 
in the chamber and measurement was started with open chambers to measure the maximal 
solubility of oxygen as it depends on air pressure it can vary from day to day. When the 
oxygen level is constant the monocyte suspension (5-7x10
6
 in 2.5 ml, fresh after elutriation or 
incubated over night in the fridge) in RPMI+10%FCS +IL4 +GM-CSF could be put in the 
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chambers and the actually cell number was determined. After the oxygen signal was stable 
(after 15-20 minutes) the substances (D-2-HG or media) were added, followed by the addition 
of LPS (1 ng/ml). Oxygen consumption was measured 1-1.5 h, then oligomycin was added.  
Oligomycin inhibits ATP synthase (complex V), after the signal was stable the cells were 
uncoupled with Carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP). FCCP was 
added stepwise (0.5 µM steps) till the signal did not increase by further addition. Complex II 
was inhibited with Rotenone before Myxothiaxol was added (Inhibitor of complex I) which 
should set the oxygen consumption to a minimum. Concentration of inhibitors and FCCP are 
shown in the following table (Table 26). After the run the chamber was washed with 
Millipore water three times and incubated 20 minutes with 70% ethanol, 10 minutes with 
100% ethanol and then stored in 70% ethanol. 
 
Table 28: Substances used to modulate oxygen consumption 
Compound Final concentration in chamber  
LPS 1 ng/ml 
Oligomycin 2 μg/ml  
FCCP 1-7 µM 
Rotenone 0.5 μM 
Myxothiazol 0.5 μM 
 
2.2.3.9.2 Oxygen measurement in permeabilized cells 
Oxygen concentrations can also be measured after adding specific substrates if the membrane 
of the cells assayed is destroyed with digitonin 
99
. For this oxygraph protocol the cells were 
resuspended in MIRO5 media (pH 7.1), which is a suitable media to stabilize mitochondria 
(for composition see following Table 29).  
 
Table 29: Components of MIRO5 used for permeabilzed cells in oxygraph 
Compound  Final concentration 
EGTA 0.5 mM 
MgCl2 6 H2O 3 mM 
Lactobionic acid 60 mM 
Taurine 20 mM 
KH2PO4 10 mM 
HEPES 20 mM 
D-Sucrose 110 mM 
BSA, Essentially Fatty Acid Free 1 g/l 
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As with the culture media in the protocol described in section 2.2.2.9.1 first the 
maximum oxygen saturation is measured with the MIRO5 media. If the oxygen consumption 
rate (OCR) in stable after adding the cells Malate is added. Malate stabilizes the mitochondria 
but does not increase OCR. Membrane permeabilization is done with digitonin. Digitonin act 
as a cholesterol-complex agent, which binds cholesterol molecules located in the cell 
membrane. Complex formation leads to a reorganization of the cell membrane where pores 
are formed.  Through these pores all substrates flush out of the cell and OCR decreases. Now 
defined substrates can be added and the increase of OCR can be measured. OCR was 
measured in the two chambers in parallel. In one chamber water was added as a vehicle 
control in the other D-2-HG solved in water, followed by the addition of ADP and MgCl2 as a 
substrate for ATP synthase. Then other substrates of complex I like pyruvate and glutamate, 
or complex II succinate can be added (concentrations in Table 30). Cells were uncoupled with 
FCCP and inhibited with rotenone and myxothiaxol, then Ascorbate and TMPD was added. 
TMPD is an artificial substrate of complex IV and leads to a high increase in OCR. Ascorbate 
is used to reduce TMPD, which gets easily oxidized. At last sodium azide is added to kill the 
cells and measure auto oxidation of the added substances. Champers were cleaned like 
described in section 2.2.2.9.1. 
 
Table 30: Substrates used to measure activity of different complexes of electron transport chain 
Compound Final concentration  
Malate 2 mM 
Digitonin 10 μg/10-6 cells 
ADP 5 mM 
MgCl2 5 mM 
D-2-HG 2-3 mM 
Pyruvate 5 mM 
Glutamate 10 mM 
Succinate 10 mM 
FCCP 1-7 µM 
Rotenone 0.5 or 0.1 μM 
Myxothiazol 0.5 μM 
Ascorbate 2 mM 
TMPD 0.5 mM 
Sodium azide 100 mM 
 
2.2.3.10 Analyze of pH value and oxygen concentration of DCs during differentiation 
from monocytes 
With the PreSens technology pH and oxygen concentration was monitored on line during DC 
differentiation for 7 days. The tissue culture plates were coated with a sensor in the middle of the well. 
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The sensor can monitor either pH or oxygen non-invasive in living cells. An LED lamp excites the 
sensor, which emits fluorescence in response. Molecules like oxygen and protons quench the 
fluorescence signal and by this the concentration of this molecule can be measures in 24-well plates 
0.7x10
6
 monocytes were seeded in 1 ml of RPMI culture medium in oxo or hydro dishes. DCs 
were treated with different concentrations of D-2-HG. DCs were cultured 7 days. 
Measurements were performed at 37°C, concentration was measured every 5 minutes. 
2.2.3.11 Lactate and glucose determination 
Lactate was determined in collaboration with the clinical chemistry of the University Hospital 
Regensburg. Glucose measurement was done with an enzymatic assay performed by 
Stephanie Färber (AG Kreutz, Internal Medicine III, University Hospital Regensburg). 
2.2.3.12 Methylation analysis  
During differentiation from monocyte to DC there are regions which get demethylated. 
Demethylated regions are associated with an active gene expression. Methylation analysis 
was performed by EpiTyping technology. With this method methylated CpG loci can be 
determined by mass spectrometry.  
2.2.3.12.1 Culture and treatment of DCs for methylation analysis 
For the d 0 sample monocytes were washed twice with cool PBS and cell pellet was frozen at 
-20°C. For the other time points monocytes were seeded on 6 well plates, per well 3x10
6
 cells 
were seeded in 3 ml RPMI supplemented with 10% FCS, glutamine (2mM), penicillin 
(100 U) streptomycin (100 µg/ml), HEPES (10 mM), IL4 (150 U/ml), GM-CSF (230 U/ml). 
Four different treatments were cultured: 
1) DC 
2) 20 mM D-2-HG 
3) 2 mM vitamin C 
4) 20 mM D-2-HG and 2 mM vitamin C 
DCs were harvested after 16 h, 66 h and 7 d. As with the d 0 monocytes, DCs were washed 
twice with cold PBS and the cell pellet was stored at -20°C. 
2.2.3.12.2 Isolation of DNA with DNeasy Blood and tissue Kit from Qiagen and 
methylation analysis 
For the isolation of DNA the DNeasy Blood and tissue Kit from Qiagen was used.  Samples 
are first lysed using proteinase K. Buffering conditions to provide optimal DNA binding 
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Conditions. The lysate is loaded onto spin columns, during centrifugation, DNA is selectively 
bound to the membrane as contaminants pass through. DNA is then eluted in DNA was eluted 
by 200 μl Buffer AE and was further processed to analyze methylation status of DCs during 
differentiation in cooperation with the working group of Prof. Michael Rehli (Internal 
Medcine III, University Hospital Regensburg).  
  The genomic position of the analyzed CpG residues are summarized in Table 31 the 
corresponding amplicons have been described in reference 
100
 and 
101
. 
 
Table 31: Genomic position of analyzed CpG residues 
 
 
2.2.3.13 Protein isolation  
Monocytes (4x10
6
) or DCs (2.5x10
6
) were washed twice with cold PBS (5 minutes, 
1500 rpm) and transferred to a 1.5 ml tube. Pellet was resuspended in 50 µl RIPA buffer 
(50 mM NaCl, 1.0% IGEPAL
 
CA-630, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, 
pH 8.0) and mixed thoroughly by vortexing for 1 minute. Tube was incubated 5 minutes at -
20°C, thawed and mixed again. Tube was frozen in liquid nitrogen. Lysate was stored 
at -80°C or centrifuged immediately on high speed (13000 rpm) for 15 minutes. Supernatant 
was at -80°C. 
2.2.3.14 Fractionized protein isolation 
Lysates of cytosolic separated from other proteins were used to analyze the activity of protein 
kinase C (PKC). PKC is only active in the membrane, so the level of PKC in the cytosol 
compared to the membrane fraction give rise of PKC activity. 
Buffer 1  
150 mM NaCl 
50mM HEPES 
Buffer 2  
RIPA Buffer 
Protease Inhibitor Cocktail 
Gene Chromosomal Location  
(GRCh38/hg38) 
Amplicon (for bisulfite-
treated DNA) 
CCL13 chr17:34356259-34356559 Epi00109_CCL13.1 
a
 
STAT5 chr17:42283625-42283783 Epi00104_STAT5A.2 
a
 
C9ORF78 chr9:129839252-129839471 Epi00148_C9ORF78.3 
a
 
MMP7 chr11:102530563-102530766 Epi00162_MMP7.1 
a
 
HOXB1 chr17:48530488-48530489 Epi00193_HOXB1_01 
a
 
CD207 chr2:70837911-70838410 Epi00116_CD207.2 
a
 
CLEC10A chr17:7079646-7080109 Epi00184_CLEC10A.1
 a
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Protease Inhibitor Cocktail 
10 mM NaF (Phosphatase inhibitor) 
10 mM NaF (Phosphatase inhibitor) 
 
 DCs or monocytes were washed twice with cold PBS (1500 rpm, 5minutes) and 
counted. Pellet was resuspended in 100µl buffer 1 supplemented with 1 µl digitonin per 
million cells. Cells were mixed and incubated 10 minutes on ice, while mixing several times. 
Cell lysis was confirmed by tryphan staining. Tube was centrifuged 10 minutes at 2000 g at 
4°C. Supernatant containing the cytoplasmic proteins was transferred in a new tube and stored 
at -80°C. Pellet was resuspended in buffer 2 and mixed thoroughly by vortexing 1 minute. 
Tube was incubated 5 minutes at -20°C, thawed and mixed again. Tube was shock frozen in 
liquid nitrogen. Lysate was stored at -80°C or centrifuged immediately on high speed 
(13000 rpm) for 15 minutes. Supernatant and pellet was stored at -80°C. 
2.2.3.15 Protein determination by Lowry 
Protein determination was done like previously described by Lowry et al. 
102
. Samples were 
thawed on ice. In the meantime, bovine serum albumin was diluted from a 30 mg/ml stock to 
1.5 µg/µl (1:20). This first standard solution was further serial diluted 1:2 to get 
concentrations of 0.750-0.047 µg/µl. Samples were diluted 1:10. 5 µl sample and standard 
was transferred in a well of a flat button 96 well plates. In each well 25 µl of a mixture of 
solution A containing the alkaline copper tartrate solution (1 ml) and solution S (surfactant 
20 µl) and 200 µl solution B containing Folin reagent. Plate was incubated 15 minutes at 
room temperature while shaking. In this time proteins react with the copper and reduce Folin 
reagent by the loss of oxygen atoms. This results in a color reaction from yellow to blue. This 
shift in the absorption spectrum was measured at 650 nm. 
2.2.3.16 Analyzing protein of interest by western blot 
2.2.3.16.1 SDS gel electrophoresis 
Protein samples were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) with a discontinuous gel composed of a stacking and separating gel layers, 
which differed in salt and acrylamide (AA) concentration. The stacking gel contained of only 
5% AA and therefore was used to concentrate the sample on the edge to the separation gel 
containing a higher but varying concentration of AA depending on the protein size to detect.  
Required Buffers and solutions 
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1) Separating gel buffer 1.5 M Tris/HCL (pH 8.8) 
2) Stacking gel buffer 0.5 M Tris/HCl (pH 6.8)  
3) SDS sample buffer (2 x): 20% v/v Glycerin, 125mM Tris/HCL, 4% SDS, 10% 
2-Mercaptoethanol, 0.02% Bromphenolblue  
4) Laemmli buffer (5×): 40 mM Tris/HCL, 0.95 M Glycine, 0.5% SDS 
 
 Separating Gel Stacking Gel  
 7.5% 10% 12% 15% 5% 
Stacking Gel 
Buffer  
- - - - 2.5 ml 
Separating 
Gel Buffer  
2.5 ml 2.5 ml 2.5 ml 2.5 ml - 
SDS (10%)  0.1 ml 0.1 ml 0.1 ml 0.1 ml 0.1 ml 
AA (30%)  2.5 ml 3.3 ml 4.0 ml 5.0 ml 1.665 ml 
Millipore 
Water  
4.9 ml 4.1 ml 3.4 ml 2.4 ml 5.735 ml 
 
First the separation gel was produced and transferred between the glass plates in a gel 
caster, followed by the stacking gel containing the comb where the samples are loaded. 10-
20 µg protein was loaded, and gel was run in laemmli buffer at 80 V. The volts were 
increased to 100 V and 120 V in the separation gel. The gel ran 1.5-2 h. 
2.2.3.16.2 Western blot 
After SDS-PAGE separated proteins were transferred on a polyvinylidene fluoride (PVDF) 
membrane using a three-buffer semi-dry system (Towbin et al. 1979). On the membrane one 
specific protein was detected with a corresponding antibody. 
2.2.3.16.3 Protein transfer on membrane 
Required buffers:  
Buffer A: 0.3 M Tris (pH 10.4), 20% methanol in water 
Buffer B: 25 mM Tris (pH 10.4), 20% methanol in water  
Buffer C: 4 mM ε-amino-n-caproic acid (pH 7.6), 20% Methanol in water  
The membrane was cut to gel size, activated with 2-propanol and incubated in buffer B. Three 
whatman filter pre-wet with buffer A were placed on the anode followed by three filter pre-
Material and Methods 
 
46 
 
wet with buffer B. On top the membrane was put covered by the SDS-PAGE gel. Three 
whatman filter pre-wet with buffer C were put above the gel. In between air bubbles were 
removed. Protein transfer was conducted for 50-60 minutes depending on the size of the 
protein of interest.  
 
2.2.3.16.4 Detection of protein of interest 
After protein transfer membrane was blocked with 5% milk in wash buffer for 1 h at room 
temperature during shaking. Membrane was incubated over night with the first antibody 
recognizing the protein of interest at 4°C under continuous shaking. Antibodies and dilutions 
are summarized in Table 10. On the next day membrane was washed three times for 15 
minutes. Membrane was incubated with the secondary antibody tagged with horse radish 
peroxidase (HRP) recognizing the constant domain of the first antibody for 1 h at room 
temperature under continuous shaking. After another three washes membrane was developed 
with ECL solution. It contains a substrate, which gets converted by HRP light. This light 
signal was detected by a chemiluminescence imager. 
2.2.3.16.5 Elimination of antibodies bound on membrane 
As a loading control actin was detected on all membranes, for that the antibodies were 
removed by a re-blot solution. Membrane was incubated 15 minutes with the re-blot solution 
at room temperature on the shaker. Membrane was washed three times, blocked and further 
processed like described above. 
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3 Results  
3.1 Generation of IDH 2 R140Q specific T cell 
In this part of the project the aim was to generate IDH2 R140Q specific T cells. For this, two 
main approaches were used one was the stimulation of T cells with autologous IDH2 R140Q 
peptide loaded DCs the other the stimulation with autologous DCs expressing mutant IDH2 
R140Q protein upon mRNA electroporation. 
3.1.2 HLA binding prediction by in silico programs  
To find IDH2 R140Q-derived peptides for specific T cell stimulation online available in silico 
tools were used to predict peptide binding to specific HLA molecules. Algorithms for HLA 
class I binding prediction are in general more reliable than HLA class II specific 
103
, so the 
focus was on HLA class I restricted peptides, which mostly consist of 8-10 amino acids. The 
programs BIMAS 
89
, SYFPETHI 
88
 and NET MHC Pan 
90
 were used for prediction of 9- or 
10-mers binding to HLA class I molecules. 
Table 3.1: Result scores of in silico HLA binding prediction 
Amino acid sequence 
(one letter code) 
HLA restriction BIMAS SYFPETHI NET MHC 
Pan 
IRNILGGTVF B*15:01 0.7 13 2843 
IQNILGGTVF B*15:01 274.0 23 12 
IRNILGGTV B*15:01 0.0 1 25522 
IQNILGGTV B*15:01 11.4 11 1437 
TIRNILGGTV A2 0.0 20 7075 
TIQNILGGTV A2 1.2 20 2559 
SPNGTIRNI B7 8.0 18 255 
SPNGTIQNI B7 8.0 18 562 
 
Scores were calculated for peptides overlapping the mutated amino acid of the IDH2 
R140Q mutation, each for the wild type (black) and mutated sequence (red) (Table 1). 
Peptides with the mutated sequence having a better score than the wild type sequence were 
selected for T cell stimulation (Table 1). Peptides which bound stronger to HLA molecules 
are more likely to stimulate T cells because they are presented for a longer time. The 9mer 
caring the IDH2 R140Q mutation at position 2 (IQNILGGTV) showed the highest increase in 
HLA binding probability compared to the wild type sequence and all other peptides, 
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respectively (e.g. BIMAS wild type 0.0 compared to 11.4 (mutated)). Only the 10-mer with an 
additional phenylalanine (F) at the C-terminus showed better scores (e.g. BIMAS wild type 
0.7 compared to 274.0(mutated)). T cell stimulation experiments were done with all peptides 
shown in Table 1. However, only with the peptides IQNILGGTV (IQN9) and IQNILGGTVF 
(IQN10) loaded on APC a specific T cell recognition was seen, so the focus will be on them. 
3.1.3 T cell stimulation with peptide loaded antigen presenting cells 
3.1.2.1 T cell stimulation with peptide loaded PBMC 
Bulk CD8 T cells of an HLA B*15:01 positive donor were stimulated with IQN9 or IQN10-
peptide loaded autologous peripheral blood mononucleated cells (PBMCs), to gain a IDH2 
R140Q specific T cell population. In Figure 1 results of an IFNγ ELISpot assay are shown. In 
the IFNγ ELISpot assay CD8 T cells were stimulated with autologous PBMCs loaded with 
different concentrations of the mutated peptides IQN9 or IQN10 (IDH2 R140Q specific) or 
the wild type peptides IRN9 or IRN10 (negative control). T cells stimulated with IQN9-
peptide loaded PBMCs secreted IFNγ when they were co-cultured with IQN9 peptide loaded 
PBMCs during the assay incubation time of 20h. In contrast these T cells showed reactivity 
against the wild type IRN10- and the IQN10-peptide (IDH2 R40Q specific) to the same extent 
(Figure 3.1A). Also, T cells stimulated with IQN10 peptide loaded PBMCs only showed 
activation by IQN10 loaded PBMCs (Figure 3.1B). 
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Figure 3.1: CD8 T cells (HLA-B*15:01) stimulation with autologous IDH2 R140Q specific peptide loaded PBMCs. (A) 
On d35+5 of primary stimulation and weekly restimulation with IQN9 peptide loaded PBMCs, CD8 T-cell responders were 
tested for IFNγ ELISpot reactivity against PBMCs loaded with IQN9 or IQN10 (0.1-10 mM) or the corresponding wild type 
peptides (10 mM). E:T ratio in the assay was 0.3:1. Data are shown as means of duplicates from one experiment 
representative of four performed with different T-cell donors (wherein one donor showed no reactivity). Error bars represent 
the range. (B) On d35+5 of primary stimulation and weekly restimulation with IQN10 peptide loaded PBMCs, CD8 T-cell 
responders were tested for IFNγ ELISpot reactivity against PBMCs loaded with IQN9 or IQN10 (0.1-10 mM) or the 
corresponding wild type peptides (10 mM). E:T ratio in the assay was 0.3:1. Data are shown as means of duplicates from one 
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experiment representative of four performed with different T-cell donors (wherein one donor showed no reactivity). Error 
bars represent the range. 
In 3 of 4 different HLA-B*15:01 positive donors a peptide specific recognition of 
IQN9 and IQN10 loaded PBMCs was detected. In contrast no peptide specific T cells could 
be generated in 4 different donors using the HLA-A2 and HLA-B7 restricted 9mers 
TIQNILGGTV and SPNGTIQNI, respectively (data not shown). 
3.1.2.2 T cell stimulation with peptide loaded DCs 
PBMCs consist of mainly two types of antigen presenting cells (APCs) DCs and B cells 
1
. 
DCs were generated by plastic adherence and the FAST-DC protocol and activated with a 
cytokine cocktail. DCs are professional APCs and should be more effective in stimulating T 
cells 
1
. 
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Figure 3.2: CD8 T cells (HLA-B*15:01) stimulation with autologous IDH2 R140Q specific peptide loaded DCs. (A) On 
d28+5 of primary stimulation and weekly restimulation with IQN9 peptide loaded PBMCs, CD8 T-cell responders were 
tested for IFNγ ELISpot reactivity against DCs loaded with IQN9 or IQN10 (0.1-10 mM) or the corresponding wild type 
peptides (10 mM). E:T ratio in the assay was 3:1. Data are shown as means of duplicates from one experiment representative 
of three performed with different T-cell donors (wherein one donor showed no reactivity). Error bars represent the range. (B) 
On d42+5 of primary stimulation and weekly restimulation with IQN9 peptide loaded DCs, CD8 T-cell responders from the 
same donor as in a were tested again for IFNγ ELISpot reactivity against DCs loaded with IQN9 or IQN10 (0.1-10 mM) or 
the corresponding wild type peptides (10 mM). E:T ratio in the assay was 3:1. Data are shown as means of duplicates from 
one experiment representative of five performed with different T-cell donors (two donors showed no reactivity). Error bars 
represent the range. 
In Figure 3.2 results of an IFNγ ELISpot assay are showing the recognition of T cells 
stimulated with IQN9-peptide loaded autologous DCs. T cells of the same donor were tested 
on day 33 (Figure 3.2A) and 57 (Figure 3.2B) of culture to analyze the T cell specificity over 
time. For these assays 15,000 T cells were co-cultured with 5,000 IQN9/10 or IRN9/10 loaded 
autologous DCs for 20 hours. On day 33 of culture T cells recognized IQN9 better than 
IQN10-peptide loaded DCs, while the corresponding wild type-peptide (IRN9 and IRN10) 
loaded DCs did not activated T cells to secrete IFNγ (Figure 3.2A). Two weeks later the 
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specificity of the same T cells improved. For IQN9-peptide loaded DCs 1 mM peptide (IQN9) 
was enough to induce IFNγ secretion to levels comparable to the one seen with 10 mM 
peptide (IQN9) on day 33. Furthermore, T cells stimulated with IQN10 loaded DCs showed a 
higher reactivity against IQN10 loaded DCs, while IFNγ secretion against wild type peptide 
loaded DCs remained low (Figure 3.2B).  
3.1.2.2.1 Stimulation with peptide pools in 96-well format 
Because in silico prediction tools are based only on already known antigen HLA molecule 
pairs in some cases it does not depict the actual situation in vivo. Furthermore, different 
prediction tools results in different scores 
103
. And the promising peptide epitope candidate 
IQN9 is HLA-B*15:01 restricted, which is not a common HLA isotype 
104
. So, overlapping 
peptides were used for stimulation to find peptide epitopes which were not predicted in silico 
but processed as an antigen in vitro. The peptides used are listed in Table 2. They all cover the 
mutated amino acid glutamine (Q, depicted in red) which moves one position in each peptide. 
CD8 T cells were seeded in 96-well plates together with autologous DCs (E:T, 3:1) loaded 
with peptide mixtures 1, 2 or 3 (Table 3.2).  
Table 3.2: Peptides used for peptide pool stimulation in 96-well format 
 
 
 
 
 
 
 
Figure 3.3 shows an IFNγ ELISpot assay, in which the activation of T cells stimulated 
with one peptide-pool (1,2 or 3)-loaded DCs were tested against the same peptide-pool loaded 
DCs. As negative control unloaded DCs were used. T cell populations from well A1 and D4 
(T cell populations (well) indicated below the bars) stimulated with peptide pool 1 showed 
recognition of the peptides with a low background. Also, T cells stimulated with peptide pool 
2 recognized these peptides from peptide pool 2, but to a lower extent. T cells generated with 
peptide pool 3 showed the lowest reactivity (Figure 3.3).  
Peptide # Sequence Peptide pool 
A QNILGGTVF 
 
B IQNILGGTV 1 
C TIQNILGGT  
D GTIQNILGG   
E NGTIQNILG 2 
F PNGTIQNIL  
G SPNGTIQNI   
H KSPNGTIQN 3 
I WKSPNGTIQ  
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Figure 3.3: CD8 T cells stimulation with autologous IDH2 R140Q specific peptide pool loaded DCs. On d25+5 of 
primary stimulation and weekly restimulation with one of the three peptide pools loaded on autologous DCs, CD8 T-cell 
responders were tested for IFNγ ELISpot reactivity against DCs loaded with the same peptide pool (10 mM). On the day of 
the assay T cell culture was resuspended and 10 µl T cell suspension was transferred in the assay plate to be tested against 
5,000 peptide pool loaded DCs. Below the bars the T cell populations from different wells are indicated. Data are shown as 
means of duplicates from one experiment representative of three performed with different T-cell donors. Error bars represent 
the range.  
During further culture reactivity was lost in all T cell populations. While 23 T cell 
populations (out of nine 96-well plates) showed peptide recognition in at least one IFNγ 
ELISpot, T cell populations reliable recognizing one of the IDH2 R140Q derived peptide 
could not be generated in 3 of 3 different donors (data not shown). 
T cell populations of all stimulation cultures, which specifically and reliable 
recognized IQN9- and/or IQN10-peptide loaded DCs, were tested against DCs expressing 
IDH2 R140Q protein. However, no specific recognition of the IDH2 R140Q protein was 
observed. 
 
3.1.2.3 Summary of stimulation with peptide loaded antigen presenting cells 
In Table 3 the results of the peptide stimulation are summarized. It was only possible to 
stimulate T cells with the in silico-predicted HLA B*15:01 binding peptides (IQN9 and 
IQN10). But no T cell populations could be generated, which recognized endogenous 
processed IDH2 R140Q protein. 
Table 3.3: Summary of results of stimulation with peptide loaded antigen presenting cells 
Stimulation  HLA 
restriction 
n n peptide recognition n endogen recognition 
IQNILGGTV peptide B15:01 7 5 0 
TIQNILGGTV/SPNGTIQNI 
peptide 
HLA-A2 and 
HLA-B7 
4 0 0 
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Overlapping peptides pools 
96 well plate 
 - 3 23  0 
 
3.1.3 T cell stimulation with electroporated DC 
In another approach CD4 T cells were stimulated with DCs expressing IDH2 R140Q protein 
upon mRNA electroporation. For expression control via flow cytometry a HIS tag was added 
on the C terminus of the amino acid sequence of IDH2 R140Q. For each experiment 
expression of the electroporated mRNA was confirmed by staining the HIS tag after overnight 
rest. 
First, the kinetics of mRNA expression was measured after 4, 6, 8, 12, 16, 20 and 24 h 
to confirm expression of transferred mRNA for the first 24h. As an example, the expression of 
IDH2 wild type (blue) and IDH2 R140Q (red) 4 and 24h after electroporation are shown in 
Figure 3.4. 
 
Figure 3.4: Transfection efficiency 4 and 24h after electroporation. After electroporation of IDH2 wild type or R140Q 
mRNA transfection efficiency was analyzed by flow cytometry. Data shown here are one representative histogram were 
IDH2 wild type transfected DCs are shown in blue and IDH2 R140Q transfected in red. Unstained DCs are shown in grey. 
Two histograms are shown at two different time points 4 and 24h.  
Because it is unknown if the IDH2 R140Q protein is processed to a peptide antigen 
and if this peptide antigen would be presented on HLA class I or II molecules CD8 and CD4 
T cells were used for stimulation with IDH2 R140Q expressing DCs. But CD8 T cell 
stimulations with IDH2 R140Q protein expressing DCs was not successful in 5 out of 5 
donors (data not shown), the focus was on CD4 T cells. With CD4 T cells stimulation was 
done in 24 (data not shown) or 96 well plate formats and with bulk and naïve (enriched for 
CD3, CD4, CD45RA) T cells (Figure 3.5).  
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Figure 3.5: CD4 T cells stimulation with autologous IDH2 R140Q protein expressing DCs. (A) On d35+5 of primary 
stimulation and weekly restimulation with IDH2 R140Q protein expressing DCs, bulk CD4 T-cell responders were tested for 
IFNγ ELISpot reactivity against DCs expressing IDH2 R140Q protein. E:T ratio in the assay was 3:1. Below the bars the T 
cell populations from different wells are indicated. Data are shown as means of duplicates from one experiment 
representative of five performed with different T-cell donors. Error bars represent the range. (B) On d21+5 of primary 
stimulation and weekly restimulation with IDH2 R140Q protein expressing DCs, naïve CD4 T-cell (enriched for CD3, CD4, 
CD45RA) responders were tested for IFNγ ELISpot reactivity against DCs expressing IDH2 R140Q protein. E:T ratio in the 
assay was 3:1. Below the bars the T cell populations from different wells are indicated. Data are shown as means of 
duplicates from one experiment representative of three performed with different T-cell donors. Error bars represent the range. 
Bulk CD4 T cell populations stimulated with autologous IDH2 R140Q expressing 
DCs in a 96-well plate format were not able to specifically recognize the mutated IDH2 
R140Q protein in all five of the tested donors. An example is depicted in Figure 3.5A, where 
none of the cell populations secreted more IFNγ in the co-cultivation with IDH2 R140Q 
protein compared to IDH2 wild type expressing DCs. Naïve T cell populations showed in 
some tests a higher IFNγ secretion against IDH2 R140Q protein than IDH2 wild type protein 
expressing DCs (Figure 3.5B), but the reactivity was not stable in further experiments. We 
hypothesized that IDH2 R140Q is not sufficiently presented on the surface of DCs to 
stimulate a T cell reaction. To improve the processing and presentation of the IDH2 R140Q 
protein a signaling sequence was added (DC lamp1) known to improve targeting to the 
antigen processing pathway 
105–107
. However, also this modification did not result in T cell 
populations, which specifically recognize the IDH2 R140Q protein expressed by DCs (data 
not shown). 
3.1.4 Stimulation of T cells with Influenza peptide 
CD8 T cell stimulation with the IQN9- and IQN10-peptide was possible but based on our 
results these peptides were not processed from the IDH2 R140Q protein. To explain why 
these T cells even exist, a natural epitope close to the structure of the IQN9/10 peptide may 
occur 
108
. NCBI BLAST analysis of the IQN9 sequence resulted in a match on an influenza A 
peptide derived from the neuraminidase surfaceprotein of the virus. This peptide was used to 
stimulate T cells and to check reactivity of IQN9/10 stimulated T cells to the influenza A 
peptide (SQNILGTQE, Ifn A NA). 
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Bulk CD8 T cells were stimulated with autologous IQN9- or influenza A-peptide 
loaded PBMCs and tested in an IFNγ ELISpot for cross reactivity. In one donor T cells 
stimulated against IQN9-peptide loaded DCs showed recognition of IQN9- as well as 
influenza A-peptide loaded DCs. In the other case, were the influenza A (Ifn A NA) peptide 
was used for T cell stimulation there was no specific recognition neither of the influenza A 
nor the IQN9-loaded DCs. The experiment was repeated with two other donors, but no IFN 
secretion against influenza A-peptide loaded target cells could be generated, neither with T 
cells stimulated with IQN9- nor influenza-peptide loaded DCs (Figure 3.6). 
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Figure 3.6: CD8 T cells (HLA-B*15:01) stimulation with autologous IDH2 R140Q or influenza peptide loaded DCs. 
(A) On d21+5 of primary stimulation and weekly restimulation with IQN9 peptide loaded DCs, CD8 T-cell responders were 
tested for IFN-γ ELISpot reactivity against DCs loaded with IDH2 R140Q (IQN9) or influenza A neuramidase (Inf A NA) 
peptide (0.1-10 mM). E:T ratio in the assay was 3:1. Data are shown as means of duplicates from one experiment of three 
performed with different T-cell donors (wherein no reactivity was seen in the other two donors). Error bars represent the 
range. (B) On d21+5 of primary stimulation and weekly restimulation with influenza A neuramidase peptide (Inf A NA) 
peptide loaded DCs, CD8 T-cell responders were tested for IFN-γ ELISpot reactivity against DCs loaded with IQN9 or Inf A 
NA peptide (0.1-10 mM). E:T ratio in the assay was 3:1. Data are shown as means of duplicates from one experiment of three 
performed with different T-cell donors (wherein no reactivity was seen in the other two donors). Error bars represent the 
range. 
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3.2 Effect of D-2-HG on metabolism and differentiation of monocyte-
derived dendritic cells 
The second part of my project was to analyze the effect of the oncometabolite D-2-HG on 
monocyte-derived DCs. As mentioned in the introduction metabolites secreted by cancer cells 
can modify the function of immune cells. Therefore influence of D-2-HG on the 
differentiation of monocytes into DCs was elucidated. 
3.2.1 Uptake of D-2-HG in monocytes 
Before the effects of D-2-HG were analyzed, 2-HG levels in monocytes were measured after 
20 h incubation in the presence or absence of 10 mM D-2-HG. Monocytes were harvested, 
washed with PBS and further processed for liquid chromatography followed by mass 
spectrometry performed to determine the concentration of 2-HG in monocytes. Protein 
contents of cell pellets were also determined to normalize to µg of protein. These analyses 
were performed in cooperation with Prof. Peter Oeffner and PD Dr. Katja Dettmer at the 
Department of Functional Genomics, University Regensburg. 
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Figure 3.7: 2-HG concentration in cell pellets of monocytes (MO). Uptake of D-2-HG by monocytes was analyzed in the 
presence or absence of 10 mM D-2-HG for 20 h. Cells were washed with PBS and intracellular levels of D-2-HG were 
analyzed by mass spectrometry. Single values and median of 3 independent experiments with different donors is shown. 
Statistical analysis for group differences were performed with the Wilcoxon-Test (paired). 
In untreated monocytes 2-HG content was beyond the limit of detection, showing that 
monocytes of healthy donors did not produce 2-HG (2-HG level 0.04 pmol/µg protein). In 
monocytes treated with D-2-HG the 2-HG median levels were 252.9 pmol/µg protein (Figure 
3.7). The analysis was not specific for one enantiomer, but as D-2-HG was added, we 
concluded that most of the HG measured is D-2-HG and that D-2-HG entered the cell. So far, 
the mechanism of D-2-HG uptake of monocytes is not clear. 
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3.2.2 Changes of DC morphology upon D-2-HG treatment 
After confirming the uptake of D-2-HG into monocytes, monocytes were seeded with or 
without 20 mM D-2-HG. After 7 days of D-2-HG treatment there was no influence on DC 
viability and cell yield determined by a cell counter (Figure 3.8A and B). Appropriate cursor 
settings for determining cell number and viability were established for DCs. But the mean 
diameter significantly increased with D-2-HG treatment (Figure 3.8C). 
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Figure 3.8: Viability (A), cell yield (B) and mean diameter (C)of D-2-HG treated DCs on day 7. DCs were differentiated 
in the absence or presence of 20 mM D-2-HG. Cell viability, yield and mean diameter were analyzed using the CASY cell 
analyzer system in. Cell yield was calculated with cell number of monocytes seeded on day 0 Single values and median of 6 
independent experiments with different donors is shown. Statistical analyses for group differences were tested with Wilcoxon 
test (paired). (*p≤0.05 were considered significant, ns means not significant). 
There was also no difference seen by bright-field microscopy on day 7, DCs from 
same donors had similar grades of adherence and cluster structures in both treatments (Figure 
3.9).  
 
      
Figure 3.9: Bright field pictures of DCs (A) and DCs treated 7 days with D-2-HG (B). DCs were cultured 7 days in the 
presence or absence of D-2-HG [20 mM]. DCs were analyzed by light microscopy in bright field with a 40x magnification, 
bar represents 100 µm. This picture is one representative of 25 analyzed donors. 
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3.2.2.1.1 Dendritic cell structures analyzed by electron microscopy 
DCs were differentiated in the presence or absence of 10 mM D-2-HG, on day 7 LPS was 
added for activation in one flask of each treatment. On day 8 DCs from each condition were 
harvested and fixed for electron microscopy (EM). Samples were further processed in 
cooperation with Prof. Brochhausen-Delius at the Department of Pathology of the University 
Hospital Regensburg. 
First in smaller magnifications the shape of immature DCs (iDCs) treated with 
D-2-HG was compared to immature control DCs. In all three donors analyzed, less and 
shorter dendrites were visible in DCs treated with D-2-HG compared to control DCs. In most 
donors the dendrites were also (Figure 3.10). 
       
Figure 3.10: Electron microscope images of day 8 DCs treated with D-2-HG. DCs were cultured with D-2-HG (10 mM) 
(B) or without (A) for 8 days, harvested, fixed and further processed for electron microscopy. Pictures show one 
representative section of each group of DCs differentiated in the absence or presence of D-2-HG. EM analysis was performed 
with three different donors, for each donor 10 cells were analyzed with different magnifications. The magnification used here 
was 5000x, bar indicates 5 µm. 
 Next the effect of LPS on dendrite formation was analyzed. After activation of iDCs 
with LPS for 24h the number of dendrites increased in both groups (with or without D-2-HG). 
But there was still a difference in their appearance, dendrites of D-2-HG treated DCs were 
less and shorter as in the control cells (Figure 3.11). 
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Figure 3.11: EM images of day 8 mature DCs treated with (B) or without (A) D-2-HG and activated with LPS. DCs 
were cultured with D-2-HG [10 mM] (B) or without (A) for 7 days and activated 24h with 100 ng/mL LPS, harvested, fixed 
and further processed for electron microscopy. Pictures show one representative section of each group of DCs differentiated 
in the absence or presence of D-2-HG. EM analysis was performed with three different donors, for each donor 10 cells were 
analyzed with different magnifications. The magnification used here was 5000x, bar indicates 5 µm. 
 
3.2.2.1.2 Vesicle structure of D-2-HG treated DCs analyzed by electron microscopy 
Another finding from the electron microscopy (EM) pictures was the differences in 
intracellular vesicles. In control DCs (Figure 3.12A) the vesicles were bigger with low 
electron density (bright) than in D-2-HG treated DCs (Figure 3.12B). Some of these vesicles 
contained small electron dense particles or membrane fragments. These vesicles get more 
dominant in control DCs treated with LPS.  
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Figure 3.12: EM image of control (A) and D-2-HG treated DCs (B). DCs were cultured in the presents (B) or absence (A) 
of D-2-HG. On day 8 DCs of each group were harvested, fixed and further processed for electron microscopy. Pictures show 
one representative section of each group of DCs differentiated in the absence or presence of D-2-HG. EM analysis was 
performed with three different donors, for each donor 10 cells were analyzed with different magnifications. The 
magnification used here was 5000x, bar indicates 5 µm. 
In D-2-HG treated DCs these structures were less abundant. D-2-HG treated DCs 
contained more small vesicles with higher electron density (dark structures, Figure 3.12). 
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Figure 3.13: EM images of d8 DCs treated with D-2-HG. DCs were cultured in the presents (B) or absence (A) of D-2-
HG. On day 8 DCs of each group were harvested, fixed and further processed for electron microscopy. Pictures show one 
representative section of each group of DCs differentiated in the absence or presence of D-2-HG. EM analysis was performed 
with three different donors, for each donor 10 cells were analyzed with different magnifications. Multi-laminar structures are 
indicated with arrows. The magnification used here was 40000x, bar indicates 500 nm. 
In both donors, multi-membrane structures were visible as seen in Figure 3.13 
indicated by the white arrows. In the control DCs (Figure 3.13A) multi-laminar structures 
were more electron dense and packed tighter than in the DCs treated with D-2-HG (Figure 
3.13B). We saw difference in the abundance of the multi-laminar structures although both 
types could be seen in both treatments.  
Differences in the structure of the vesicles may also have an influence on autophagy 
(microtubule-associated proteins 1A/1B light chain 3B, LC-3B) and late endosomes 
(Ras-related protein 9, Rab9) generation. Especially because these processes are important for 
antigen processing and presentation of DC as well as the multi-laminar vesicles.  
3.2.2.3 Expression analyze of late endosome marker Rab9 by western blot 
Rab9 is known to be present in late endosomes and can be used to analyze abundance of late 
endosomes. DCs differentiated in the presence or absence of D-2-HG were lysed with RIPA 
buffer and protein was isolated. 15 µg protein was analyzed separated in a gel and transferred 
on a membrane to analyze Rab9 expression.  
 Rab9 was expressed in all three donors analyzed. In one donor there was a 50% 
reduction of Rab9 in D-2-HG treated DCs compared with control DCs of the same donor and 
normalized on actin expression. In the other two donors a slight decreased expression after 
B 
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D-2-HG treatment was observed (Figure 3.14). Overall there was no significant effect of 
D-2-HG on the abundance of late endosomes. 
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Figure 3.14: Rab9 expression analysis in DC treated with D-2-HG by western blot. DCs were harvested after 7 days of 
D-2-HG [20 mM] treatment. Whole protein was isolated and 15µg protein was loaded on a 14% SDS acrylamide gel. 
Membrane was stained with rabbit anti-Rab9 primary antibody (1:1000) and HRP linked anti-rabbit secondary antibody 
(1:2500). Antibodies were removed by membrane stripping and analyzed for actin with rabbit anti-actin (1:1000) and anti-
rabbit (1:2500). Rab9 signal was measured after an exposure time of 51s. (B) Quantification was done by normalization on 
actin expression and expression of corresponding control DCs by ImageJ. Single values and median of 3 independent 
experiments with different donors is shown. Statistical analyses for group differences were tested with Wilcoxon test 
(paired). (*p≤0.05 were considered significant, ns means not significant). 
 
3.2.2.4 Expression analyze of the autophagy marker LC-3B by western blot 
After differences in the vesicle structure were observed in electron microscope pictures the 
amount of autophagosomes were analyzed by western blot detection of LC-3B. LC-3B is a 
protein involved in the formation of autophagosomes.   
LC-3B was expressed in all donors. There are different forms of LC-3B which were 
detected by the antibody. The biggest form is pro-LC-3B (about 37kD) it gets converted in 
LC-3B I (band visible at about 15kB) and finally to LC-3B II (band visible at about 13kD). 
Expression in control DCs was in all donors higher than in D-2-HG treated DCs for LC-3B I 
and II. Overall expression of LC-3B I and II was about 50% decreased in D-2-HG treated 
DCs. Levels of pro-LC-3B were comparable in all treatments and donors (Figure 3.15).  
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Figure 3.15: LC-3B expression analysis in DC treated with D-2-HG by western blot. DCs were harvested after 7 days of 
D-2-HG [20 mM] treatment. Whole protein was isolated and 15µg protein was loaded on a 14% SDS acrylamide gel. 
Membrane was stained with rabbit anti-LC-3B primary antibody (1:1000) and HRP linked anti-rabbit secondary antibody 
(1:2500). Antibodies were removed by membrane stripping and analyzed for actin with rabbit anti-actin (1:2500) and anti-
rabbit (1:2500). LC3B signal was measured after an exposure time of 50s. (B) Quantification was done by normalization on 
actin expression and expression of corresponding control DCs. T Single values and median of 3 independent experiments 
with different donors is shown. Statistical analyses for group differences were tested with Wilcoxon test (paired). (*p≤0.05 
were considered significant, ns means not significant). 
In a second set of experiments monocytes were treated with Bafilomycin A1 (BafA1, 
autophagy inhibitor) in the presence or absence of D-2-HG for 7 days. In cell lysates of these 
treatments pro-LC-3B and LC-3B II as seen in the first western blot were not detectable. The 
only visible band was at the height of 15 kD, most likely corresponding to the LC-3B I. 
Analyses of these lysates did not reveal a strong reduction of the LC-3B signal as seen in 
Figure 3.15. Addition of BafA1 slightly increased the levels of LC3B.in the control cells as 
well as in the D-2-HG treated cells.  
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Figure 3.16: LC-3B expression analysis in DC treated with D-2-HG by western blot. (a) DCs were harvested after 7 days 
of D-2-HG [20 mM] treatment. Whole protein was isolated and 15µg protein was loaded on a 14% SDS acrylamide gel. 
Membrane was stained with rabbit anti-LC-3B primary antibody (1:1000) and HRP linked anti-rabbit secondary antibody 
(1:2500). Antibodies were removed by membrane stripping and analyzed for actin with rabbit anti-actin (1:2500) and anti-
rabbit (1:2500). LC-3B signal was measured after an exposure time of 40s. (B) Quantification was done by normalization on 
actin expression and expression of corresponding control DCs. Single values and median of 3 independent experiments with 
different donors is shown. Statistical analyses for group differences were tested with Friedman test (paired). (*p≤0.05 were 
considered significant, ns means not significant). 
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3.2.2.5 HLA-class II expression of bafilomycin A1 treated DCs 
After effects of D-2-HG on LC-3B (present in autophagosomes) abundance in DCs were 
observed, HLA class II expression was analyzed in BafA1 treated cells. We hypothesis, that 
reduced LC-3B levels could cause a decrease in HLA class II expression as autophagy is 
involved in the antigen processing machinery.  
BafA1 treatment alone had no influence on HLA-DP (Figure 3.17A) expression and 
slightly reduced HLA-DR expression in 2 out of three donors. In combination with D-2-HG 
BafA1 had no positive effect, neither on HLA-DP, nor on HLA-DR expression (Figure 
3.17B). 
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Figure 3.17: HLA-DP (A) and HLA-DR (B) expression of bafilomycin treated DCs. DCs were cultured in the presents or 
absence of 20 mM D-2-HG or 10 nM bafilomycin A (Baf A1) or both. HLA-DP (A) and HLA-DR (B) surface expression 
was analyzed by flow cytometry. Median (background corrected) intensity of the fluorescence signal (MFI) were used and 
results were normalized to the level in control. Single values and median of 3 independent experiments with different donors 
is shown. Statistical analyses for group differences were tested with Friedman test (paired). (*p≤0.05 were considered 
significant, ns means not significant). 
 
3.2.3 Effect of D-2-HG differentiation and maturation of DCs 
Next, the effects of D-2-HG on differentiation, maturation and activation monocyte derived 
DCs were analyzed by flow cytometry. 
3.2.2.1 CD14 and CD1a expression of D-2-HG treated DCs  
In a first set of experiments the expression of a panel of differentiation related surface markers 
was investigated. 
CD14 (involved in LPS signaling response) is expressed on monocytes and 
macrophages but not on DCs 
109
. Expression of CD14 was high in monocytes but decreased 
during culture with IL-4 and GM-CSF in control DCs and D-2-HG treated cells. On day 7 
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DCs there was no expression of CD14 in all treatments, thus D-2-HG did not impact the 
differentiation related down-regulation of CD14 (Figure 3.18A).  
CD1a, involved in lipid and glycolipid antigen presentation, is mainly expressed on 
DCs, but not on monocytes 
110
. Hence, the expression should rise during DC differentiation. 
As expected there was a low expression of CD1a in monocytes but expression was 
significantly increases in DCs on day 7. In D-2-HG treated cells. However, expression 
increased only slightly to 19% of the level of control DCs Figure 3.18B). 
M
O
D
C
D
C
+
D
-2
-H
G
0
1 0 0
2 0 0
3 0 0
4 0 0
C
D
1
4
 [
M
F
I]
A
*
M
O
D
C
D
C
+
D
-2
-H
G
0
5 0
1 0 0
1 5 0
C
D
1
a
 M
F
I
n
o
r
m
a
li
z
e
d
 t
o
 c
o
n
tr
o
l 
[%
]
*
B
 
Figure 3.18: CD14 (A) and CD1a (B) expression of D-2-HG treated DCs. DCs were differentiated in the presence or 
absence of 20 mM D-2-HG. Monocytes (MO) were stained directly after isolation. On day 7 DCs were harvested and 
analyzed for CD14 (A) and CD1a (B) surface expression. Single values and median of 4 independent experiments with 
different donors is shown. For CD14 expression median (background corrected) intensity of the fluorescence signal were 
used and results were normalized to the level in control. For CD1a expression median (background corrected) intensity of the 
fluorescence signal is shown. Statistical analyses for group differences were tested with Friedman test (paired). (*p≤0.05 
were considered significant). 
 
3.2.2.2 DC-SIGN expression on D-2-HG treated DCs  
Another marker for DCs is dendritic cell-specific, intercellular adhesion molecule (ICAM) -3 
grabbing non-integrin (DC-SIGN), an adhesion molecule mainly expressed on DCs but also 
on some subpopulations of macrophages 
111
. DC-SIGN is involved in migration, antigen 
capture and T cell priming  of DCs 
112
. 
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Figure 3.19: Surface expression of DC-SIGN after 7d incubation with D-2-HG. DCs were differentiated in the presence 
or absence of 1-20 mM D-2-HG. Monocytes (MO) were stained directly after isolation. On day 7 DCs were harvested and 
analyzed for DC-SIGN surface expression by flow cytometry. Single values and median of 3-20 independent experiments 
with different donors is shown. median (background corrected) intensity of the fluorescence signal were used Statistical 
analyses for group differences were tested with Kruskal-Wallis test (paired). (*p≤0.05 were considered significant****p≤ 
0.00001). 
DC-SIGN expression was absent on monocytes and significantly increase in untreated 
DCs on day 7. D-2-HG decreased the expression concentration-dependent (Figure 3.19), and 
20 mM D-2-HG strongly reduced the expression compared to untreated control DCs (Figure 
3.19).  
 
3.2.2.3 HLA class I molecules of D-2-HG of DCs 
Another class of surface molecules important for antigen presentation of DCs are HLA 
molecules. HLA class I molecules are expressed on an all nucleated cells and present antigens 
to CD8 T cells 
1
. The expression of HLA class I molecules was measured in immature and 
mature (activated with 100 ng/ml LPS) DCs in the absence or presence of D-2-HG, results are 
shown in Figure 3.20. 
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Figure 3.20: Impact of D-2-HG on surface expression of HLA-class I molecules after 7 days of culture. DCs were 
differentiated in the presence or absence of 20 mM D-2-HG. On day 7 DCs were activated with 100 ng/ml LPS for 24h. DCs 
were harvested and analyzed for HLA-class I surface expression with HLA-A, -B and –C specific antibody by flow 
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cytometry. Single values and median of 9 independent experiments with different donors is shown. Median (background 
corrected) intensity of the fluorescence signal were used and results were normalized to the level in control DCs. Statistical 
analyses for group differences were tested with Friedman test (paired). (*p≤0.05 were considered significant, no significance 
was found). 
HLA class I expression increased after LPS incubation in D-2-HG treated and 
untreated DCs. The levels of HLA class I expression in D-2-HG treated DCs were comparable 
to untreated controls before and after LPS addition. Taken together, D-2-HG did not alter the 
expression and translocation of HLA class I molecules on the surface of DCs. 
3.2.2.4 Surface expression of HLA class II molecules 
Next, HLA class II molecule expression was investigated. HLA class II molecules also 
present antigens to T cells, but in contrast to HLA class I molecules HLA class II molecules 
present antigens to CD4 T cells 
1
. In contrast to HLA class I, HLA class II is more selectively 
expressed on antigen presenting cells under not inflammatory conditions 
1
. 
The surface expression of HLA-DR, DP and DQ was analyzed on monocytes and DCs 
in the absence or presence of D-2-HG. Monocytes expressed low levels of HLA-DR 
molecules which increased during differentiation of untreated monocytes as well as in 
monocytes treated with increasing concentrations (1-20 mM) of D-2-HG. However, mean 
fluorescence intensity (MFI) of HLA-DR expression decreased with increasing D-2-HG 
concentrations. For 20 mM D-2-HG there was significantly less HLA-DR present on the 
surface compared to control DCs (Figure 3.21). 
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Figure 3.21: Analyses of HLA-DR expression of D-2-HG treated DCs (titration). DCs were differentiated in the presence 
or absence of 1-20 mM D-2-HG. Monocytes (MO) were stained directly after isolation. On day 7 DCs were harvested and 
analyzed for HLA-DR surface expression by flow cytometry. Single values and median of 3-4 independent experiments with 
different donors is shown. Median (background corrected) of fluorescence signal were used to normalize to control DCs. 
Statistical analyses for group differences were analyzed with Kruskal-Wallis test (paired). (* p≤ 0.0505 were considered 
significant, ****p≤ 0.00001).  
The expression of the two other HLA class II molecules HLA-DQ and -DP was also 
analyzed. Expression of HLA-DQ (Figure 3.22A) and -DP (Figure 3.22B) was also elevated 
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during differentiation from monocytes to DCs. This upregulation was blocked by D-2-HG. In 
some donors D-2-HG did not only limit the upregulation but even reduced the expression of 
HLA-DQ and DP below the level measured in respective monocytes. On days 4 only HLA-
DR expression was elevated compared to the monocyte level (Figure 3.22C), the upregulation 
of HLA-DQ and -DP started later. 
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Figure 3.22: HLA-DQ (A), -DP (B) and -DR expression of D-2-HG treated DCs. DCs were differentiated in the presence 
or absence of 20 mM D-2-HG. Monocytes (MO) were stained directly after isolation. On day 4 and 7 DCs were harvested 
and analyzed for HLA-DQ (A, n=3-10), HLA-DP (B, n=3-15) and HLA-DR (C, n=3-25) surface expression. Medians 
(background corrected) of fluorescence signal were used to normalize to control DCs. Single values and median of 3-25 
independent experiments with different donors is shown. Statistical analyses for group differences were analyzed with 
Kruskal-Wallis test (paired). (* p0.05 were considered significant, *** p0.001, **** p0.0001).  
 
3.2.2.4.1 Intracellular staining of HLA class II molecules 
Since a reduced surface expression of HLA class II molecules was seen in D-2-HG treated 
DCs, it was checked if this was due to an inhibition of the HLA molecule transport to the 
surface or the result of reduced expression of HLA molecules. To answer this question, 
intracellular staining of HLA class II molecules was performed. HLA-DQ and -DP were not 
detected, so there is neither an intracellular HLA molecule storage nor a deficit in transport to 
the cell surface. For HLA-DR the intracellular staining showed similar results as the surface 
staining, D-2-HG treated cells showed less HLA-DR abundance than control DCs (Figure 
3.23). 
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Figure 3.23: Intracellular staining of HLA class II molecules in D-2-HG treated DCs. DCs were differentiated in the 
presence or absence of 20 mM D-2-HG. On day 7 DCs were harvested and analyzed for intracellular HLA-DQ, HLA-DP and 
HLA-DR expression. Single values and medians (background corrected) of fluorescence signal are shown for three different 
donors. Statistical analyses for group differences were analyzed with Wilcoxon test (paired). (* p0.05 were considered 
significant, no significance was found).  
 
3.2.2.4.2 Western blot analyses of HLA class II molecules 
To confirm our results on the expression of HLA class II obtained by flow cytometry, the 
expression of HLA class II molecules was also determined by western blot. The antibody used 
binds to all three HLA class II molecules. 
 When compared to untreated controls, HLA class II expression was decreased in all 
lysates analyzed from D-2-HG treated DCs, but there were still HLA class II molecules 
detectable (Figure 3.24).  
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Figure 3.24: HLA class II expression analysis in DC treated with D-2-HG by western blot. (A)DCs were harvested after 
7 days of D-2-HG [20 mM], protein was isolated with RIPA buffer. 10 µg were loaded on a 12% SDS acrylamide gel. 
Membrane was stained with mouse anti-HLAII primary antibody (1:2000) and HRP linked anti-mouse secondary antibody 
(1:2500). Antibodies were removed by membrane stripping and analyzed for actin with rabbit anti-actin (1:2500) and anti-
rabbit (1:2500). HLA class II signal was measured after an exposure time of 18s. (B) Quantification of three different donors 
was done by normalization on actin expression and expression of corresponding control DCs by ImageJ. Single values and 
median of 3 independent experiments with different donors is shown. Statistical analyses for group differences were analyzed 
with Wilcoxon test (paired). (* p0.05 were considered significant, no significance was found).  
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3.2.2.5 Expression of co-stimulatory molecules CD80/CD86 
To analyze the effect of D-2-HG on DC activation the co-stimulatory molecules CD80 and 
CD86 were analyzed in immature DCs on day 7 as well as after LPS activation on day 8. 
CD80 and CD86 are co-stimulatory molecules which bind to CD28 on T cells leading to T 
cell activation 
1
.  
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Figure 3.25: Expression of CD80 (A) and CD86 (B) in D-2-HG treated immature and mature DCs. DCs were 
differentiated in the presence or absence of 20 mM D-2-HG. On day 7 DCs were activated with 100 ng/ml LPS for 24h. DCs 
were harvested and analyzed for CD80 (A) and CD86 (B) expression by flow cytometry. Median (background corrected) 
intensity of the fluorescence signal were used. Single values and median of 7 independent experiments with different donors 
is shown. Statistical analyses for group differences were tested with Wilcoxon test (paired). (*p≤0.05 were considered 
significant, no significance was found). 
Expression of CD80 and CD86 was low in immature DCs with or without D-2-HG. As 
expected LPS exposure induced the expression of CD80 and CD86 in both groups, but in DCs 
treated with D-2-HG and LPS the effect on CD86 was less pronounced and some donors had 
an even higher CD86 expression after D-2-HG treatment. Overall there was no significant 
effect on the expression of CD80 and CD86 (Figure 3.25). 
 
3.2.3 Effects of D-2-HG on DC function 
3.2.3.1 Effect of D-2-HG on cytokine production in DCs  
After activation of D-2-HG treated or control DC for 24h with LPS supernatants were 
collected for measurements of cytokine concentrations. IL-12 levels of D-2-HG treated 
mature DCs were significantly lower than those in the untreated controls. In contrast for IL-10 
there was a higher secretion in some of the tested donors in the D-2-HG treated DCs. Levels 
of IL-6 and TNF were comparable in both treatments (Figure 3.26). To summarize, DCs 
treated with D-2-HG showed less IL-12 secretion and a trend to a higher IL-10 secretion. 
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Figure 3.26: IL-12, IL-10, TNF and IL-6 secretion of mature DCs treated with D-2-HG. DCs were differentiated in the 
presence or absence of 20 mM D-2-HG. On day 7, DCs were activated with 100 ng/ml LPS for 24h. Supernatants were 
collected and analyzed for cytokine concentrations by ELISAs. Results from 7 different donors are shown. Cytokine 
concentrations of D-2-HG treated DCs were normalized to corresponding control. Single values and median of 6-10 
independent experiments with different donors is shown. Statistical analyses for group differences were tested with Wilcoxon 
test (paired). (*p≤0.05 were considered significant, ** p0.01). 
Taken together D-2-HG reduced the expression of MHC class II molecules and 
strongly impaired IL-12 secretion of DCs. Both effects could have a strong impact on the 
stimulation of T cells, especially of CD4 T cells, hence the stimulatory capacity of DCs 
differentiated in the presence or absence of D-2-HG was investigated on CD4 T cells.  
 
3.2.3.2 Effect of D-2-HG on T cell stimulatory capacity of DCs 
3.2.3.2.1 IFN secretion and proliferation of bulk and naïve enriched T cells  
DCs cultured 7 days with or without D-2-HG were used as stimulators in an allogeneic mixed 
lymphocyte reaction (MLR) with naïve (CD4/CD45RA) or bulk enriched CD4 T cells in a 
DC to T cell ratio 1:10. For Stimulation of naïve enriched T cells, DCs were activated with 
LPS during MLR culture to stimulate production of pro-inflammatory cytokines like IL-12. 
For bulk CD 4 T cells DCs were activated with LPS for 24 hours and subsequently used in the 
MLR culture. After 5 days of MLR culture, supernatants were collected to analyze IFNγ 
secretion of T cells by ELISA. Results for bulk and naïve CD4 T cells are summarized in 
Figure 3.27A.  
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Figure 3.27: IFNγ secretion of bulk CD4 and CD4/CD45RA enriched T cells stimulated with allogeneic DCs treated 
without or with D-2-HG. Immature DCs differentiated in the presence or absence of 20 mM D-2-HG were cultured together 
with allogeneic naïve enriched T cells in a ration (1:10). (A) On day 5 supernatants were collected to analyzed IFNγ 
concentration by ELISA. (B) On day 7 T cell numbers were determined and cell numbers of T cells cultured with D-2-HG 
treated DCs were normalized to those obtained from T cells stimulated with untreated DCs. Single values and median of 4 
independent experiments with different donors is shown. Statistical analyses for group differences were tested with Wilcoxon 
test (paired). (*p≤0.05 were considered significant, no significance was found). 
 IFNγ secretion of naïve enriched T cells stimulated with D-2-HG treated DCs was 
strongly affected in 2 of 4 donors tested and slightly reduced in one additional donor. The 
impact was stronger in the setup with bulk derived T cells, which could be related either to the 
application of bulk T cells or to the different stimulation protocol. IFNγ concentrations 
decreased from 894 pg/ml to 508 pg/ml. Although not statistically significant there was a 
strong trend to a reduced IFNγ concentration in both, bulk and naïve C T cells stimulated with 
D-2-HG treated DCs (Figure 3.27A). 
On day 7 of MLR culture T cells were harvested and counted to analyze T cell 
proliferation. In the case of bulk CD4 T cells proliferation of T cells stimulated with D-2-HG 
treated DCs was reduced in all donors tested. By comparing the two medians a 43% reduction 
of proliferation was seen in T cells stimulated with D-2-HG treated DCs compared to T cells 
stimulated with control DCs (p= 0,1250, Figure 3.27B). 
For naïve enriched T cells, there were less T cells in cultures with D-2-HG treated 
DCs compared to control DCs in 3 of 4 donors tested. But the reduction of T cell proliferation 
was not significant. In summary there was a reduction of about 20%. 
3.2.3.2.2 Impact of D-2-HG on differentiation of regulatory T cells 
In naïve T cells the expression of the activation marker CD25 and FoxP3 was analyzed by 
flow cytometry in addition. CD25 is a subunit of the IL-2 receptor which is only expressed on 
activated T cells 
113
. In Figure 3.28 the percentage of CD25 expressing CD4 T cells is shown. 
On day 7 of MLR culture nearly all T cells (over 80%), were CD25 positive. There was no 
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striking difference in the CD25 expression of T cells stimulated with DCs differentiated in the 
absence or presence of 20 mM D-2-HG.  
Regulatory T cells, which control the activity of conventional T cells also highly 
express CD25. To identify regulatory T cells, cells were stained intracellular for FoxP3. 
FoxP3 is an important transcription factor for the function of regulatory T cells 
113
. The 
portion of CD4/CD25/FoxP3 positive cells was comparable in T cells stimulated with DCs 
differentiated in the absence or presence of D-2-HG. Frequency of Treg was about 11% of all 
CD4 T cells (Figure 3.28). 
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Figure 3.28: CD4/CD25 (A) and CD4/CD25/FoxP3 (B) positive T cells after 7 days of MLR with allogeneic DCs 
treated without or with D-2-HG. Immature DCs differentiated in the presence or absence of 20 mM D-2-HG were cultured 
together with allogeneic naïve enriched T cells in a ration (1:10). On day 7 T cells were analyzed for CD4, CD25 and 
FoxP3expression. (A) Summarized data of CD4 and CD25 co-expressing cells of 4 different donors analyzed. (B) Median 
(background corrected) intensity of the fluorescence signal were used. Single values and median of CD4, CD25 and FoxP3 
co-expressing cells of 4 different donors analyzed. Statistical analyses for group differences were tested with Wilcoxon test 
(paired). (*p≤0.05 were considered significant, no significance was found). 
To sum up CD25 and FoxP3 expression was not influenced during stimulation with D-
2-HG treated DCs, whereas a reduction in proliferation as well as IFNγ secretion by T cells in 
an allogenic MLR was detected.  
3.2.3.3 Expression of inhibitory molecules on D-2-HG treated DCs 
Activity of DCs can be modified by the expression of surface molecules. Stimulatory 
molecules can be less expressed and/or inhibitory molecules can be up-regulated. D-2-HG did 
not change expression of co-stimulatory molecules (CD80/CD86), next inhibitory molecules 
were analyzed. 
Inhibitory molecules like programmed cell death ligand 1 (PD-L1), HLA-G, T cell 
immunoglobulin and mucin domain 3 (TIM-3), B- and T-lymphocyte attenuator (BTLA), Ig-
like transcript 2 (ILT-2) and ILT-3 can be expressed on DCs and inhibit the activity of T cells. 
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To find out if the expression of these markers change during D-2-HG treatment they were 
analyzed on DCs after 7 days of culture. 
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Figure 3.29: Expression of inhibitory molecules on D-2-HG treated DCs. DCs were differentiated in the presence or 
absence of 20 mM D-2-HG. On day 7 DCs were harvested and analyzed for the expression of inhibitory molecules PD-L1, 
HLA-G, TIM-3, BTLA, ILT-2 and ILT-3 by flow cytometry. Median (background corrected) intensity of the fluorescence 
signal were used. Single values and median are shown for 4-7 different donors. Statistical analyses for group differences were 
analyzed with Wilcoxon test (paired). (* p0.05 were considered significant, no significance was found).  
Expression of nearly all inhibitory molecules analyzed was less expressed in D-2-HG 
treated DCs. PD-L1, BTLA and ILT-3 showed a slight, while HLA-G, TIM-3 and ILT-2 
showed a strong decrease in their expression (Figure 3.29). In conclusion D-2-HG did not 
induce the expression, but rather reduce the surface expression of inhibitory molecules in 
DCs. Therefore the reduced HLA class II and IL-12 secretion caused the reduced stimulatory 
capacity of D-2-HG treated DCs rather than the expression of inhibitory molecules. 
3.2.3.4 Effect of D-2-HG on phagocytosis activity of immature DCs 
One important function of immature DCs is the uptake and presentation of antigens. Immature 
DCs can kill and take up pathogens (like bacteria) and present parts of the pathogen on the 
surface to T cells. To investigate functional consequences of D-2-HG treatment, phagocytosis 
activity of immature DCs was analyzed on day 7 of DC culture before activation with LPS.  
DCs were incubated 10 minutes with E.coli expressing green fluorescent protein 
(GFP), to allow phagocytosis of bacteria. The uptake was monitored by measuring 
fluorescence intensity of DCs after several washing steps. As background control, DCs were 
incubated for 2h with GFP expressing E.coli, in this time intracellular bacteria and GFP were 
phagocytized and degraded, so only the fluorescent signal of the bacteria on the surface of the 
DCs was measured. As a result, there was no difference in phagocytosis activity in D-2-HG 
treated DCs compared with untreated controls (Figure 3.30). Also, the signal of the 
background did not change with D-2-HG treatment. In control DCs a median of about 30% of 
the DCs were GFP positive, as mentioned above the levels of D-2-HG treated DCs were 
comparable. 
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Figure 3.30: Phagocytose positive cells of D-2-HG treated DCs on day 7. Immature DCs differentiated in the presence or 
absence of 10-20 mM D-2-HG were used to analyze phagocytose activity. Percentages of green fluorescent DCs after 
incubation with GFP expressing E-coli were analyzed by flow cytometry. Single values and median of 4 independent 
experiments with different donors is shown. Statistical analyses for group differences were tested with Wilcoxon test 
(paired). (*p≤0.05 were considered significant, no significance was found). 
 
3.2.4 Effect of D-2-HG on G protein receptor signaling 
As mentioned above it is not yet clear how D-2-HG enters cells, but it was taken up by 
monocytes. Besides having intracellular effects D-2-HG could also impact signaling from the 
outside. To find out if D-2-HG is a ligand of G protein coupled receptors (GPCRs) protein 
kinase C (PKC) and cyclic AMP (cAMP) levels were analyzed in DCs.  
Activation of Gq/11 (heterotrimeric G protein subunit) coupled receptors leads to an 
increase in inisitol triphosphate which activates diacylglycerol and release calcium from the 
endoplasmatic reticulum. Both lead to an activation of PKC and translocation to the 
membrane 
114
. 
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 PKC levels were analyzed in lysates enriched for cytosolic and membrane proteins. In 
D-2-HG treated DCs PKC was more abundant in the cytosol and the membrane. In the donor 
shown here PKC (Figure 3.31A) was only detected in the D-2-HG treated DCs this was not 
true in the other two donors. In one of the three donors tested PKC was less abundant in D-2-
HG treated DCs (Figure 3.31B). In the same donor also the inhibitory effect of D-2-HG was 
only seen in HLA-DQ and not for –DP and –DR (data not shown). Actin was present in both 
lysates and was used for normalization. For the membrane fraction it was a parameter of 
purity as it is no membrane protein (Figure 3.31B).  
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Figure 3.31: Western blot Analysis of PKC protein in cytosol and membrane fractions of DCs. (A) DCs were harvested 
after 7 days of D-2-HG [20 mM] treatment. Whole protein was enriched either for cytosolic or membranes proteins. 15µg 
protein was loaded on a 10% SDS acrylamide gel. Membrane was stained with rabbit anti-PKC (α,β,γ) primary antibody 
(1:1000) in and HRP linked anti-rabbit secondary antibody (1:2500). Antibodies were removed by membrane stripping and 
analyzed again for actin contents with rabbit anti-actin (1:1000) and anti-rabbit (1:2500). PKC signal was measured after an 
exposure time of 1 min 20s. Data are shown from one experiment representative of three performed with different donors. (B) 
Quantification of three experiments was done by normalization to actin expression and expression of corresponding control 
DCs by ImageJ. Single values and median are shown for 3 different donors. Statistical analyses for group differences were 
analyzed with Wilcoxon test (paired). (* p0.05 were considered significant, no significance was found).  
As activation of Gi and Gs coupled receptors alters cAMP levels of the cells, cAMP 
level of DCs treated with D-2-HG were analyzed in parallel to the analyses of PKC 
translocation. Analyses of cAMP levels revealed slightly higher levels in D-2-HG treated DCs 
compared to the untreated control, but only in one donor an increase by 60% was detected 
(Figure 3.32). 
Results of the analysis of GPCR signaling showed no significant impact of D-2-HG, 
further studies have to be performed to finally answer the question if D-2-HG is a ligand for 
GPCRs. 
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Figure 3.32: cAMP levels of D-2-HG treated DCs. 5 x106 DCs differentiated in the absence or presence of 20 mM D-2-HG 
were lysed and cAMP measurement was performed. Single values and median of 3 independent experiments with different 
donors is shown. Statistical analyses for group differences were tested with Kruskal Wallis Test (paired). (*p≤0.05 were 
considered significant, here no significance was found). 
 
3.2.5 Impact of D-2-HG on DC metabolism 
As PKC is involved in calcium signaling and calcium is a regulator of metabolism also the 
impact of D-2-HG was analyzed. The transfer of calcium is important for oxidative 
phosphorylation (OXPHOS) and activated key decarboxylases of the TCA. Calcium also 
regulated the activity of pyruvate dehydrogenase and therefore provides sufficient amounts of 
pyruvate to either fuel the TCA or lactate production 
115
. During the last years it became 
evident, that also metabolic alterations play an important role in immune cell differentiation 
and activation. Reduced oxygen consumption but increased glycolytic activity have been 
shown in activated murine DCs and have been linked to their function 
116
. As mentioned in 
the introduction accumulation of metabolites or oncometabolites like D-2-HG may influence 
the metabolism of DCs and thereby their function due the high similarity to -ketoglutarate. 
3.2.5.1 Lactate production and glucose consumption of D-2-HG treated DCs 
To characterize the glycolytic activity of DCs lactate secretion and glucose uptake was 
determined in supernatants of DCs differentiated in the presence or absence of D-2HG on day 
7 of culture. DCs treated with D-2-HG produced more lactate than untreated control cells. 
Control DCs produced a median of 10.4 mM lactate, while D-2-HG treated DCs produced 
16.9 mM. In addition, glucose consumption was also increased in DCs treated with D-2-HG 
(7.8 mM glucose in D-2-HG treated DC versus 5.6 mM in untreated DCs, Figure 3.33A, B).  
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Figure 3.33: Lactate production (A) and glucose consumption (B) of D-2-HG treated DCs. DCs were differentiated in 
the presence or absence of 20 mM D-2-HG. On day 7 supernatants were collected to measured lactate (A) and (B) glucose 
concentrations. Glucose consumption was calculated by subtracting the remained (measured) glucose from total glucose in 
the media. Concentrations measured in D-2-HG treated DCs were normalized to untreated control DCs. Single values and 
median of 3 independent experiments with different donors is shown. Statistical analyses for group differences were tested 
with Wilcoxon test (paired). (*p≤0.05 were considered significant, no significance was found). 
In addition, pH values were monitored continuously during culture using the PreSens 
technology. Until day 2 the pH value was constant (7.4), beyond the pH dropped in D-2-HG 
treated DCs slowly until day 5 and remained constant at 6.6 after day 5. In control DCs pH 
values changed later in all donors tested (in one donor no pH drop was visible). In the donor 
shown in Figure 3.34 pH drop started at day 5 and continued until the end of the culture.  
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Figure 3.34: Online measurement of pH value during 7 days of culture. Monocytes were seeded in the presence or 
absence of 20 mM D-2-HG on 24-well hydro-dish, pH values were monitored during culture time by PreSens technology. 
One representative measurement out of 4 is shown.  
 
3.2.5.2 Effect of D-2-HG on mTOR phosphorylation in DCs 
Glucose metabolism can be regulated by different pathways, one is the mTOR pathway. The 
key protein is mTOR, which activity is regulated by phosphorylation on the serine residue 
2448. To check a possible impact of D-2-HG on the activation status of mTOR, 
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phospho-mTOR was stained intracellular in monocytes after overnight incubation with 
D-2-HG. 
 Phospho-mTOR staining was not changed by overnight D-2-HG treatment. In both 
conditions monocytes were positive for phospho-mTOR and signal intensities were 
comparable between control monocytes and D-2-HG treated monocytes as shown in Figure 
3.35A. However, in one donor a difference in the isotype control staining was observed 
(Figure 3.35B). In donor 2 shown in Figure 3.35B mTOR signal was similar in both donors, 
but the isotypes were different (median for D-2-HG treated monocytes was 16 and for 
untreated monocytes 27). In conclusion, rapid changes in mTOR activity might not be 
involved in the early metabolic alterations. Furthermore, after 7 days of culture there were 
also no differences in the phospho-mTOR staining in DCs cultured in the absence or presence 
of D-2-HG (data not shown).  
 
Figure 3.35: mTOR phosphorylation (Ser2448) of monocytes after overnight incubation with 20 mM D-2-HG. 
Monocytes were cultured overnight in the presence or absence of 20 mM D-2-HG. mTOR phosphorylation was measured by 
flo cytometry. One Histogram of population gates for living cells. Representative example of donor 1 (A) and donor 2 (B) 
analyzed. 
 
3.2.5.3 Effect of D-2-HG on respiration of DCs 
To analyze mitochondrial respiration in intact cells two different approaches were used. The 
PreSens technology allows the measurement of cellular oxygen consumption under culture 
conditions, whereas absolute values of oxygen consumption and functional parameters as 
maximum mitochondrial capacity can be determined high-resolution respirometry due to the 
possibility to apply substrates, inhibitors and uncouples through a port.  
A B 
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Applying the PreSens techonology revealed an immediate increase in cellular 
respiration upon the addition of D-2-HG, in all four donors analyzed. In Figure 3.36 one 
representative donor is shown.  
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Figure 3.36: Oxygen concentration over time in DC cultures treated with D-2-HG. Monocytes were seeded in the 
presence or absence of 20 mM D-2-HG in 24-well oxy-dish, oxygen concentrations were monitored during culture time by 
PreSens technology. One representative measurement out of 4 is shown.  
To further investigate alterations in mitochondrial activity high resolution 
respirometry was used. DCs were transferred into the oxygraph chambers at a density of 
approximately 5x10
5
. After determining basic respiration (ROUTINE) a protocol applying the 
mitochondrial ATP synthase inhibitor oligomycin to determine LEAK respiration, followed 
by titrating the uncoupler FCCP to measure the maximum capacity of the electron transfer 
system (ETS) and a subsequent administration of the mitochondrial respiratory complex I 
inhibitor rotenone and complex III inhibitor myxothiazol was used 
117,118
. 
All respiratory parameters analyzed were normalized to cell number and expressed as 
pmol/s/10
6
 cells. To compare the impact of D-2-HG between different donors respiratory 
parameters of D-2-HG treated DCs were further normalized to values of control DC of the 
same donor. In the course of differentiation from monocytes to DCs ROUTINE respiration 
increased independent of the treatment, however, the increase was much more pronounced in 
cells treated with D-2-HG. Already monocytes cultured overnight and cells differentiated for 
4 days in the presence of D-2-HG showed slightly higher ROUTINE respiration compared to 
untreated control cells. On day 4 D-2-HG treated DCs had an 166% increased oxygen 
consumption rate, on day 7 the value rose to 185% of control levels (Figure 3.37). 
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Figure 3.37: Oxygen consumption of D-2-HG treated DCs after 16 hours, 4 and 7 days. Oxygen consumption was 
measured by high resolution respirometry after overnight incubation (MO), 4 and 7 days. Monocyte or DCs were placed in 
oxygraph chambers in culture medium. ROUTINE respiration was measured (basal respiration) stabilization of respiration 
signal (basal respiration). Single values and median of 3-14 independent experiments with different donors is shown. 
Statistical analyses for group differences were tested with Wilcoxon test (paired). (*p≤0.05 were considered significant, *** 
p0.001). 
To elucidate the possibility that D-2-HG might serve as a substrate D-2-HG was 
applied to permeabilized DCs. In this protocol the cell membrane was disrupted with 
digitonin. By permeabilization of the cell membrane, mitochondria can be analyzed without 
performing a time-consuming mitochondria isolation 
99
. The application of different 
substrates (glutamate, malate, pyruvate, succinate) allows the determination of the maximum 
mitochondrial capacity. To investigate whether D-2-HG has a direct impact on mitochondrial 
activity, D-2-HG was added to permeabilized DCs in the presence of saturating complex I and 
complex II substrates and ADP. In all donors tested there was increase in maximum OXPHOS 
after adding malate, pyruvate, glutamate, succinate and D-2-HG and ADP (solved in water) 
compared to adding water instead of D-2-HG (Figure 3.38A). Those data suggest that D-2-
HG might serve as a mitochondrial substrate or immediately and directly turns on respiration. 
The same experiment was performed with the lymphocyte fraction gained by elutriation after 
overnight storage, to check whether this increase also is seen in other cell types. Overall, T 
cells consumed less oxygen than DCs. DCs had oxygen consumption rates of about 40 
pmol/s/10
6
, T cells at most 8 pmol/s/10
6
. Moreover, in T cells D-2-HG addition did not lead 
to an increase in maximum OXPHOS (Figure 3.38B). 
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Figure 3.38: OXPHOS the presence and absence of D-2-HG in DCs (A) and T cells (B). (A) DCs were harvested on day 
7 and placed in the oxygraph chamber wherein DCs were permeabilized with digitonine to analyze oxygen consumption of 
complexes of the respiratory chain. ROUTINE respiration after addition of water or D-2-HG together with substrates of 
comlex I and II (malat, glutamate, pyruvate and succinate) was measured. Single values and median of 8 independent 
experiments with different donors is shown. (B) The same was done in T cells from lymphocyte fraction after overnight 
storage. Single values and median of 5 independent experiments with different donors is shown. Statistical analyses for group 
differences were tested with Wilcoxon test (paired). (*p≤0.05 were considered significant, no significance was found). 
 
3.2.5.4 Determination of mitochondrial content in DCs 
The higher oxygen consumption of D-2-HG treated DCs (Figure 37) could also be related to a 
long-term adaption and increase in respiratory complexes or even in elevated mitochondrial 
content. To test this hypothesis two additional parameters were analyzed; maximum ETS 
capacity in the uncoupled state as well as mitochondrial content. The latter was determined 
applying a cationic fluorescence dye mainly intercalating in mitochondria independent of their 
membrane potential.  
In most of the analyzed donors the mitochondrial mass was increased in D-2-HG 
treated DCs on day 7 compared to untreated control DCs. Although not significant D-2-HG 
treated DCs had 44% more mitochondrial mass than untreated controls (Figure 3.39A). 
Maximum ETS capacity can be measured by the addition of an uncoupling agent like 
Carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP). FCCP destroys the proton 
gradient and thereby stimulate the complexes to maximal capacity. FCCP treatment resulted 
in an increased maximal capacity of ETS of D-2-HG treated DCs compared to the control 
DCs (Figure 3.39B). 
So in summary one part of the increased respiration could be explained by an 
increased mitochondrial mass another part by the increased maximal capacity of ETC. 
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Figure 3.39: Mitochondrial mass (A) and maximum capacity of electron transport chain (B) of day 7 DCs treated with 
D-2-HG. DCs were differentiated in the presence or absence of 20 mM D-2-HG. (A) On day 7, mitochondrial mass was 
measured with Mitotracker Green by flow cytometry. Median (background corrected) intensity of the fluorescence signal 
were used. Single values and median of 6 independent experiments with different donors is shown. (B) DCs were placed in 
oxygraph chambers in culture medium on day 7 wherein maximum capacity of electron transport system (ETC) was 
measured after addition of carbonyl cyanide p trifluoromethoxyphenylhydrazone (FCCP) by high resolution respirometry 
oxygraph technology. Single values and median of 9 independent experiments with different donors is shown. Statistical 
analyses for group differences were tested with Wilcoxon test (paired). (*p≤0.05 were considered significant, no significance 
was found). 
 
3.2.5.5 Measurement of ATP content of DCs 
A higher respiration could result in a higher production of ATP, thus in higher ATP levels. To 
test this, ATP concentration was measured in D-2-HG treated DCs via bioluminescence. On 
day 7, D-2-HG treated DCs had significantly higher intracellular ATP levels (180%) 
compared to untreated controls (Figure 3.40A). A higher ATP production was already 
indicated calculating the effect of oligomycin on oxygen consumption. In D-2-HG treated 
DCs oligomycin exerted a stronger reduction in respiration, suggesting that more oxygen was 
used for ATP production (Figure 3.40B). 
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Figure 3.40: ATP content (A) and oxygen consumed to produce ATP (B) in D-2-HG treated DCs. DCs were 
differentiated in the presence or absence of 20 mM D-2-HG. (A) On day 7 ATP content was measured by luminescence. 
Signals of D-2-HG treated DCs was normalized to control. Median of 6 experiments with different donors is shown. (B) DCs 
were placed in oxygraph chambers in culture medium. Oxygen consumption was measured by oxygraphy. DCs were 
incubated with LPS for one hour, after that oligomycin (ATPase inhibitor) was added to inhibit ATP synthase. Difference in 
oxygen consumption before and after addition of oligomycin was used to calculate the oxygen used to produce ATP. Single 
values and median of 8 independent experiments with different donors is shown. Statistical analyses for group differences 
were tested with Wilcoxon test (paired). (*p≤0.05 were considered significant ** p0.01). 
 
3.2.5.5.1 Effect of mutant IDH1/2 protein expression on respiration of DCs 
Because a higher respiration rate in D-2-HG treated DCs was observed, DCs expressing wild 
type or mutant IDH1 and 2 (IDH1 R132H and IDH2R140Q) upon electroporation with in 
vitro transcribed mRNA were analyzed. To check if in situ produced D-2-HG by mutant IDH 
does mimic the effects of exogenous added D-2-HG.  
After electroporation on day 7 of DC culture, DCs were stored overnight and stained 
intracellular with an anti-HIS antibody to check the expression of IDH proteins. An example 
for a corresponding histogram is depicted in Figure 3.4. 
Electroporation itself did influence oxygen consumption of DCs. In most donors 
electroporation resulted in a decreased oxygen consumption (Figure 3.41A). Thus, DCs 
expressing wild type (wt) IDH were compared to DCs expressing mutant IDH. The 
expression of mutant IDH, IDH1 and IDH2 led to higher oxygen consumption (ROUTINE 
respiration) and higher maximal electron transport capacity (ETC), comparable to the effect of 
exogenously added D-2-HG (Figure 3.41B, C). 
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Figure 3.41: Oxygen consumption of DCs electroporated with IDH1 wild-type, IDH1 R132H, IDH2 wild-type or IDH2 
R140Q. Immature DCs (day 7) were electroporated with in vitro transcribed mRNA coding for wild-type or mutated IDH1 
and 2 (IDH1 R132H and IDH2 R140Q. DCs were placed in oxygraph chambers in culture medium. ROUTINE was measured 
after stabilization of respiration signal (basal respiration). Single values and median of 4 independent experiments with 
different donors is shown. Statistical analyses for group differences were tested with Wilcoxon test (paired). (*p≤0.05 were 
considered significant, no significance was found). 
In parallel, monocytes were electroporated directly after isolation from PBMCs with 
mRNA coding for wild type and mutant IDH1 and 2 (IDH1 R132H and IDH2 R140Q). 
Transfection efficiency was comparable with the one in DCs but the viability after 
electroporation was lower. After 7 days of culture oxygen consumption was analyzed. Even 
after 7 days a negative impact of the electroporation was observed. DCs derived from 
electroporated monocytes consumed less oxygen compared to DCs derived from non-
eletroporated monocytes (data not shown). Nevertheless, expression of mutant IDH resulted 
in a trend towards increased respiration compared to monocytes expressing wild type IDH. 
Again, this was true for IDH1 and for IDH2 (Figure 3.42A). A higher effect of mutant IDH 
expression was seen in the maximum capacity of electron transport system. Here the median 
for IDH1 R132H expressing DCs reached 183% of wild type expressing cells. For IDH2 
R140Q expressing DCs the effect was less pronounced (133%, Figure 3.42B). 
ID
H
1
 w
t
ID
H
1
 R
1
3
2
H
ID
H
2
 w
t
ID
H
2
 R
1
4
0
Q
0
5 0
1 0 0
1 5 0
R
O
U
T
IN
E
n
o
r
m
a
il
z
e
d
 t
o
 w
il
d
 t
y
p
e
 [
%
]
n s
A
      
ID
H
1
 w
t
ID
H
1
 R
1
3
2
H
ID
H
2
 w
t
ID
H
2
 R
1
4
0
Q
0
5 0
1 0 0
1 5 0
2 0 0
2 5 0
E
T
C
n
o
r
m
a
il
z
e
d
 t
o
 w
il
d
 t
y
p
e
 [
%
]
n s
B
 
Figure 3.42: Oxygen consumption of DCs derived from monocytes electroporated with IDH1 wild-type, IDH1 R132H, 
IDH2 wild-type or IDH2 R140Q. Monocytes were electroporated with in vitro transcribed mRNA coding for wild-type or 
mutated IDH1 and 2 (IDH1 R132H and IDH2 R140Q and differentiated for 7 days. DCs were placed in oxygraph chambers 
in culture medium. (A) ROTINE respiration was measured after stabilization of respiration signal (basal respiration). (B) in 
the same experiments also, the maximum capacity of the electron transport system (ETC) was measured after the addition of 
FCCP. Single values and median of 3 independent experiments with different donors is shown. Statistical analyses for group 
differences were tested with Wilcoxon test (paired). (*p≤0.05 were considered significant, no significance was found). 
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A 
Taken together, the expression of mutated IDH1 or IDH2 exerted similar effects on 
respiration as the addition of exogenously added D-2-HG, indicating that intracellular levels 
of D-2-HG are responsible for the observed alterations in respiration.  
3.2.5.5.2 Effect of D-2-HG on mitochondrial structure of DCs 
Basal respiration of D-2-HG treated DCs was significantly higher than in the control DCs and 
they showed a trend towards an increased mitochondrial mass. To further elucidate 
mitochondrial alterations, mitochondrial structure was analyzed by EM of DCs cultured in the 
absence or presence of D-2-HG and harvested after 8 days. 
Only in one of three donors an effect of D-2-HG treatment on mitochondrial structure 
was observed. In all untreated control DCs mitochondria appeared well structured, with dense 
packed cristae and a dark (electron dense) mitochondrial matrix (Figure 3.43A). Compared to 
this, mitochondria in D-2-HG treated DCs of one donor seemed bloated with less dense 
cristae and a much brighter matrix. Also, the mitochondria itself were larger (Figure 3.43B). 
In the other two donors these differences were less pronounced. 
           
Figure 3.43: EM images of d8 DCs treated with D-2-HG (Donor1). DCs were cultured in the presents (B) or absence (A) 
of D-2-HG. On day 8 DCs of each group were harvested, fixed and further processed for electron microscopy. Pictures show 
one representative section of each group of DCs differentiated in the absence or presence of D-2-HG. EM analysis was 
performed with three different donors, for each donor 10 cells were analyzed with different magnifications. Multi-laminar 
structures are indicated with arrows. The magnification used here was 40000x, bar indicates 500 nm. 
 
3.2.6 Effect of D-2-HG on reactive oxygen species of DCs 
D-2-HG treated DCs showed a higher basal respiration (Figure 3.37), which could also lead to 
an increase in reactive oxygen species (ROS) levels. Complex I and III of the electron 
B 
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transport chain can generate superoxides during transfer of electron along the different 
electron acceptors 
75
. Superoxide in the mitochondria can get converted to peroxide by 
superoxide dismutase (SOD), which then can translocate through the mitochondrial 
membrane into cytosol 
75,119
. 
Determining residual oxygen consumption after inhibition of the respiratory chain 
applying rotenone revealed elevated oxygen consumption in D-2-HG treated DCs. After 
overnight (16h) D-2-HG incubation median of rotenone inhibited respiration was already 
increased to 145%, after 4 days of incubation the median peaks at 220% of control levels. 
After 7 days a significant increase of ROX was seen (Figure 3.44). This could hint to higher 
ROS levels produced in the mitochondria of DCs treated with D-2-HG.  
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Figure 3.44: Oxygen consumption after inhibition of electron transport chain with rotenone in DCs cultured for 7 
days in the presence of D-2-HG. DCs were differentiated in the presence or absence of 20 mM D-2-HG. On day 7 DCs 
were placed in oxygraph chambers in culture medium. Oxygen consumption was measured by oxygraphy. DCs were 
incubated with LPS for one hour, after that oligomycin (complex IV inhibitor), FCCP (uncoupler), rotenone (complex I 
inhibitor) were added. Single values and median of 3-14 independent experiments with different donors is shown. Statistical 
analyses for group differences were tested with Wilcoxon test (paired). (*p≤0.05 were considered significant ** p0.01). 
 
3.2.6.1 Establishment of measurement of cytosolic ROS by DCFDA 
2′,7′-Dichlorofluorescin diacetate (DCFDA) was used to measure ROS abundance in the 
cytosol. DCFDA gets oxidized by ROS (all oxidants present) which induces a fluorescence 
signal 
120
. To establish the measurement, peroxide was added to DCFDA stained monocytes 
directly after elutriaton. Peroxide can translocate through cell membranes and can be detected 
in the cytosol. In Figure 3.45 results are shown as a stacked histogram overlay. The grey 
histogram is the signal of DCFDA stained DCs without peroxide. Addition of 1 mM peroxide 
caused an increase in DCFDA signal after 5 minutes; the signal increased until 25 minutes 
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after addition and did not further increase after 30 minutes. The results showed, that the 
staining method worked properly. (Figure 3.44) 
 
Figure 3.45: DCFDA staining of monocytes after addition of H2O2. 1 mM peroxide was added to DCFDA stained 
monocytes. DCFDA signal was measured after 5-30 minutes incubation time. Filled grey curve is the signal of stained 
monocytes without H2O2. Histograms of one performed experiment. 
 
3.2.6.2 Short-term effects of D-2-HG on cytosolic ROS in DCs 
After establishment of cytosolic ROS measurement, the short-term effect of D-2-HG on 
cytosolic ROS was analyzed in monocytes. Monocytes were stained with DCFDA, then 
20 mM D-2-HG was added and fluorescence signals were measured after 5, 15, 25 and 30 
minutes. As control, RPMI was added to DCFDA stained monocytes (Figure 3.46). Since 
addition of D-2-HG or RPMI did not increase the DCFDA signals, there was no immediate 
increase in cytosolic ROS, which does not exclude the possibility that ROS subsequently 
could emerge. 
 
Figure 3.46: Short-term effects of D-2-HG on ROS levels in monocytes. 20 mM D-2-HG or media (control) was added to 
DCFDA stained monocytes. DCFDA signal was measured after 5-30 minutes incubation time. Filled grey curve is the signal 
of stained monocytes without H2O2. Histograms of one experiment performed.  
 
D-2-HG 
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3.2.6.3 Short-term effect of D-2-HG on mitochondrial ROS of DCs 
In parallel mitochondrial ROS levels were measured in monocytes by MitoSox red staining. 
MitoSox is a fluorescent dye which specifically detects superoxide in the mitochondria. 
Fluorescent signal was measured 5, 15, 20 and 30 minutes after the addition of 20 mM D-2-
HG as a vehicle control RPMI was added. Both treatments did not change the MitoSox signal 
in the first 30 minutes of incubation (Figure 3.47). To control for methodological limitations, 
peroxide was used again as peroxide inhibits SOD and thereby leads to an accumulation of 
superoxide in the mitochondria. The addition of peroxide resulted in an increase in the 
MitoSox signal, confirming that the staining protocol worked (data not shown).  
 
Figure 3.47: Short-term effect of D-2-HG on mitochondrial ROS in monocytes. 20 mM D-2-HG or media (control) was 
added to MitoSox stained monocytes. DCFDA signal was measured after 5-30 minutes incubation time. Filled grey curve is 
the signal of stained monocytes without H2O2. Histograms of one experiment performed. 
 
3.2.6.4 Long-term effect of D-2-HG ROS levels and cystine uptake in DCs 
After investigating an immediate effect of D-2-HG on cytosolic ROS in monocytes, next the 
long-term effects of D-2-HG in DCs was measured after 7 days of culture. Herein, cytosolic 
ROS levels were significantly higher in D-2-HG treated DCs compared to untreated controls 
(Figure 3.48A). 
Mitochondrial ROS was also measured in DCs treated with 20 mM D-2-HG for 7 
days. Our hypothesis was that the increased respiration might also increase ROS levels in 
mitochondria. Indeed, mitochondrial ROS levels were increased in D-2-HG treated DCs 
compared to control DCs in 50% of all donors analyzed, nevertheless the effect was not 
significant (Figure 3.48B). 
On day 7 DCs treated with D-2-HG had a higher amount of cytosolic and 
mitochondrial ROS compared to untreated DCs. To elucidate if this can be explained by 
D-2-HG 
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limited scavenging of ROS by glutathione, cystine uptake was measured after 7 days of D-2-
HG treatment. Cystine is a dimer of cysteine and important for the production of glutathione 
121
. Cystine uptake was reduced in four out of five donors analyzed (Figure 3.48C). 
D
C
D
C
+
D
-2
-H
G
0
5 0
1 0 0
1 5 0
2 0 0
2 5 0
D
C
F
D
A
 M
F
I
n
o
r
m
a
li
z
e
d
 t
o
 c
o
n
tr
o
l 
[%
]
**A
D
C
D
C
+
D
-2
-H
G
0
5 0
1 0 0
1 5 0
2 0 0
2 5 0
M
it
o
s
o
x
 M
F
I
n
o
r
m
a
li
z
e
d
 t
o
 c
o
n
tr
o
l 
[%
]
n s
B
D
C
D
C
+
D
-2
-H
G
0
5 0
1 0 0
1 5 0
c
y
s
ti
n
e
F
IT
C
 M
F
I
n
o
r
m
a
li
z
e
d
 t
o
 c
o
n
tr
o
l 
[%
]
C
n s
 
Figure 3.48: DCFDA, MitoSox and cystine staining of 7 days cultured DCs in the presence or absence of D-2-HG. DCs 
were differentiated in the presence or absence of 20 mM D-2-HG. On day 7 DC stained for (A) cytosolic ROS (DCFDA), (B) 
mitochondrial ROS (MitoSox) or (C) cystineFITC. Fluorescence signal was measured by flow cytometry. Median 
(background corrected) intensity of the fluorescence signal were used. Single values and median of 5-13 independent 
experiments with different donors is shown. Statistical analyses for group differences were tested with Wilcoxon test 
(paired). (*p≤0.05 were considered significant ** p0.01).  
 
3.2.7 Effect of oxidants and antioxidants on HLA class II expression and ROS 
production of DCs 
Since D-2-HG induced an increase in cellular ROS levels (Figure 3.48), we hypothesized that 
addition of peroxide could also mimic some of the effects of D-2-HG on DC differentiation, 
vice versa the addition of antioxidants might rescue the D-2-HG triggered phenotype. 
3.2.7.1 Analyses of peroxide treatment on HLA-DP, -DR and CD1a expression on DCs 
To mimic the effect of D-2-HG on ROS levels, peroxide was added during differentiation of 
monocytes into DCs (lower HLA class II expression, no CD1a expression). The effect of 
peroxide on HLA class II expression was analyzed on day 7. Here a lower expression of 
HLA-DP and HLA-DR was seen in the peroxide treated DCs compared to untreated control 
(Figure 3.49A, B). However, HLA-DQ expression was too low to analyze in these donors 
even in control DCs (data not shown). CD1a expression was also significantly decreased in D-
2-HG treated DCs compared to untreated control DCs. With peroxide treatment CD1a 
expression was higher compared to control DCs (Figure 3.49C).  
In summary peroxide treatment of DCs did only mimic the inhibitory effect of 
D-2-HG on HLA-DP expression. 
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Figure 3.49: HLA class II expression of peroxide treated DCs. DCs were differentiated in the presence or absence of 20 
mM D-2-HG or 1 mM peroxide. On day 7 DC stained for (A) HLA-DP, (B) HLA-DR and (C) CD1a expression. 
Fluorescence signal was measured by flow cytometry. Median (background corrected) intensity of the fluorescence signal 
were used. Single values and median of 3-4 independent experiments with different donors is shown. Statistical analyses for 
group differences were tested with Friedmann test (paired). (*p≤0.05 were considered significant, no significance was found).  
 
3.2.7.2 Antioxidant treatment to rescue D-2-HG treated DCs 
3.2.7.2.1 HLA class II expression on trolox and vitamin C treated DCs 
Higher ROS levels were detected in D-2-HG treated DCs, in addition peroxide was able to 
mimic the effect of D-2-HG on HLA-DP expression. Both results suggested that an 
antioxidant might be able to rescue the effects of D-2-HG. In a set of experiments the water-
soluble vitamin E derivative trolox (50 µM) and vitamin C (2 mM) were used as rescue 
substances. As before, trolox and vitamin C were added to monocytes at the beginning of the 
culture in the presence or absence of D-2-HG. 
Donors used for trolox treatment showed very low expression of HLA-DP and were 
excluded from the analysis of HLA class II expression. In one out of three donors with 
enough HLA-DP expression there was a positive effect of trolox treatment in the presence of 
D-2-HG (data not shown). 
As seen before, D-2-HG treatment decreased HLA-DP and -DR expression. Vitamin C 
treatment lowered HLA-DP expression and HLA-DR expression of DCs (data not shown). All 
donors tested showed slightly higher expression of HLA-DR in vitamin C and D-2-HG 
co-treated DCs compared to DCs treated with D-2-HG alone (Figure 3.50A).Vitamin C in the 
presence of D-2-HG was able to rescue HLA-DP expression in 2 out of 4 donors tested 
(Figure 3.50 B). In the other 2 donors only, the D-2-HG effect was measurable. HLA-DQ 
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could not be analyzed in these donors because control DCs showed no expression (data not 
shown). 
 
Figure 3.50: HLA class II expression after vitamin C treatment DCs. DCs were differentiated in the presence or absence 
of 20 mM D-2-HG or 2 mM vitamin C. On day 7 DC stained for (A) HLA-DP and (B) HLA-DR. Fluorescence signal was 
measured by flow cytometry. Representative histograms of one out of four donors are shown. 
 
3.2.7.2.2 DC-SIGN and CD1a expression of trolox and vitamin C treated DCs 
In parallel DC-SIGN and CD1a expression was analyzed in DCs treated with trolox, vitamin 
C in the presence or absence of D-2-HG as these surface markers were also reduced in D-2-
HG treated DCs. Expression of DC-SIGN and CD1a was changed by trolox treatment. In one 
of three donors trolox treatment rescued DC-SIGN and CD1a expression of D-2-HG treated 
DCs (Figure 3.51A, B).  
Expression of CD1a was not change neither by vitamin C treatment alone nor in the 
presence of D-2-HG. In contrast, DC-SIGN expression was increased in vitamin C treated 
DCs compared to untreated control DCs. Furthermore, in the presence of D-2-HG vitamin C 
treatment increased DC-SIGN to levels higher than levels of untreated control DCs (Figure 
3.51A, B) 
A B 
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Figure 3.51: CD1a (A) and DC-SIGN (B) expression after trolox and vitamin C treatment. DCs were differentiated in 
the presence or absence of 20 mM D-2-HG, 50 µM trolox or 2 mM vitamin C. On day 7 DC stained for (A) CD1a and (B) 
DC-SIGN. Fluorescence signal was measured by flow cytometry. Median (background corrected) intensity of the 
fluorescence signal were used. Single values and median of 3 independent experiments with different donors is shown. 
Statistical analyses for group differences were tested with Friedmann test (paired). (*p≤0.05 were considered significant, no 
significance was found).  
 
3.2.7.2.3 IL-12 secretion of trolox and vitamin C treated DCs 
DCs treated with trolox and vitamin C, in the presence of D-2-HG were activated on days 7 
for 24h with LPS and IL-12 was analyzed in supernatants by ELISA. Trolox treatment alone 
lead to an increase in IL-12 secretion and was able to also increase IL-12 secretion in two of 
three donors tested. In the 3
rd
 donor trolox treatment alone did also lower IL-12 levels, this 
was in contrast to the effects seen in the other donors and could be an explanation for the 
inconsistent results in the presence of D-2-HG (Figure 3.52A). 
Surprisingly vitamin C treatment did lower IL-12 secretion of activated DCs and was 
not able to rescue the effects of D-2-HG when added in the presence of D-2-HG (Figure 
3.52B).  
D-2-HG 
Vitamin C 
- -  
Vitamin C 
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Figure 3.52: IL-12 secretion after trolox treatment. DCs were differentiated in the presence or absence of 20 mM D-2-HG, 
50 µM trolox (A) or 2 mM vitamin C (B). On day 7 DCs were activated with 100 ng/ml LPS, after 24h supernatants were 
collected to analyze IL-12 concentration by ELISA. Single values and median of 3 independent experiments with different 
donors is shown. Cytokine concentrations of D-2-HG treated DCs were normalized to corresponding control. Statistical 
analyses for group differences were tested with Friedmann test (paired). (*p≤0.05 were considered significant, no 
significance was found).  
 
3.2.7.2.4 Reactive oxygen species of Vitamin C treated DCs 
Also ROS levels were determined in vitamin C treated DCs after 7 days of culture. There was 
no effect seen on mitochondrial ROS in any of the treatments (D-2-HG, vitamin C, D-2-HG 
and vitamin C) (Figure 3.53A). Cytosolic ROS was increased in DCs treated with D-2-HG or 
vitamin C alone. The combination of both treatments had no additive effects on cytosolic 
ROS levels (Figure 3.53B). 
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Figure 3.53: Mitochondrial (A) and cytosolic (B) ROS levels of vitamin C treated DCs. DCs were differentiated in the 
presence or absence of 20 mM D-2-HG or 2 mM vitamin C. On day 7 DC stained for (A) mitochondrial ROS (MitoSox) (B) 
or cytosolic ROS (DCFDA). Fluorescence signal was measured by flow cytometry. Median (background corrected) intensity 
of the fluorescence signal were used. Single values and median of 4 independent experiments with different donors is shown. 
Statistical analyses for group differences were tested with Friedmann test (paired). (*p≤0.05 were considered significant, no 
significance was found).  
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 ROS levels in vitamin C treated DCs were analyzed because a decrease in ROS was 
expected, but as seen here there was no change of ROS levels with vitamin C treatment or 
even an increase. This could be explained by the fact that ROS level of DCs after 7 days of 
culture were analyzed and might not be stable. It is also known that the addition of vitamin C 
leads to an increase in extracellular ROS 
122
. Because no reduced ROS level were seen with 
vitamin C treatment, ROS levels were not measured in trolox treated DCs. 
 
3.7.8 Rescue experiments with modulator of metabolism 
As 2-D-HG induced an immediate and persisting increase in respiration (Figure 3.37, partially 
inhibiting DC respiration might rescue the inhibitory effects of D-2-HG on DC marker 
expression and IL-12 secretion. As anti-diabetic drugs are capable to reduce respiration, 
metformin and pioglitazone were selected. Metformin is an anti-diabetes drug, which has 
many targets in the cell, e.g. complex I of the respiration chain 
123
.  
The anti-diabetes drug pioglitazone is a synthetic ligand of the peroxisome 
proliferator-activated receptor (PPAR)γ, which alters transcription of genes involved in 
carbohydrate and lipid metabolism. This leads to a metabolic shift towards glycolysis and an 
increased sensitivity to insulin 
124
. Moreover, it has been shown that pioglitazone reduces 
cellular respiration.  
3.7.8.1 Respiration of metformin and pioglitazone treated DCs 
In these set of experiments metformin (5 mM) and pioglitazone (25 µM) were added to 
monocytes in the absence or presence of D-2-HG (20 mM) and cultured for 7 days. First the 
oxygen consumption of DC treated with metformin and pioglitazone in the presence or 
absence of D-2-HG was measured by high resolution respirometry.  
Metformin treatment slightly reduced respiration of untreated as well as D-2-HG 
treated DCs when added on day 0 of culture. But in the presence of D-2-HG metformin was 
not able to reduce the respiration to control levels (Figure 3.54A).  
In the presence of D-2-HG, pioglitazone was able to reduce the oxygen consumption 
to the levels of untreated DCs. Pioglitazone alone did not change the oxygen consumption 
(Figure 3.54B). 
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Figure 3.54: Basal respiration of DCs treated with metformin. Oxygen consumption was measured by high resolution 
respirometry after 7 days of treatment with (A) 5 mM metformin (Met), (B) 25 µM pioglitazone (Pio) in the presence or 
absence of 20 mM D-2-HG. DCs were placed in oxygraph chambers in culture medium. ROUTINE respiration was measured 
(basal respiration). Single values and median of 3-4 independent experiments with different donors is shown. Statistical 
analyses for group differences were tested with Wilcoxon test (paired). (*p≤0.05 were considered significant, no significance 
was found). 
 
3.7.8.2 HLA class II expression of metformin and pioglitazone treated DCs 
In parallel, expression of HLA class II molecules in metformin and pioglitazone treated DC 
was analyzed. Metformin treatment did not normalize respiration of D-2-HG treated DCs and 
was not able to rescue the expression of HLA-DR or HLA-DP expression in the presence of 
D-2-HG. Metformin treatment alone partially lowered HLA-DP expression and increased 
HLA-DR expression (Figure 3.55A, B). Control DCs of these donors did not express HLA-
DQ, so an analysis of HLA-DQ was not possible (data not shown).  
Pioglitazone treatment alone decreased HLA-DP expression and increased HLA-DR 
expression. Pioglitazone treatment of DCs did not rescue the HLA-DP expression in the 
presence of D-2HG, but increased HLA-DR expression to levels above the levels of the 
untreated control DCs (Figure 3.55C, D). HLA-DQ could not be analyzed in these donors 
because control DCs showed no expression (data not shown). 
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Figure 3.55: HLA-DP (A) and HLA-DR (B) expression on metformin treated. DCs were differentiated in the presence or 
absence of 20 mM D-2-HG, 5 mM metformin (met) or 25 µM pioglitazone (pio). On day 7 DC stained for (A) HLA-DP and 
(B) HLA-DR. Fluorescence signal was measured by flow cytometry. Median (background corrected) intensity of the 
fluorescence signal were used. Single values and median of 3-4 independent experiments with different donors is shown. 
Statistical analyses for group differences were tested with Friedmann test (paired). (*p≤0.05 were considered significant).  
 
3.7.8.3 DC-SIGN expression after pioglitazone treated DCs 
CD1a and DC-SIGN expression was also reduced in D-2-HG DCs, because of that CD1a and 
DC-SIGN was analyzed after metformin and pioglitazone in the presence or absence of D-2-
HG treated DCs after 7 days of culture.  
In Figure 3.58A CD1a expression is shown. Metformin treatment decreased CD1a 
expression in all donors tested. In the presence of D-2-HG, metformin had no influence on 
CD1a expression. CD1a expression stayed low as seen in DCs treated with D-2-HG. 
Pioglitozone even further decreased CD1a expression as D-2-HG or metformin.  
 Metformin treatment increased DC-SIGN expression in two of three donors tested. In 
the presence of D-2-HG, metformin increased DC-SIGN expression in the same two donors. 
In DCs treated with metformin and D-2-HG DC-SIGN expression reached 94% of expression 
of untreated DCs. Pioglitazone treatment alone did reduce DC-SIGN expression in 2 out of 3 
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donors. In DCs treated with pioglitazone and D-2-HG, DC-SIGN levels were comparable 
with those of DCs treated with D-2-HG alone. To conclude this result pioglitazone was not 
able to rescue the effects of D-2-HG on DC-SIGN expression (Figure 3.58B). 
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Figure 3.58: CD1a (A) and DC-SIGN (B) expression on metformin and pioglitazone treated DCs. DCs were 
differentiated in the presence or absence of 20 mM D-2-HG, 5 mM metformin or 25 µM pioglitazone. On day 7 DC stained 
for (A) CD1a and (B) DC-SIGN expression. Fluorescence signal was measured by flow cytometry. Median (background 
corrected) intensity of the fluorescence signal were used. Single values and median of 3-5 independent experiments with 
different donors is shown. Statistical analyses for group differences were tested with Friedmann test (paired). (*p≤0.05 were 
considered significant, no significance was found).  
 
3.7.8.4 IL-12 secretion of metformin and pioglitazone treated DCs 
DCs treated with metformin and pioglitazone in the presence of D-2-HG were activated on 
days 7 for 24h with LPS and IL-12 was analyzed in supernatants by ELISA.  
As previously shown also in these samples IL-12 secretion was decreased after D-2-
HG treatment. Metformin alone also lowered IL-12 secretion. DCs treated with D-2-HG in 
combination with metformin did further decrease the levels of IL-12 (Figure 3.56A).  
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In the donors analyzed to evaluate the effect of pioglitazone treatment, the IL-12 
secretion was low in control DCs. D-2-HG treatment reduced IL-12 secretion about 50%. 
Pioglitazone alone did even further reduce IL-12 levels. In supernatants of DCs treated with 
pioglitazone in the presence of D-2-HG IL-12 was nearly absent. In conclusion it was not 
possible to rescue IL-12 secretion with pioglitazone (Figure 3.56B). 
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Figure 3.56: IL-12 secretion of DCs treated with metformin and pioglitazone. DCs were differentiated in the presence or 
absence of 20 mM D-2-HG, (A) 5 mM metformin (met) or (B) 2 mM vitamin C. On day 7 DCs were activated with 100 
ng/ml LPS, after 24h supernatants were collected to analyze IL-12 concentration by ELISA Single values and median of 3 
independent experiments with different donors is shown. Cytokine concentrations of D-2-HG treated DCs were normalized to 
corresponding control. Statistical analyses for group differences were tested with Friedmann test (paired). (*p≤0.05 were 
considered significant).  
 
3.7.8.5 ROS levels in metformin and pioglitazone treated DCs 
On day 7 ROS levels were also analyzed in metformin and pioglitazone treated DCs. In these 
experiments the mitochondrial ROS levels in the D-2-HG treated cells were not increased 
compared to the untreated control. 
Metformin treatment increased the levels of mitochondrial ROS in the presence or 
absence of D-2-HG (Figure 3.57A). Metformin treatment rescued the increased cytosolic ROS 
levels in the presence of D-2-HG, while metformin treatment alone had no influence on 
cytosolic ROS levels (Figure 3.57B).  
Pioglitazone alone or in combination with D-2-HG had also no effect on mitochondrial 
ROS levels. As seen before (Figure 3.48), also in these experiments cytosolic ROS was 
increased in D-2-HG treated DCs. Pioglitazone alone lowered cytosolic ROS levels to 50% of 
control DCs. Pioglitazone in combination with D-2-HG reached similar levels as with 
pioglitazone alone (Figure 3.57A, B). In summary, pioglitazone was able to reduce cytosolic 
ROS in the presence or absence of D-2-HG. 
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Figure 3.57: Mitochondrial (A) and cytosolic (B) ROS levels in metformin and pioglitazone treated DCs. DCs were 
differentiated in the presence or absence of 20 mM D-2-HG , 5 mM metformin or 25 µM pioglitazone. On day 7 DC stained 
for (A) mitochondrial ROS (MitoSox) (B) or cytosolic ROS (DCFDA). Fluorescence signal was measured by flow 
cytometry. Median (background corrected) intensity of the fluorescence signal were used. Single values and median of 5 
independent experiments with different donors is shown. Statistical analyses for group differences were tested with 
Friedmann test (paired). (*p≤0.05 were considered significant, no significance was found).  
 
In summary pioglitazone lowered the respiration and cytosolic ROS levels of D-2-HG 
treated DCs to levels comparable to untreated control DCs. Pioglitazone was able to partly 
rescue HLA-DR expression but had no effect on IL-12 secretion. 
 
3.7.9 Methylation analysis of DC differentiation 
Vitamin C rescued HLA-DP and DC-SIGN expression (Figure 3.50 and Figure 3.51). 
Furthermore, vitamin C is a co-factor of TET2 (demethylase) and is known to be able to 
restore TET2 activity 
125,126
. Methylated promotors are associated with low gene expression 
127
. To find out if these effects of vitamin C on HLA-DP and DC-SIGN expression were 
Results 
 
100 
 
changed by epigenetic regulation, vitamin C (2 mM) was added to monocytes at the beginning 
of the culture in the presence or absence of D-2-HG. DNA of monocytes (directly after 
elutration), 16 h, 66 h and 7 days cultured DCs was isolated for each treatment (untreated, 
vitamin C, D-2-HG, vitamin C and D-2-HG). 
 In cooperation with the working group of Prof. Rehli methylation analyses were 
performed using epityper technology. This was done to address the question if D-2-HG also 
inhibits demethylation of loci getting demethylated during DC differentiation. DNA 
methylation analysis revealed a delayed demethylation pattern of D-2-HG treated DCs in loci 
which get demethylated during physiological DC differentiation, like C9ORF78, CD207, 
CCL13 and CLEC10A, which can be nicely monitored in methylation pattern of non-treated 
DCs from monocytes to 16 h, 66 h and 7 days cultured DCs changing from 100% methylated 
(blue) to lower methylation percentages (yellow). STAT5 is a gene locus which is 
demthylated later during DC differentiation, STAT5 was only in untreated and vitamin C 
treated DCs demethylated. Vitamin C alone did speed up demethylation in all genes analyzed 
compared to control DCs but was only in part able to counteract the inhibitory effect of 
D-2-HG. As expected the control genes MMP7 and HOXB1 did not change methylation 
status during DC differentiation (Figure 3.59).  
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Figure 3.59: Methylation analysis of DC differentiation. MassARRAY analysis of bisulfite-converted DNA, at five loci 
showing active DNA demethylation during monocyte to DC differentiation (C9ORF78, CD207, CCL13, CLEC10A, 
STAT5), as well as for two control regions (MMP7 and HOXB1). Data are presented as heatmaps (mean of three different 
donors). The methylation ratio (including both 5mC and 5hmC) at single CpGs dinucleotides (individual boxes) is indicated 
by shades of yellow to blue (yellow: no methylation, dark blue: 100% methylation). Grey boxes indicate CpGs that were not 
detected by MALDI-TOF MS. 
 
 
 
Results 
 
102 
 
3.7.10 Primary AML blast from IDH mutated leukemias 
3.7.10.1 RNAseq data of primary AML IDHMUT blasts from the cancer genome atlas 
As mentioned before DCs treated with D-2-HG had a significantly lower surface expression 
of HLA-class II molecules (Figure 3.21 and Figure 3.22). To analyze if this is also true in 
primary AML blasts harboring IDH mutations (only separated in IDH1 and 2 mutation), we 
analyzed RNA sequencing data of the online available data base the cancer genome atlas 
(TCGA). Alleles of HLA genes, which are mainly expressed are selected and shown in Figure 
3.60. For all genes, expression of HLA-class II genes was reduced in IDH1 mutated blasts 
compared to IDH non-mutated blasts. The gene for the HLA-DQA1 alpha chain was 
significant lower expressed in IDH1 mutated blasts compared to blasts expressing wild type 
IDH. For AML blasts with IDH2 mutation this effect was not observed (Figure 3.60). 
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Figure 3.60: RNAseq Data of the Cancer Genome Atlas. RNA sequencing data were downloaded on the TCGA website. 
Medians of reads per kilobase million (RPKM) are shown of 158 IDH wild type and 16 IDH1 and 2 expressing blasts each. 
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RPKM means reads of RNAseq were normalized to fragment length. Statistical analyses for group differences were tested 
with One-way Anova (unpaired). (*p≤0.05 were considered significant).  
 
3.7.10.2 HLA class II protein expression of primary AML IDHMUT blasts 
RNAseq data showed a lower HLA class II molecule mRNA levels in AML blasts with an 
IDH1 mutation. Surface expression of HLA class II molecules was analyzed in primary AML 
blasts. IDH mutated (IDH1 and IDH2 mutated blasts were combined) AML blasts had a 
significant lower surface expression of HLA-DP compared to AML blasts expressing 
wildtype IDH. For HLA-DQ the levels was comparable in both groups. HLA-DR was in 
tendency lower expressed in AML blasts expressing mutated IDH. The red dots represent 
IDH2 mutated, the triangles represent IDH1 mutated AML blasts. In contrast to the RNAseq 
data, the surface staining of HLA class II molecules expression of blasts expressing mutated 
IDH1 were similar to those in IDH2 expressing blasts (Figure 3.61A, B, C).  
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Figure 3.61: HLA-DP (A), -DQ (B) and -DR (C) expression of AML blasts with and without IDH mutation. AML 
blasts were thaw and stained for HLA-class II surface expression. Single values and median of 10 IDH wild type AML blasts 
and 9 IDH 1 (triangles) or 2 (dots) mutated AML blasts are shown. Median (background corrected) intensity of the 
fluorescence signal were used. Statistical analyses for group differences were tested with Mann Whitney test (paired). 
(*p≤0.05 were considered significant).  
 
3.7.10.3 HLA expression on AML blasts analyzed by western blot 
Surface staining of HLA-DR and HLA-DP molecules revealed a lower expression in IDH 
mutant compared with IDH wild type AML blasts. To confirm this data, protein lysates were 
produced and analyzed by western blot. 
In line with the surface staining of IDH mutant blasts showing less HLA class II 
expression, also the total HLA class II signal was lowered in IDH mutant blasts. Signals of 
HLA class II specific antibody was normalized to actin signal (loading control). However, in 
one IDH wild type patient (#4) expression of HLA class II molecules was low, but in all other 
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wild type expressing donors HLA class II molecules expression exceeded those in IDH 
mutated blasts (Figure 3.62).  
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Figure 3.62: HLA class II expression of IDH mutant and wild type blasts analyzed by western blot. PBMCs from AML 
patients were thawed and proteins were extracted. 10 µg were loaded on a 12% SDS acrylamide gel. Membrane was stained 
with mouse anti-MHCII primary antibody (1:2000) and HRP linked anti-mouse secondary antibody (1:2500). Antibodies 
were removed by membrane stripping and analyzed for actin with rabbit anti-actin (1:2500) and anti-rabbit (1:2500). HLA 
class II signal was measured after an exposure time of 18s. (B) Quantification of three different donors was done by 
normalization on actin expression and expression of corresponding control DCs by ImageJ. Statistical analyses for group 
differences were analyzed with Wilcoxon test (paired). (* p0.05 were considered significant, no significance was found).  
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4 Discussion  
4.1 Generation of IDH2 R40Q specific T cells  
4.1.1 T cell stimulation with peptide and protein of mutant IDH2 R140Q 
T cell stimulation with IDH2 R140Q specific peptides IQN9 and IQN10 gave rise to T cells 
that specifically recognize these peptides with low background activity (Figure 3.1 and 3.2). 
But these T cells were not able to recognize DCs expressing IDH2 R140Q. This could be 
explained by the possibility that there is no peptide antigen presented on HLA molecules, 
which is specific for the amino acid exchange (R140Q) or even for the IDH2 protein. It is 
known that not all proteins expressed in a cell are presented on HLA molecules. Bassani-
Sternberg et al. showed results of advanced mass spectrometry (MS) analysis wherein they 
analyzed the melanoma-associated immune-peptidome (up to 95,500 patient-presented 
peptides each) from 25 melanoma tissue samples. Out of 1,100 nonsense mutations in each 
patient only eleven mutated peptide ligands were found, wherein four were found to be 
immunogenic 
128
. In addition, the protein should be expressed in an adequate level. In animal 
experiments, irradiation of cancer cells cultures generated mutation specific T cells only for 
antigens overexpressed in tumor cells 
129,130
. We can exclude that the expression was an issue 
in our experiments because we saw sufficient expression (Figure 3.4) and mRNA 
electroporation is known to be a potent tool for T cell stimulation with foreign proteins 
107
. In 
summary, we concluded that IDH2 R140Q proteins are not guided to the antigen processing 
and presentation machinery and therefore IDH2 R140Q derived peptides are not presented on 
HLA molecules.  
4.1.2 Peptide prediction with in silico algorithms 
The results from in silico prediction tools showed a lower binding affinity (to HLA-B*15:01) 
for the IDH2 wild type (IRN9) peptide than for the mutated peptide (IQN9) (Table 3.1). 
Analysis of binding positions of 9mer amino acid peptides presented by HLA class I 
molecules to TCRs revealed positions 1-3 and position 9 as anchor positions with no contact 
to the TCR. While positions 4-8 were in close contact with the TCR 
131
. Thus, position 2 
where the mutated amino acid is located in the IQN9-peptide is most likely an anchor 
position, which explains the different binding affinities of IRN9 (wild type) and IQN9 
(mutated) predicted by BIMAS, SYFPETHI and NET MHC Pan.  
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Amino acids at positions 4-8 which are possibly recognized by TCRs do not differ in 
the wild type and mutated peptide. T cells recognizing these amino acids would have been 
most probably already deleted in the thymus 
132
. This is not the possibility in our experiments 
because it was possible to generate IQN9-peptide specific T cells. So, most likely there is an 
antigen with a similar amino acid sequence.  
4.1.3 Influenza peptide is similar to mutant IDH2 R140Q derived peptide IQN9 
To find this similar antigen, the sequence around the mutated amino acid glutamine (Q) was 
used for an NCBI BLAST (aligned input amino acid sequence to protein sequences in the 
NCBI data base) to find viral proteins with similar amino acid sequences. We were focused 
on viral proteins because it is known that TCRs specific for viral or bacterial peptides are also 
able to recognize structural similar self-antigens. This is called molecular mimicry 
108,133
. The 
most promising hit was the neuramidase protein of influenza A virus where 5 amino acids 
(QNILG) were identical to the sequence of IQN9-peptide. The enzyme neuramidase is located 
on the surface of the virus and so a component of influenza A vaccination. People who had an 
influenza infection or vaccination generate specific T cells against the surface molecules of 
the virus.  
Stimulation with the influenza A peptide did not result in any specific T cell response, 
but IQN9-peptide stimulated T cells were able to recognize the influenza A peptide (Figure 
8). It seemed that the influenza A peptide used in our stimulation experiment is not an 
endogenous processed peptide of the influenza A neuramidase protein. The physiological 
sequence of the peptide could be different in length or bind to an HLA molecule which was 
not expressed in the tested donors. The fact that IQN9-peptide stimulated T cells were able to 
recognize the influenza A peptide showed that influenza A specific T cells were generated. 
This was only possible in one of the three donors tested. This might be due to the different 
infections or vaccinations background of the analyzed donors. The donor who showed 
reactivity was yearly vaccinated against influenza viruses, vaccination frequencies of the 
other two donors tested is not known and might not be as regular. 
It is estimated that 10
12
 T cells are present in the human body expressing less than 10
8
 
different TCRs so it is very unlikely that one TCR only recognize one specific antigen 
134
. 
Therefore, it is reasonable that TCRs only bind to the amino acids in the middle of a peptide 
to increase the peptides which can possibly be recognized by this TCR. Furthermore, this 
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could be a possible explanation why we could generate IQN9-peptide specific T cells but no T 
cell population recognizing the endogenously processed IDH2 R140Q protein. 
4.2 Effects of D-2-HG on differentiation and metabolism of monocytes 
derived dendritic cells 
Cancer associated D-2-HG produced by mutant IDH showed inconsistent impacts on cell 
metabolism 
13,72,123,135
. Dendritic cell (DC) differentiation and activation is accompanied with 
changes in their metabolism 
80
. In the second part of the project the impact of D-2-HG on the 
metabolism and differentiation of primary human myeloid cells was investigated. 
4.2.1 Uptake of D-2-HG 
Monocytes treated with D-2-HG had higher 2-HG level than monocytes only incubated with 
media (Figure 3.7). This is in line with experiments done with DCs (unpublished data) and 
two recently published paper wherein D-2-HG uptake was shown in T cells 
72,136
. Bunse et al. 
showed a higher D-2-HG uptake in DCs compared to T cells 
136
. How D-2-HG enters the cell 
is not yet clear. In one study, Hagos et al. analyzed different transporters for 2-HG. They 
identified Organic anion transporter 1 (OAT1, solute carrier family 22 member 6 (SLC22A6)) 
and Solute carrier family 13 member 3 (SLC13A3) as possible transporters 
137
. According to 
BIOGPS, SLC22A6 is mainly expressed in kidney but also in monocytes, myeloid cells, DCs 
and all T cells subtypes analyzed. Expression of SLC13A3 in T cells, DCs and monocytes 
was higher than the expression of SLC22A6. A recently published study in nature medicine 
showed a positive correlation of SLC13A3 expression and D-2-HG uptake, which was not 
seen with SLC22A6. In addition, a reduced D-2-HG uptake was shown in SLC13A3 
knockdown cells 
136
. Already proven is that D-2-HG is able to translocate out of the cell, as it 
was measured in the sera of AML and glioma patients harboring an IDH mutation 
32,33,138
. 
In conclusion there is no need to use ester derivatives of D-2-HG to get D-2-HG into a 
cell. The derivatization may potentially lead to additional effects which would not be seen 
with endogenously produced D-2-HG.  
4.2.2 D-2-HG inhibits DC differentiation 
In electron pictures of D-2-HG treated DCs, a reduced length and number of dendrites was 
seen before and after activation with LPS (Figure 3.10, 11). Besides morphology, expression 
of DC marker and IL-12 secretion was reduced (Figure 3.18, 19, 22 and 26). From this we 
concluded that the differentiation and activation was impaired in D-2-HG treated DCs.  
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4.2.2.1 T cell stimulation activation in an allogeneic MLR 
In allogeneic MLRs with CD4 T cells a reduced proliferation and IFNγ production was 
measured when co-cultured with D-2-HG treated DCs (Figure 3.37). This could be explained 
by the reduced IL-12 secretion in these cells. This was in line with allogenic MLR 
experiments performed by Böttcher et al., wherein lymphocytes and immature DCs were 
seeded together with LPS in the presence of 10 mM D-2-HG, resulted in a reduced T cell 
proliferation. In contrast to our results no change in IFNγ secretion was seen72. This can be 
explained by the lower D-2-HG concentration (10 mM instead of 20 mM) or the different 
experimental setting as DCs were already differentiated when D-2-HG was added to the MLR 
culture. We saw no influence on Treg frequencies after co-culture with D-2-HG treated DCs. 
In contrast Böttcher et al. showed increased Treg frequencies in D-2-HG treated T cells
72
. Xu 
et al saw a hypermethylation at the FoxP3 locus which led to a reduced FoxP3 expression in 
TH17 cells with high level of D-2-HG 
73
. 
4.2.2.2 Multi-laminar vesicles in DCs 
Our hypothesis was that the vascular multi-laminar vesicles seen in DCs were HLA molecule 
containing vesicles of the antigen presentation pathway. Calafat et al. showed similar 
structures to carry HLA-DR molecules by gold labeling 
60
. In D-2-HG treated DCs these 
multi-laminar vesicles contained a less dense matrix compared to control DCs (Figure 3.13). 
Our theory was that the antigen presentation pathway could be impaired in DCs because we 
saw a reduced HLA class II abundance on the surface. The analysis of intracellular HLA class 
II levels showed no HLA-DP and –DQ expression, but HLA-DR expression was measurable 
and decreased in D-2-HG treated DCs (Figure 3.22). Western blot analysis with whole protein 
lysates revealed a reduced HLA class II expression in D-2-HG treated DCs (Figure 3.24). 
Taken together, our results suggest that there is no intracellular accumulation of HLA class II 
molecules; HLA class II molecules were in general less expressed in DCs treated with 
D-2-HG. 
4.2.2.3 Impact of D-2-HG on autophagy 
Some studies suggested that increased ROS levels inhibit autophagy 
139,140
. We saw increased 
ROS levels in D-2-HG treated DC (Figure 3.48) and hypothesized that this may influence 
autophagy by impairing the levels of LC-3B (a molecule present in autophagosomes). LC-3B 
is present in three forms pro-LC-3B, LC-3B I and LC-3B II. LC-3B I is formed out of pro-
LC-3B which is much bigger than LC3B I/II, ATG7 (essential protein for autophagy) then 
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conjugates phosphatidylethanolamine (PE) to LC-3B I to form LC3B II 
141
. We analyzed LC-
3B levels by western blot technique (Figure 3.15). D-2-HG treatment led to a reduced 
abundance of LC-3B II, the active form present in autophagosomes. The reduction of LC-3B 
II abundance by D-2-HG could be either due to a higher degradation rate or a reduced 
formation of autophagosomes. To clarify that, DCs were additionally treated with BafA1, an 
inhibitor of autophagy. BafA1 inhibits the final fusion and degradation of autophagosomes so 
BafA1 treatment should lead to a higher LC3B II abundance 
142
. In western blots performed 
with lysates of BafA1 treated DCs, the three isoforms (pro-LC-3B, LC-3B I and II) could not 
be detected. There was only one band at the height of 18kD where the LC-3B I signal was 
previously detected. After quantification of this signal, results could not be concluded because 
they were inconsistent and an increased LC-3B signal was only seen in two out of three 
donors (Figure 3.16). The influence of D-2-HG on autophagy has to be further investigated. 
Other reasons to investigate autophagy were the differences seen in vascular structures 
in the EM pictures and differences in HLA class II expression. HLA molecules are more 
stable when peptides are bound and autophagy is involved in antigen processing 
56
. We 
hypothesized that the lower LC-3B abundance could also be an explanation for the reduced 
HLA class II abundance on the surface. But BafA1 treatment of DCs did not influence the 
abundance of HLA class II molecules on the surface (Figure 3.22). This was in line with 
reports from Mintern et al. wherein the authors analyzed the role of autophagy in antigen 
presentation. They demonstrated that the antigen presentation of HLA class II molecules was 
not influenced in ATG7 deficient DCs in general, but cross-presentation of soluble factors 
was decreased 
143
.  
4.2.2.4 Intracellular signaling of D-2-HG 
Experiments performed in the working group of Prof. Marina Kreutz with a cell permeable 
substance, which is converted to D-2-HG inside the cell showed different effects than D-2-
HG itself (not shown unpublished data). This suggests that D-2-HG also binds to the cell 
membrane and is involved in signaling. D-2-HG could be a ligand of a G protein–coupled 
receptor (GPCR). Depending on the G-protein, different signaling pathways would be 
activated. Gi and Gs coupled receptors are involved in cyclic AMP (cAMP) and protein kinase 
A signaling. While Gq/11 coupled receptors activate phospholipase C (PLC) followed by 
inositol 3 phosphate increase, calcium signaling and protein kinase C (PKC) activation. G12/13 
and Gβ/ coupled receptors activate glykogensynthase-kinase 3 and phosphoinositid-3-kinase 
144
.  
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 Here we analyzed the transloctaion of PKC (isoform α, β and γ) to find out if D-2-HG 
bind to a Gq/11 coupled receptor. PKC is known to be active when it is located in the cell 
membrane and inactive when located in the cytosol 
145
. Cell lysates enriched for cytosolic or 
membrane-bound and nuclear proteins were generated. In the cytosol as well as the membrane 
fraction of D-2-HG treated DCs PKC levels were increased compared to the untreated control 
DCs (Figure 3.31). This could indicate that D-2-HG bind to Gq/11 coupled receptors. To 
confirm these findings further upstream calcium measurements were started, but so for no 
conclusive results were obtained (data not shown).  
 PKC is also involved in DC differentiation, so a change in translocation caused by D-
2-HG could explain its impact on differentiation. PKC α is known to regulate cytokine 
production in DCs. In PKC α -/- bone morrow derived murine DCs there was a decreased 
TNF- and IL-12p40 production 146. Farren et al. showed that inhibition of PKC β II led to an 
inhibition of DC differentiation 
147
. This is in line with a report of Cejas et al. showing that 
PKC β II is important of DC differentiation 148. These reports are inconsistent to our results on 
D-2-HG causing an inhibition of DC differentiation and an increased PKC level. In contrast to 
Cejas et al. we did not use an isoform specific antibody, which might explain the different 
results. 
Furthermore, oxidants can interfere with PKC activation. Oxidation of regulatory 
elements like the zinc finger resulted in a calcium independent PKC activation. If the 
oxidation takes place at the C-terminal catalytic domain, this leads to an inactivation of PKC. 
In addition, intracellular distribution of PKC isoforms was influenced by redox status 
114
. 
Thus, the increased abundance of PKC in the cytosol could be caused by increased ROS level 
in D-2-HG treated DCs. But the higher overall abundance of PKC could also be partly the 
cause of the higher ROS levels as Pinton et al. reported that PKC β is also able to produce 
ROS 
149
. 
In another series of experiments, another GPCR pathway involving activation of Gi 
and Gs coupled receptors was analyzed by measuring cAMP levels. High levels of cAMP 
activate protein kinase A, which leads to the activation of cAMP response element-binding 
protein (CREB). On one hand Gi receptor activation leads to an inhibition of adenylyl cyclase 
(AC) and results in lower cAMP level. On the other hand Gs coupled receptor activate AC and 
lead to higher cAMP level 
144
. 
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 In our results cAMP levels were slightly higher in D-2-HG treated DCs than in 
untreated DCs (Figure 3.32). The results shown here were measured in DCs after 7 days of 
culture, where D-2-HG was added in the beginning. For future experiments it would be 
reasonable to study the short-term impact of D-2-HG in monocytes as cAMP levels might not 
be stable for several days.  
 Based on our results on PKC and cAMP it cannot be exclude that D-2-HG bind to a 
GPCR, but further analyses need to be performed to prove the binding of D-2-HG. 
4.2.3 Effect of D-2-HG on metabolism 
4.2.3.1 Effect of D-2-HG on glycolytic activity 
Higher glycolytic activity of D-2-HG treated DCs was seen to have higher glucose 
consumption and lactate production (Figure 3.33). It is known that lactate inhibits T cell 
70
 
and DC function 
71
. But in our experiments addition of lactate to monocytes did not lead to 
the same effect on HLA class II expression and other DC markers as seen with D-2-HG 
treatment (data not shown). In line with the higher lactate concentrations in supernatants of 
DCs treated with D-2-HG, the pH values dropped first in D-2-HG treated DCs (lactate lowers 
pH value) (Figure 3.34). This was in line with studies from Malinarich et al., wherein induced 
tolerogenic DCs showed  a higher glycolytic capacity compared to control DCs 
87
. In contrast 
Guak et al. reported an important role of glycolysis for DC migration 
150
. Thus, the important 
part might be the balance between glycolysis and OXPHOS activity. 
To elucidate which signal molecule is involved in D-2-HG associated increase in 
glycolysis mTOR phosphorylation was analyzed. No significant effect of D-2-HG on mTOR 
phosphorylation (activation) was seen in short term or after 7 days of culture (Figure 3.35). 
But, the problems with isotype staining of one donor made it difficult conclude the results so 
far. Based on our data we cannot exclude the possibility that mTOR is involved in D-2-HG 
signaling, which would explain some results measured in D-2-HG treated DCs. Wei et al. 
showed that inhibition of mTOR led to a reduced IL-12 secretion in DCs 
151
. Furthermore, as 
mentioned in the introduction, mTOR is important for differentiation and metabolism of DCs. 
Results from mice lacking the mTOR signaling complex 1 (mTORC1) gene showed a 
disruption of DC development 
152
. The mTORC1 predominantly contains mTOR 
phosphorylated at serine 2448 
153
, the phosphorylation site analyzed here. In another study, 
short-term (48 h) addition of rapamycin (mTOR inhibitor) caused apoptosis in DCs but not in 
monocytes 
154
. Chen et al. incubated immature human DCs with rapamycin for 24h and 
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observed a dose dependent inhibition of DC-SIGN, as we also saw after D-2-HG incubation 
154
. But in contrast to them, in our experiments D-2-HG was already added to monocytes at 
the beginning of the culture. In studies of Ferreira et al. rapamycin was able to rescue HLA-
DR expression in vitamin D3 induced tolorogenic DCs 
116
. Thus, rapamycin could be used in 
further experiments to investigate if this is also possible in D-2-HG treated DCs. 
4.2.3.2 Effect of D-2-HG on respiration 
Analysis of OXPHOS activity of D-2-HG treated DCs and DCs expressing mutant IDH 
showed higher ROUTINE (Figure 3.36, 41, 42). In literature the effects of D-2-HG on 
respiration are inconsistent. In neuronal cell cultures D-2-HG seemed to inhibit ATP synthase 
(complex V of respiration chain) 
155
. In line Chen et al. demonstrated an inhibition of complex 
IV by D-2-HG in the human leukemic monocyte cell line THP-1 
13
. In contrast Grassian et al. 
showed a higher respiration in HT1080 cells expressing mutant IDH1 (R132H or R132C) 
under hypoxia compared to the parental wild type cells 
156
. In line with this, experiments done 
with an IDH1-R132H mutant human oligodendroglioma xenograft model revealed increased 
mitochondrial activity and mitochondrial content in IDH1 mutant tumor cells compared to 
IDH1-wild type xenografts 
157
. D-2-HG added to T cells increased respiration activity 
72
. As 
DCs switch from OXPHOS to glycolysis during maturation it is not unexpected that 
tolerogenic DCs showed higher oxidative phosphorylation rates 
158,159
. This is in accordance 
to our findings where D-2-HG caused an increase in oxidative phosphorylation and an 
impaired T cell stimulation capacity (Figure 3.27). 
4.2.4 IDH mutant cells and D-2-HG addition interfere with ROS level 
As shown in Figure 3.48 cytosolic ROS levels were increased in D-2-HG treated DCs. These 
findings are in line with previous work in chick neurons, wherein the addition of 1 mM 
D-2-HG lead to higher ROS levels 
155
. In line, studies in U87 cells expressing mutant IDH1 
R132H and glioma cells expressing IDH1 R132C showed higher ROS compared to the wild 
type cells, respectively 
9,160
. The higher ROS level of IDH mutant cells could be explained by 
the increased consumption of NADPH for D-2-HG production 
45
. But in the experiments 
performed here and in Kölker et al. the addition of D-2-HG also led to an increase in cytosolic 
ROS. Therefore, D-2-HG itself might increase ROS levels in addition 
155
. 
In Figure 3.48 a reduced cystine uptake of D-2-HG treated cells is shown, this is in 
line with results published by D’Angelo et al. where an inhibition of the cystine/glutamate 
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antiporter also inhibits DC differentiation 
161
. A reduced uptake of cystine could also be an 
explanation for the higher ROS levels seen in D-2-HG treated DCs. 
We saw an increased cytosolic ROS level and a reduced differentiation in D-2-HG 
treated DCs. In contrast, others suggested ROS are important for DC differentiation and 
activation 
83,84,86
. So we hypothesize that as shown for T cells 
97,162
 ROS level have to be 
carefully balanced also in DCs and that DC function is impaired if ROS level are out of 
balance. 
4.2.5 Rescue of D-2-HG effects with trolox treatment 
Trolox is a water soluble derivative of vitamin E 
163
. We hypothesized that the anti-oxidative 
capacity of trolox would lower the increased ROS level (D-2-HG caused) thereby rescuing the 
effects of D-2-HG on HLA class II, CD1a and DC-SIGN expression as well as IL-12 
secretion (Figure 3.50-52). 
 Results of trolox treatment are difficult to conclude as HLA class II expression was 
low and D-2-HG treatment did not reduce DC-SIGN expression in these donors. Also the IL-
12 secretion was highly variable in these donors. But in median trolox and D-2-HG treated 
cells had IL-12 levels comparable with control levels. This is in contrast to Xuan et al. who 
saw an inhibitory effect on IL-12 secretion after addition of vitamin E 
164
 and reports showing 
an inhibitory effect of antioxidants and catalase on DC differentiation 
83,86
  
4.2.5 Rescue of D-2-HG effects on metabolism with metformin  
Surprisingly metformin alone did not reduce respiration (Figure 3.54). The limited effect of 
metformin could be explained by an insufficient expression of the metformin transporter in 
the donors tested, but in general metformin transporter were shown to be expressed in DCs 
165,166
. Although respiration was not inhibited by metformin, cytosolic ROS was rescued to 
control levels by co-treatment of D-2-HG and metformin (Figure 3.54, 57). 
In mice Shin et al. showed that metformin inhibits antigen presentation of DCs by 
suppressing both HLA class I and II expression and expression of co-stimulatory molecules 
like CD80/CD80 in bone marrow derived DCs. Metformin treatment was performed 2 hours 
on day 5 of in vitro culture 
167
. In our experiments, HLA-DP expression was slightly 
decreased and HLA-DR expression slightly increased in metformin treated DCs compared to 
control DCs. This discrepancy can be explained by the fact that in the experiments of Shin et 
al. murine bone marrow was used instead of blood of healthy human donors to generate DCs. 
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4.2.6 Rescue of D-2-HG effects on metabolism with pioglitazone 
Peroxisome proliferator-activated receptor γ (PPARγ) is important for DC metabolism and is 
activated by pioglitazone. Pioglitazone is used as an anti-diabetic drug, it has the ability to 
shift the metabolism towards glycolysis 
124
. We hypothesized that pioglitazone treatment 
would lower the increased respiration (caused by D-2-HG) to control levels and thereby also 
rescuing the D-2-HG effects on DC differentiation. Indeed, pioglitazone treatment rescued the 
increased respiration and cytosolic ROS levels (Figure 3.54, 57) but had only minor effects on 
other parameters analyzed (HLA-DP, DC-SIGN and CD1a protein expression and IL-12 
secretion). Pioglitazone mono-treatment reduced HLA-DP, DC-SIGN and CD1a expression 
and IL-12 secretion. This is in line with results of Yan et al. wherein pioglitazone was added 
to DCs for 24h and a downregulation of DC-SIGN was observed 
168
. Furthermore, Gosset et 
al. showed that the addition of pioglitazone significantly reduced IL-12 secretion in DCs 
169
.  
In conclusion, regulation of respiration to control levels and cytosolic ROS was not 
sufficient to rescue all inhibitory effects seen be D-2-HG. This means that not all effects 
caused by D-2-HG in DCs were connected to the same pathway and that D-2-HG might 
interfere with several pathways. 
4.2.7 Effect of D-2-HG on DNA methylation and vitamin C treatment 
As D-2-HG is an epigenetics modulator and expression of HLA class II molecules is known 
to be also regulated by epigenetics 
170
, analysis of DNA methylation was performed. D-2-HG 
treatment was combined with vitamin C, as vitamin C is a co-factor of the demethylase TET2. 
Addition of vitamin C to TET2 deficient mice increased demethylation and suppressed human 
leukemic colony formation 
126
. Thus, it was hypothesized that a vitamin C treatment of IDH 
mutant blasts producing D-2-HG could be beneficial. This was done in a murine leukemic 
model expressing IDH1 R132H. Mingay et al. showed that vitamin C treatment led to 
demethylation at enhancer sequences involved in myeloid differentiation 
122
. Other studies 
showed that vitamin C enhances TET2 activity 
125
. In a murine model vitamin C was mainly 
found in hematopoietic stem cells (HSC) and less if cells were more differentiated. 
Agathocleous et al. concluded that vitamin C accumulated in HSCs to promote TET2 activity, 
to limit HSC frequency and suppressed leukemogenesis 
171
.  
In our experiments, addition of vitamin C once at the beginning of the monocyte 
culture led to a faster demethylation of loci which should get demethylated during DC 
differentiation (Figure 3.59). D-2-HG treatment decreased demethylation velocity. These 
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results were expected and in accordance with published literature 
125,170
. An increased level of 
methylation correlated with impaired murine hematopoietic differentiation 
41
. This is in line 
with the results shown with D-2-HG treatment of DCs resulting in an impaired differentiation 
and hypermethylation compared to untreated control. But in presence of D-2-HG, vitamin C 
had only a minor effect on some loci analyzed. The effect of vitamin C was not strong enough 
to counteract the effect of D-2-HG. Using a lower D-2-HG or higher vitamin C concentration 
might be beneficial. With these results we cannot finally answer the question if the positive 
effects of vitamin C seen on HLA class II and DC-SIGN expression were regulated 
epigenetically or not. 
In addition, an involvement of ROS in epigenetics regulation was reported. Studies 
showed that DNA damage caused by ROS resulted in a reduced methylation status due to the 
impaired binding of methylases (like DNMTs) to the damaged DNA 
172
. In contrast, a study 
showed that ROS can induce DNA methylation of promotors like the catalase promotor to 
further increase ROS 
173
. 
The results of the experiments with vitamin C treated cells cannot be finally 
concluded. We saw a slight improvement in the HLA class II molecule expression (Figure 58) 
and a minor effect on demethylation by vitamin C treatment in the presence of D-2-HG. To 
get a final answer how the differentiation is inhibited by D-2-HG further experiments need to 
be planned regarding the mechanisms. For example, with TET2 knockout cells one needs to 
check if the effect of D-2-HG is due the inhibition of TET2 or there is an additional cellular 
target. 
4.2.8 Expression of mutant IDH protein versus exogenous D-2-HG  
We saw higher respiration rates in DCs treated with D-2-HG (Figure 3.37) and in DCs 
expressing mutant IDH after electroporation with in vitro transcribed mRNA (Figure 3.41, 
42). This was in line with the lower expression of HLA class II molecules in DCs treated with 
D-2-HG as well as AML blasts expressing mutant IDH (Figure 3.18, 19, 22, 61 and 62).  
However, there are obvious differences in cells expressing mutant IDH and cells 
where D-2-HG was added. Chaturvedi et al. showed gene set enrichment data of D-2-HG 
treated cells and cells expressing mutant IDH each compared to untreated wild type cells. 
Gene sets enriched in D-2-HG treated and IDH mutant cells did only overlap for 16% of gene 
sets. Results from methylation analyses also separated samples of IDH mutant expressing 
from D-2-HG treated cells in different clusters 
174
. Oizel et al. looked at the metabolism of 
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IDH mutant and D-2-HG treated cells and concluded that D-2-HG does not mimic all effects 
of mutant IDH 
175
. For sure, in cells expressing mutant IDH and endogenous converting 
D-2-HG from -ketoglutarate, the NADPH balance is more affected. Wild type IDH produce 
NADPH during the conversion of -ketoglutarate to isocitrate, mutant IDH consumes 
NADPH by the production of D-2-HG 
45
. 
As shown in Figure 3.61, mRNA levels of HLA-DP were significantly reduced in 
AML patients expressing mutant IDH1, but not in IDH2 mutant blasts. This could be due to 
the different locations inside the cell. IDH1 is present in the cytosol, whereas IDH2 is 
expressed in mitochondria. If D-2-HG produced by mutant IDH2 can translocate into the 
cytosol is not yet clarified. But as IDH2 and IDH1 mutant cells have epigenetic alterations, it 
is likely that D-2-HG is able to translocate in different compartments including the nucleus 
41
.  
Analysis of surface expression of HLA class II molecules showed a reduced 
expression in primary AML blasts expressing mutant IDH compared to wild type blasts. The 
downregulation of HLA molecules on solid tumors as well as AML blasts is a well-known 
immune-escape mechanism 
176
. The data shown here with IDH mutant AML blasts and D-2-
HG treated DC clearly show an impact of D-2-HG on immune cells. This is in line with two 
studies on D-2-HG impairing T cell function 
72,73
 and another recently published paper were 
D-2-HG was shown to inhibit T cell function and abundance in glioma patients 
177
. In addition 
Kohanbash et al. showed improved T cell infiltration in a mutant IDH1 expressing glioma 
model 
178
. 
Taken together our results D-2-HG seemed to inhibit the differentiation of monocytes to 
DCs and thereby also reduced the immunological anti-tumor activity. D-2-HG promoted 
immune escape on both sites; it reduced the stimulatory capacity of DCs and decreased the 
immunogenicity of the AML blast by reduced HLA-class II expression.  
The effect of D-2-HG could partially be rescued by pioglitazone and the antioxidants 
trolox and vitamin C. But during the work of this thesis it was not possible to find a drug 
which fully rescues all effects of D-2-HG on surface marker and metabolism. In future 
experiments drugs like diclofenac or rapamycin could be used in rescue experiments. 
Diclofenac was found to lower glucose uptake and lactate secretion 
98
, in addition also 
oxidative phosphorylation was found to be inhibited 
179
. Thus, diclofenac could be used to 
normalize the metabolic reprogramming of DCs caused by D-2-HG treatment. The 
normalization of the metabolism may also have a positive effect on DC differentiation and 
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fully rescue the D-2-HG effects on differentiation. This could also be combined with agent 
interfering with DNA methylation, as this might also play a role for the altered phenotype. In 
a long perspective, the substance which rescued the D-2-HG effects on DCs and AML blasts 
could be used to prevent immune escape of IDH mutant tumors or other diseases with 
elevated D-2-HG or L-2-HG concentration. 
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5 Summary 
5.1 Generation of IDH2 R140Q specific T cells 
In the last decades, immunotherapy has become an important part of cancer treatment. For a 
cancer-specific immunotherapy, it is essential to find a target structure which is restricted to 
cancer cells but is not expressed on other cells. This is possible with “tumor-specific” 
antigens. In the first part of the project the goal was to create a T cell population expressing a 
T cell receptor specifically recognizing the mutated IDH2 R140Q enzyme. T cells were either 
stimulated with antigen presenting cells (APCs) loaded with a IDH2 R140Q protein specific 
peptide or with APCs transfected with the IDH2 R140Q protein. Suitable peptides were 
estimated by online tools (BIMAS, SYFPETHI and NET MHC Pan). The most promising 
binding properties were found for the HLA-B*15:01 restricted 9mer IQNILGGTV (IQN9) 
having the mutated amino acid at the second position (anchor position). Although we 
successfully generated IQN9-peptide specific T cells, it was not possible to find a T cell 
population specifically recognizing APCs expressing the IDH2 R140Q protein upon 
transfection. This could be explained by the fact that the mutated aminoacid was on an anchor 
position and not in the T cell receptor binding region. T cells stimulated with IQN9-peptide 
loaded APCs recognized a neuramidase protein (expressed by influenza A viruses) derived 
peptide which showed a similar amino acid sequence, in addition to the IQN9-peptide. 
Apparently, neuramidase-specific T cells were re-stimulated by the IDH2 R140Q derived 
peptide, a phenomenon known as molecular mimicry.  
5.2 Effect of D-2-HG on metabolism and differentiation of monocyte-
derived dendritic cells 
In the second part of the project the impact of the onco-metabolite D-2-Hydroxyglutarate 
(D-2-HG), produced by the mutated IDH, on myeloid cells was analyzed. D-2-HG is known 
to be released by different tumor entities as leukemia or glioma harbouring IDH mutations. 
The impact of D-2-HG on the differentiation of monocytes into DCs and on DC metabolism 
was examined. Monocytes are able to take up D-2-HG. Besides increased cell sizes, D-2-HG 
treated DCs had less and shorter dendrites than control cells after 7 days of culture. Cell yield 
and viability remained unaffected by D-2-HG treatment. CD1a, a differentiation marker was 
not expressed in D-2-HG treated DCs. DC-SIGN, HLA-DR and –DP, required for T cell 
priming and activation, were also significantly less expressed on D-2-HG treated DCs. 
Furthermore, D-2-HG treatment changed the cytokine profile of mature DCs. The pro-
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inflammatory cytokine IL-12 was significantly less secreted in the presence of D-2-HG. To 
analyze the functional consequences of the D-2-HG induced DC phenotype on T cell 
stimulation, we performed allogenic mixed lymphocyte reactions with CD4 T cells. D-2-HG 
treated DCs were characterized by a reduced stimulatory capacity, indicated by a reduced 
IFN production and diminished proliferation of CD4 T cells.  
In a next step, the metabolic profile of DCs was analyzed in the presence of D-2-HG. 
Respiration analyses revealed higher oxygen consumptions in D-2-HG treated DCs as well as 
in DCs expressing mutated IDH1 or IDH2 enzyme. Moreover, glycolytic activity analyzed by 
glucose consumption and lactate secretion was increased, in line with the earlier pH drop 
measured by the PreSens technology. The higher respiratory and glycolytic activity resulted in 
increased ATP levels. Furthermore, cytosolic reactive oxygen species (ROS) levels were 
significantly increased in the presence of D-2-HG. Since respiration displays an important 
source of ROS, we hypothesized that, antioxidants like vitamin C might reduce the increased 
ROS levels and thereby also the inhibitory effect of D-2-HG on DC differentiation. Vitamin C 
had a positive effect on HLA-DP expression, but only a minor effect on HLA-DR expression. 
DC-SIGN expression reached control levels in vitamin C and D-2-HG treated DCs.  
In another series of experiments, anti-diabetic drugs modulating the metabolism were 
applied with the aim to rescue inhibitory D-2-HG effects on DC differentiation, as metformin 
(an inhibitor of complex I of the electron transport chain) and pioglitazone (a ligand for 
peroxisome proliferator-activated receptor ). In contrast to metformin, pioglitazone treatment 
partially neutralized the effects induced by D-2-HG.  
As D-2-HG is a known modulator of DNA methylation, DCs were analyzed by 
MassARRAY in the presence of D-2-HG and vitamin C. Vitamin C acts as a co-factor for 
TET2, an important demethylase in DC differentiation. We hypothesized that vitamin C could 
rescue marker expression on an epigenetic level. As expected, D-2-HG delayed the 
demethylation of sites, which are known to be important for DC differentiation. A single 
treatment with vitamin C did speed up the demethylation process. Vitamin C was able to 
partly compensate for the inhibitory effect of D-2-HG on demethylation in some regions, but 
levels of untreated DCs were not reached.  
Finally, primary AML blasts with IDH mutations were analyzed, regarding their HLA 
class expression. In line with the results obtained for D-2-HG treated monocyte-derived DCs, 
HLA class II expression was also decreased in primary IDH mutated AML blasts.  
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Taken together, our results indicate that D-2-HG inhibits the differentiation of monocyte 
to DCs, which can have in turn an impact on T cell stimulation. Thereby D-2-HG is indirectly 
able to reduce the immunological anti-tumor response. D-2-HG can promote immune escape 
by reducing HLA class II expression in an autocrine and paracrine way. Moreover, D-2-HG 
diminishes the stimulatory capacity of DCs and decreases the immunogenicity of AML blasts. 
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6 Zusammenfassung 
6.1 Generierung von IDH2 R140Q spezifischer T Zellen 
In den letzten Jahrzenten ist die Immuntherapie ein wichtiger Bestandteil in der Behandlung 
von Krebsleiden geworden. Für eine Krebs-spezifische Immuntherapie ist es essentiell, eine 
geeignete zelluläre Zielstruktur zu finden, die ausschließlich von Tumorzellen, jedoch nicht 
von anderen Zellen exprimiert wird. Dies ist mit tumor-spezifischen Antigenen möglich. Ein 
Ziel im ersten Teil dieses Projekts war die Generation von T Lymphozyten, die spezifisch die 
mutierte Isozitrat Dehydrogenase (IDH) 2 (R140Q) erkennen. T Zellen wurden mit Antigen 
präsentierenden Zellen (APCs) stimuliert, die entweder mit dem IDH2 R140Q Peptid 
beladenen wurden oder mit dem IDH2 R140Q mRNA transfiziert wurden. Geeignete Peptide 
wurden mittels Online-Vorhersageprogrammen (BIMAS, SYFPETHI und NET MHC Pan) 
ermittelt. Die erfolgversprechendsten HLA-Molekül-Bindungseigenschaften hatte das HLA-
B*15:01 restringierte 9mer IQNILGGTV (IQN9), bei dem die Aminosäure an der zweiten 
Stelle mutiert ist (Ankerposition). Obwohl wir erfolgreich IDH2 R140Q Peptid spezifische T 
Zellen generierten, war es nicht realisierbar eine T Zell Population zu generieren, die das 
IDH2 R140Q Protein auf transfizierten APCs erkennt. Grund hierfür war vermutlich, dass die 
mutierte Aminosäure an eine Ankerposition und nicht in der Region in der der T Zellrezeptor 
bindet lag. T Zellen, die mit IQN9-Peptid beladenen APCs stimuliert wurden, erkannten 
zusätzlich zum IQN9-Peptid ein Neuramidase Protein (exprimiert von Influenza A Viren). 
Scheinbar wurden Neuramidase spezifische T Zellen durch das von der IDH2 R140Q 
abstammende Peptid re-stimuliert, ein Phänomen, das als molekulares Mimikry bekannt ist. 
6.2 Effekt von D-2-HG auf den Metabolismus und die Differenzierung von 
aus Monozyten gereiften dendritischen Zellen  
Im zweiten Teil des Projekts wurde der Effekt des Onko-Metabolits D-2-Hydroxyglutarat (D-
2-HG), das von der mutierten IDH produziert wird, auf myeloide Zellen untersucht. D-2-HG 
wird von verschiedenen Tumoren, wie Leukämien oder Gliomen, die eine mutierte IDH 
aufweisen, abgegeben. Der Effekt von D-2-HG auf die Differenzierung von Monozyten zu 
dendritischen Zellen (DZs) und auf den Metabolismus von DZs wurde untersucht. Monozyten 
sind in der Lage D-2-HG aufzunehmen. Nach 7 Tagen wiesen D-2-HG behandelte DZs 
sowohl einen signifikant größeren Zelldurchmesser als auch weniger und kürzere Dendriten 
als unbehandelte Kontrollzellen auf. Die Zellausbeute und die Viabilität blieben durch die 
Behandlung mit D-2-HG unverändert. CD1a, ein Differenzierungsmarker, wurde in mit D-2-
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HG behandelten DZs nicht mehr exprimiert. Die Expression der Marker DC-SIGN, HLA-DR 
und –DP, welche wichtig für das T Zell Priming und die Aktivierung sind, war in D-2-HG 
behandelten DZs signifikant niedriger. Des Weiteren veränderte die Behandlung mit D-2-HG 
das Zytokin-Profil der ausgereiften DZs. Das pro-inflammatorische Zytokin IL-12 wurde in 
Gegenwart von D-2-HG signifikant weniger ausgeschüttet. Um die funktionellen 
Konsequenzen des durch die D-2-HG Behandlung induziert Phänotyps zu analysieren, wurde 
eine allogene Gemischte-Lymphozyten-Reaktion mit CD4 T Zellen durchgeführt. Mit D-2-
HG behandelte DZs waren durch eine verminderte Stimulationsfähigkeit gekennzeichnet, 
wobei die IFNγ Produktion und die Proliferation von CD4 Zellen erniedrigt war.  
In einem weiteren Schritt wurde das metabolische Profil von DZs in der Gegenwart 
von D-2-HG analysiert. Die Analyse der Respiration zeigte einen erhöhten 
Sauerstoffverbrauch sowohl in D-2-HG behandelten DZs, als auch in IDH1 und IDH2 
mutierten DZs. Außerdem war die glykolytische Aktivität, gemessen durch Glukoseabnahme 
und Laktatsekretion, erhöht, was mit dem verfrühten Abfall des pH-Wertes einherging, 
welcher mit Hilfe der PreSens Technologie bestimmt wurde. Die erhöhte glykolytische und 
respiratorische Aktivität führte zu höheren ATP Spiegeln. Zudem waren zytosolische reaktive 
Sauerstoff Spezies (ROS) Level in Anwesenheit von D-2-HG signifikant erhöht. Da eine 
erhöhte Atmungsaktivität eine wichtige Quelle für ROS darstellen kann, stellten wir die 
Hypothese auf, das Antioxidationsmittel wie Vitamin C erhöhte ROS Level verringern und 
hierdurch auch der inhibitorische Effekt von D-2-HG auf die Differenzierung von DZs 
reduziert werden könnte. Vitamin C erhöhte die HLA-DP Expression, hatte jedoch nur einen 
geringen Effekt auf die HLA-DR Expression. Die DC-SIGN Expression auf Vitamin C und 
D-2-HG behandelten DZs erreichte ein Level das mit dem der Kontrolle vergleichbare war.  
In weiteren Experimenten, wurden anti-diabetische Substanzen verwendet, die den 
Metabolismus modifizieren, wie Metformin (ein Inhibitor des Komplex I der Atmungskette) 
und Pioglitazon (ein Ligand für den Peroxisom Proliferator-aktivierten Rezeptor ), um den 
inhibitorischen D-2-HG Effekt auf die DZ Differenzierung auszugleichen. Im Gegensatz zu 
Metformin, war die Pioglitazon Behandlung in der Lage sowohl die Atmung als auch die 
HLA-DR Expression von D-2-HG behandelten DZs auf den Level unbehandelten DZs 
auszugleichen.  
Da D-2-HG einen bekannten Modulator der DNA Methylierung darstellt, wurden DZs, 
die mit D-2-HG und Vitamin C behandelt wurden, mit Hilfe von MassARRAY analysiert. 
Vitamin C ist ein Ko-Faktor für TET2, einer wichtigen Demethylase während der DZ 
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Differenzierung. Deshalb vermuteten wir, dass Vitamin C die Expression bestimmter Marker 
auf epigenetischer Ebene wiederherstellen kann. Wie zu erwarten, verzögerte D-2-HG die 
Demethylierung von Gen Bereichen, die bekannter Weise wichtig für die DZ Differenzierung 
sind. Eine Behandlung mit Vitamin C allein führte zu einer Beschleunigung des 
Demethylierungsprozesses. In Anwesenheit von D-2-HG, führte Vitamin C nur in geringem 
Maße zu höheren Demethyliereundsanteil, wobei vergleichbare Level zu unbehandelten DZs 
nicht erreicht werden konnten.  
Zuletzt wurde die HLA Klasse II Expression in primären AML Blasten, die eine IDH 
Mutation aufweisen, untersucht. Vergleichbar zu den Ergebnissen, die mit D-2-HG 
behandelten DZs gewonnen wurden, war die HLA Klasse II Expression in primären, IDH 
mutierten AML Blasten ebenfalls erniedrigt.  
Zusammenfassend, zeigen unsere Daten, dass D-2-HG die Differenzierung von DZs 
aus Monozyten hemmte. Durch die vermindert HLA Klasse II Expression verringert D-2-HG 
die stimulatorische Kapazität von DZs und Immunogenität von AML Blasten. So kann 
D-2-HG indirekt die immunologische anti-tumorale Antwort auf autokrinem und parakrinem 
Weise vermindern und so zur Immunevasion führen. 
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